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Platelets are known to play a crucial role in haemostasis1-3. Upon damage to the vessel wall, 
platelets become activated via different receptors and adhere to the site of injury. Subsequently, a 
platelet plug is formed, which is stabilised by the formation of fibrin, preventing further blood loss. 
Unbalanced haemostasis by impaired platelet function or increased platelet reactivity contributes 
to pathological conditions that involve bleeding or thrombosis, respectively. Yet, platelets are 
also described to be involved in tumour angiogenesis and cancer progression4, 5. In this chapter, a 
general background is provided of the different receptors that mediate platelet activation and the 
involvement of tyrosine kinases in this process. Furthermore, a brief overview is given on the role 
of platelets in malignant disease and the development of tyrosine kinase inhibitors as targeted 
therapeutic drugs. 
Involvement of tyrosine kinases in platelet signalling
For decades, the involvement of platelet function in haemostasis has been thoroughly 
investigated, which resulted in the knowledge we have today1-3. The process of haemostasis 
is initiated by vessel wall disruption and the exposure of thrombogenic components in the 
underlying matrix. Platelets can interact with these immobilised and other soluble ligands with a 
variety of receptors that induce shape change and adhesion to the vessel wall. Ensuing platelet 
activation can be triggered by different receptors interacting with ligands exposed upon injury. 
In the following sub-sections, a short description is provided of the major signalling pathways of 
platelet activation and the tyrosine kinases involved in these processes. 
GPIb-IX-V signalling
Tethering of platelets along the vessel wall is initiated by collagen-bound von Willebrand 
Factor (vWF) through the glycoprotein (GP)Ib-IX-V complex (Figure 1.1). This shear-dependent 
interaction causes platelet rolling, which enables subsequent firm adhesion to the site of injury via 
collagen6. The interaction between vWF and the GPIbα subunit in the GPIb-IX-V complex leads to 
weak downstream signalling events. The adapter protein 14-3-3ζ supports downstream signalling 
and the phosphorylation of Src family kinases (SFK) Src and Lyn7, 8. In turn, phosphatidylinositol 
3-kinase (PI3K) is activated leading to activation of integrins, stabilised vWF binding, granule 
secretion and adhesion to the surface. In addition, GPIb-IX-V signalling can also be associated with 
Fc receptor γ-chain (FcRγ) or FcRγIIa induced activation through the immunoreceptor tyrosine-
based activation motif (ITAM) in this receptor8. Phosphorylation of the FcRγ (or FcRγIIa) leads to 
the binding of Syk and induces a cascade of signals comparable to the GPVI receptor (described in 
the following paragraph). In general, GPIb-IX-V initiates only a limited activation signal in platelets, 
resulting in transient Ca2+ oscillations6, which mainly helps to induce and amplify platelet activation 





As platelets roll along the damaged vessel wall, GPVI is able to interact with collagen (Figure 
1.1). Although GPVI is most efficiently activated by collagen (type I or III), also other ligands have 
been described to activate this receptor, including physiological (laminin, fibronectin, vitronectin 
and fibrin(ogen)), synthetic ligands (collagen-related peptide, CRP) or the snake venom toxin 
convulxin10. GPVI is a member of the immunoglobulin superfamily and is associated with the 
dimeric immunoreceptor tyrosine-based activation motif (ITAM)-containing FcRγ receptor8, 
11, 12. Activation of GPVI leads to the phosphorylation of the SFKs Fyn and Lyn, which in turn 
induces clustering of GPVI and phosphorylation of the ITAM motif1, 8. This leads to the binding 
and activation of Syk that will initiate the formation of a complex involving linker for activated 
T-cells (LAT), Tec family kinases (Btk, Tec), PI3K, phospholipase C-γ2 (PLCγ2) and several other
proteins1, 2, 13. Through a cascade of signals, calcium increases in the cytosol, promoting processes
of platelet activation. As stimulation of GPVI induces strong platelet activation with high sustained
calcium elevation, it can promote integrin activation, granule secretion, thromboxane production
and procoagulant activity (exposure of phosphatidylserine (PS)), resulting in platelet adhesion,
aggregation, and thrombus formation2, 14.
Figure 1.1. Schematic overview of signalling cascades upon activation via collagen receptor GPVI, podoplanin 
receptor CLEC-2 and von Willebrand factor (vWF) receptor GPIb-IX-V. Shown are the most potent agonists for each 




A less well studied receptor that mediates platelet activation is C-type lectin-like type 
II membrane glycoprotein (CLEC-2) (Figure 1.1). CLEC-2 is activated through its natural ligand 
podoplanin or the snake venom toxin rhodocytin15, 16. The CLEC-2 receptor contains a single 
hemi-immunoreceptor tyrosine-based activation motif (hemITAM), and its signalling involves 
many molecules that are also present in the GPVI pathway. Upon activation the hemITAM motif 
becomes phosphorylated through Fyn and Lyn (and possibly Btk or Tec)1, 13, 17. This enables 
dimerization of CLEC-2 and the binding of Syk to the hemITAM motif, leading to the downstream 
signalling through the LAT complex, inducing an increase of intracellular calcium and resulting 
in platelet activation1, 2. Although GPVI and CLEC-2 signalling are in many ways alike, CLEC-2 
signalling appears to be more reliant on Syk, whereas GPVI signalling is more SFK dependent18.
Integrin activation
Upon platelet activation, one of the induced responses is the activation of integrins through 
inside-out signalling (Figure 1.2A)1, 19. Integrins are transmembrane proteins consisting of an α 
and β chain that exist as a noncovalent heterodimeric complex. Integrins are important for stable 
adhesion to the vessel wall and platelet aggregate formation1. For integrins to become active, a 
conformational change in this complex is necessary to obtain a high-affinity ligand binding state2, 
20. In the low-affinity state of integrins, Csk forms a complex with Src and maintains the β-chain
in an inactive state. Activation induces dissociation of Csk from the complex which leads to the
activation of Src8, 21. Subsequently, the actin cytoskeletal proteins talin-1 and kindlin-3 bind to
Src and provoke the conformational change that leads to the increase in affinity (Figure 1.2A).
Figure 1.2. Schematic overview of (A) inside-out and (B) outside-in signalling of platelet integrins including αIIbβ3, 
α2β1 and α6β1. Shown are the most potent agonists for each receptor. For abbreviations: see text. Modified after 




This allows integrins to interact with several adhesive or soluble compounds1, 2. There are several 
integrins expressed on platelets (α2β1, α5β1, α6β1, αƲβ3 and αIIbβ3), but for this thesis background 
only the integrins α2β1, α6β1 and αIIbβ3 are relevant.
 Integrin αIIbβ3 (GPIIb/IIIa) is the most abundant (integrin) receptor on platelets with over 
80,000 copies on the membrane and additional copies in the α-granules22, 23. Several ligands can 
interact with activated integrin αIIbβ3, including fibrin, fibrinogen, vWF and fibronectin
21, 23. Ligand 
binding to integrin αIIbβ3 contributes to platelet activation via a process called outside-in signalling 
that relies on clustering of the receptor (Figure 1.2B)1, 2. This activates a cascade of events that 
involves the activation of the SFKs Src, Lyn and/or Fyn. This can result in direct stimulation of 
PI3K and PLCγ2 signalling, although this can also occur indirectly via the activation of the ITAM 
signalling pathway involving Syk2, 8, 24. Both pathways result in an increase of intracellular calcium 
levels and drive processes such as platelet spreading, stable adhesion, aggregation, thrombus 
contraction and procoagulant activity of platelets23, 25.
 In comparison to integrin αIIbβ3, integrin α2β1 (GPIa/IIa) is less abundantly expressed with 
only 2,000-4,000 copies per platelet23. The ligands that integrin α2β1 can interact with are fibrillar 
and soluble collagens (Figure 1.2B)1. The activation of outside-in signalling of α2β1 is thought to 
be similar to that of αIIbβ3 in which activation of Src leads to the activation of the Syk-dependent 
ITAM signalling23, 26. The role of this integrin is believed to be mainly complimentary to GPVI via 
maintaining and stabilising platelet adhesion27-29.
 The integrin α6β1 is a moderately expressed protein with around 10,000 copies per 
platelet22. Integrin α6β1 serves as a receptor for laminin (Figure 1.2B) and is described to be 
moderately important in thrombus formation30. It is suggested that activation of α6β1 mainly 
involves the activation of Src and subsequently PI3K, resulting in cytoskeletal rearrangement and 
platelet spreading31. 
G-Protein Coupled Receptor signalling
Another platelet activation response is the release of soluble autocrine agonists (e.g., ADP 
and thromboxane A2 (TxA2)) at the site of injury. Several so-called secondary mediators, such as 
ADP, are secreted from the α- and δ-granules upon activation. TxA2 is formed from arachidonic 
acid in the platelet membrane via several steps involving cyclooxygenase-1. In addition, thrombin 
is an important soluble platelet agonist that arises during coagulation. In general, these soluble 
agonists activate platelets via G protein-coupled receptors (GPCRs). GPCRs are transmembrane 
proteins with seven domains passing through the cell membrane32. Members of this family 
include the ADP receptors P2Y1 and P2Y12, the TxA2 receptor (TP) and the receptors for thrombin, 
protease-activated receptor (PAR)1 and 427. Tyrosine kinases are not considered to be involved 
in the downstream signalling of these receptors, with the exception of the P2Y12 receptor (Figure 
1.3). The P2Y1, TP and PAR receptors all rely on downstream signalling via the G-proteins G12/13α 
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and/or Gqα. Activation via G12/13α leads to activation of Rho-associated protein kinase (ROCK) 
resulting in cytoskeletal rearrangement and shape change in platelets33. On the other hand, 
Gqα-induced signalling activates phospholipase Cβ (PLCβ) followed by intracellular calcium rises 
resulting in strong platelet responses such as integrin activation and granule secretion33. Only 
P2Y12 is aberrant in its signalling as compared to the other GPCRs, as it is related to the G-protein 
Giα34. Stimulation of P2Y12 induces a cascade involving the activation of tyrosine kinases (Fyn and 
Lyn) and subsequently PI3K and Akt. Eventually, this results in integrin activation and aggregation 
of platelets. In addition, stimulation of Giα reduces cAMP, which inhibits platelet activation35.
TAM signalling
Another soluble ligand is Gas6, a plasma protein that is increased in response to 
inflammation, survival, growth arrest and other biological processes27. Furthermore, Gas6 is 
present in the α-granules of platelets and released during activation36. Gas6 is the ligand for the 
tyrosine kinase receptors Tyro3, Axl and Mer (TAM), which are important in clearance of apoptotic 
cells and resolution of inflammation37, 38. In addition, a role of TAM in platelet aggregation and clot 
formation is reported38, 39. It is believed that the activation of TAM synergizes with P2Y12 signalling, 
thereby persisting αIIbβ3 activation and platelet aggregation, a pathway that is dependent on 
the phosphorylation of Akt through PI3K38. Although not much is known with regard to the 
involvement of tyrosine kinases downstream of TAM receptors in platelets, TAM receptors are 
tyrosine kinases itself and are described to signal via Src and/or Fyn resulting in downstream 
signalling of PI3K, PLCγ and ERK in other cells such as fibroblasts40-43. This might point towards a 
possible involvement of (one of) these kinases in this pathway. 
Figure 1.3. Schematic overview of signalling cascades upon platelet activation of the Gas6 receptors Tyro-3, Axl 
and Mer (TAM) and G-protein coupled receptors (GPCR), i.e. ADP receptors P2Y12 and P2Y1, thromboxane A2 (TxA2) 
receptor TP and thrombin receptors protease-activated receptors (PAR)1 and 4. Shown are the most potent agonists 




Roles of platelets in malignant disease
Platelets are not only important in haemostasis to prevent excessive bleeding or thrombosis, 
they are also involved in malignant diseases and inflammation44, 45. It is known that cancer patients 
are at risk for thrombosis46, 47, as aberrations in coagulation and haemostasis were observed in 
these patients more than 150 years ago48. Nowadays, the interactions between platelets and 
cancer have been more clearly described49. Solid tumours are known to induce thrombocytosis, 
an elevated platelet count >400x109/L, but tumour cells are also able to induce platelet activation4, 
45. Platelets (and their function) are suggested to be important in the growth of tumours and 
formation of metastasis via angiogenesis. Platelets contain many anti- and proangiogenic 
molecules in their granules which are secreted upon their activation. Platelets are also described 
as main transporters of vascular endothelial growth factor (VEGF), which is an important stimulus 
of angiogenesis50. Furthermore, platelets are able to sequester all kinds of plasma proteins into 
their granules through active endocytosis51. In order for platelets to release their granule content 
close to the tumour site, platelet activation is necessary. Tumour cells are known to express or 
secrete several proteins that are platelet-activating, such as thrombin, ADP and podoplanin52. 
Platelet activation through PAR1 and P2Y12 is proposed to mainly induce the secretion of VEGF
45. 
Other than VEGF, platelets are also able to release other pro-angiogenic growth factors, such as 
platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF-β) from specific 
α-granules. Release of these factors can promote angiogenesis, tumour neovascularization and 
growth53, 54. Besides stimulating angiogenesis and tumour growth, platelets can also be involved 
in tumour cell survival and metastasis52. Platelets express various adhesion molecules on their 
surfaces (integrins, selectins, etc.), allowing them to bind to tumour cells after entering into 
the blood vessels. This results in shielding and protection of the tumour cells from the immune 
system55, 56, as well as the high shear forces in the blood stream57, 58. In addition, platelets in these 
so-called platelet-tumour aggregates can also help in arrest and stabilisation of tumour cells to 
the endothelial wall of a distant blood vessel, hence further facilitating metastasis59. Altogether, 
this shows the involvement of platelets in tumour progression and metastasis.
Off-target effects of tyrosine kinase inhibitors
As more knowledge is gained on cancer progression and the underlying mechanisms, new 
types of therapeutic drugs have been developed to interfere with these processes, including 
angiogenesis. In the last decades, several types of tyrosine kinase inhibitors (TKIs) have been 
developed to target (multiple) receptor and/or downstream tyrosine kinases which are important 
in signalling pathways that mediate tumour progression. As these TKIs can be orally administered 
and are overall well tolerated in patients, increasing numbers are being developed and several 
have been approved for clinical use in several types of cancer27. However, given that TKIs inhibit 
important tyrosine kinases in cancer cells, due to a high tyrosine kinase expression in other cells 
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such as platelets, “off-target” effects can be expected. Hence, for several TKIs (severe) side effects 
have been reported, while also cancers can become resistant toward these drugs.
Aims and outlines of this thesis
This thesis has as overall aim to provide better insight into the off-target effects of tyrosine 
kinase inhibitors (TKIs) used for cancer treatment on platelet functions. The general introduction 
in this Chapter provides background information on key pathways of platelet activation 
and the involvement of most relevant tyrosine kinases in these pathways. Chapter 2 reviews 
nearly 40 multi-target TKIs that are currently used for treatment of different types of cancer, to 
prolong progression-free survival. This chapter describes how several TKIs can inhibit activation 
mechanisms in platelets, and which are the clinical consequences of these antiplatelet effects. 
In Chapter 3, we investigated effects of the antiangiogenic compound pazopanib on platelet 
function in vitro and in blood of advanced renal cell carcinoma (RCC) patients during treatment. 
Patients treated with pazopanib are reported to have an increased mild bleeding risk. Given the 
well-established role of protein tyrosine kinases in platelet activation, we hypothesized that the 
increased bleeding risk could be due to an off-target effect by pazopanib on platelet tyrosine 
kinases. The focus of Chapter 4 is sunitinib, another multi-target TKI used for the treatment of 
advanced RCC. Sunitinib was already described to affect collagen-induced activation under non-
coagulating conditions. We investigated the effects of sunitinib on thrombus formation induced 
by other tyrosine kinase-dependent receptors, as well as the effects under coagulating conditions 
in a whole blood microfluidics system. Since cancer patients often experience cardiovascular 
diseases as a co-morbidity, they are often on a combined therapy of sunitinib with antiplatelet 
or anticoagulant drugs. As both are associated with an increased bleeding risk, we examined the 
synergistic effects of sunitinib with aspirin, as a common antiplatelet drug, on thrombus and fibrin 
formation. In Chapter 5 we describe a patient study with sunitinib-treated RCC patients. Here 
we explored the effects of sunitinib-treatment on quantitative and qualitative platelet traits in 
relation to the sunitinib levels in plasma or serum, and also assessed the occurrence of bleeding 
to evaluate the haemostatic consequences and clinical relevance.
Several types of TKIs have also been reported to increase the bleeding risk, often lacking a 
clear explanation. It is of importance to investigate possible underlying antiplatelet mechanisms, 
to come to better-informed treatment decisions, especially when prescribed in combination with 
antiplatelet or anticoagulant drugs. Therefore, in Chapter 6, we investigated the effect of three 
Btk inhibitors (acalabrutinib, ibrutinib and MK-1026) on platelet function pathways in vitro and in 
patients. Furthermore, we assessed the off-target effects in Btk knock-out mice. 
In the literature, the effects of other TKIs on platelets have only partially been assessed. The 
reported effects of several TKIs on the GPVI pathway in platelets make those TKIs, at a lower dose, 




with an increased bleeding tendency. On the other hand, effects on other platelet signalling 
pathways remain largely unknown, which may possibly explain the reported increased risk of 
bleeding. To explore whether TKIs are of potential interest as antiplatelet drugs, we systematically 
investigated the effects of eight clinically used TKIs on (physiological) platelet function in whole 
blood under flow and isolated platelets using different agonists in Chapter 7. In the last chapter 
of this thesis, Chapter 8, the most important findings of this thesis are highlighted and brought in 
context with the current literature.
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Acquired platelet antagonism: off-target 
antiplatelet effects of malignancy treatment 
with tyrosine kinase inhibitors
Tullemans BME, Heemskerk JWM and Kuijpers MJE





Platelets can contribute to tumour progression and metastasis. Cancer patients are at 
increased risk of thrombosis, while advanced stages of cancer associate with thrombocytosis or 
increased platelet reactivity. Tyrosine kinase inhibitors (TKIs) are widely used as a targeted strategy 
for cancer treatment, aiming to prolong progression-free survival of the patients. Because of 
their broad kinase target spectrum, most TKIs inevitably have off-target effects. Platelets rely on 
on tyrosine kinase activity for their activation. Frequently observed side effects are lowering of 
platelet count and inhibition of platelet functions, whether or not accompanied by an increased 
bleeding risk. In this review we aim to give insight into: (i) 38 TKIs that are currently used for 
treatment of different types of cancer, either on the market or in clinical trials, (ii) how distinct 
TKIs can inhibit activation mechanisms in platelets, and (iii) the clinical consequences of the 
antiplatelet effects due to TKI treatment. For several TKIs, the knowledge on affinity for their 
targets does not align with published effects on platelets and reported bleeding events. Together, 
this review should raise awareness of the potential antiplatelet effects of several TKIs, which will 
be enhanced in the presence of antithrombotic drugs.
21
Off-target antiplatelet effects of tyrosine kinase inhibitors
2
Introduction
Human blood platelets are required for haemostasis, and also contribute to pathological 
thrombosis1. Platelets normally circulate in the blood at a concentration of 150-450x109/L, with 
a life span of around 10 days. Thrombocytopenia, a low platelet concentration which increases 
the bleeding risks, is defined as a count <50x109/L. By implication, only a fraction of the normally 
circulating platelets seems to be required for proper haemostasis, as could be demonstrated in 
mice2. Hence, the majority of circulating platelets are likely to contribute to other physiological 
processes, which can include maintenance of vascular integrity, tissue repair, immune responses, 
and infection prevention. The existence of different populations of platelets, primed by their 
environment3, may even suggest a certain degree of specialisation in these functions. Considering 
the ‘overload’ of circulating platelets, it is not a surprise that these a-nucleated cells also contribute 
to pathological processes, including cancer.
It is well known that cancer patients are at increased risk for thrombosis4, and that 
advanced stages of cancer are associated with increased platelet reactivity5. Recent papers 
furthermore suggest that the growth factor composition and even the RNA profile of platelets can 
change due to the presence of cancer6, 7. On top of this, malignancy can lead to thrombocytosis 
(elevated platelet count), which is regarded as a negative predictor of survival8. The suggested 
mechanism is enhanced platelet formation by megakaryocytes, due to tumour-derived 
interleukin-6 production and high thrombopoietin production in the liver9. This points to a cycle of 
tumour-induced platelet formation and activation, followed by growth factor release and tumour 
promotion and metastasis. This reciprocal interaction between platelet activation and tumour 
growth has recently been reviewed by others10. The model proposed in 2000 is that tumours 
secrete chemokines which recruit blood cells, including platelets, and thus promote the process 
of angiogenesis, i.e., the formation of new blood vessels from pre-existing vessels, in order to 
secure tumour development and metastasis11. Platelets contain numerous pro-angiogenic (next 
to antiangiogenic) molecules in their α-granules, which are either synthesised by megakaryocytes 
in the bone marrow or are taken up via endocytosis12.
In the majority of cancers, oncogene-encoded proteins or growth factor receptors 
are amplified or mutated, which carry tyrosine protein kinase activity or steer both tyrosine 
and serine/threonine kinases in the downstream signalling pathways. Accordingly, abnormal 
protein kinase activity is considered as a hallmark of tumour biology13, resulting in altered cell 
proliferation, survival, motility, metabolism, angiogenesis, and evasion of immune responses14. 
This insight has prompted the search for tyrosine kinase inhibitors (TKIs) as targeted therapeutic 
drugs in oncology.
 Protein tyrosine kinases are classified into the receptor-linked tyrosine kinases, e.g., the 
vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors; 
and the cytosolic non-receptor kinases, such as Src family kinases (SFK), Syk and Btk. In tumours, 
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often gain-of-function mutations are seen in the genes encoding for tyrosine kinases, resulting 
in constitutively active proteins. Examples of such aberrant oncoproteins are BCR-ABL and NPM-
ALK. The latter are fusion genes that originate from reciprocal translocation of genetic material 
between two chromosomes, resulting in proteins that are ‘always on’ and leading to uncontrolled 
cell division. In the past fifteen years almost 40 TKIs have been developed and approved for cancer 
treatment (Table 2.1). In most cases, these are small molecules with relatively high affinity to the 
so-called targeted kinases, but often with similar affinities to other tyrosine kinases. As many of 
these tyrosine kinases are also expressed in non-proliferative cells, including platelets, TKIs clearly 
can have relevant off-target effects.
Blood platelets are unable to proliferate or differentiate but display high tyrosine kinase 
activities in comparison to other cell types. In platelet activation, tyrosine phosphorylation is one 
of the key signal transduction mechanisms. As described below, non-receptor tyrosine kinases are 
activated by the collagen receptor, glycoprotein (GP)VI; the C-type lectin-like receptor 2 (CLEC-
2); the von Willebrand factor (vWF) receptor, GPIb-IX-V; and by adhesion-regulating integrins15, 
16. In this review we aim to give insight into: (i) the TKIs that are currently used for treatment of 
different types of cancer, either on the market or in clinical trials, (ii) how distinct TKIs can inhibit 
activation mechanisms in platelets, and (iii) the clinical consequences of the antiplatelet effects 
due to TKI treatment.
Cancer treatment with tyrosine kinase inhibitors
TKIs are defined as pharmaceutical drugs that inhibit tyrosine kinases. The TKIs that are 
currently in use are in majority small molecules that can pass the cell membrane. Their common 
mode of action is by competition with ATP in the conserved catalytic binding site in the superfamily 
of (non)receptor tyrosine kinases. Because of the comparable structure of the catalytic pocket of 
tyrosine kinases, TKIs often target multiple kinases that play a role in several signalling pathways. 
At present, around 40 drugs with TKI activity have been approved by the USA Food and Drug 
Administration or have entered clinical trials for anticancer treatment (Table 2.1).
Based on their precise action, TKIs can be classified into four categories17. Type I inhibitors 
target the active conformation of the kinase and compete with the ATP-binding site (example: 
sunitinib). Type II inhibitors instead recognise the inactive conformation, and thereby indirectly 
compete with ATP by occupying a hydrophobic pocket near the ATP-binding site. Accordingly, type 
II inhibitors are considered to modify the kinase activity in an allosteric manner (examples are 
imatinib and sorafenib). Type III compounds are the so-called allosteric inhibitors. These bind more 
distantly from the ATP-binding site and inhibit kinase activity via classical allosteric interference 
(examples are MEK1 inhibitors such as selumetinib). Type IV inhibitors are also known as covalent 
inhibitors, forming an irreversible covalent bond near the active site of the kinase, usually by 
reacting with a cysteine residue. This blocks the binding of ATP and prevents activation of the 
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kinase (examples are ibrutinib and vantedanib).
Although directed against specific targets, almost all TKIs affect multiple kinases. Table 2.1 
provides an overview of the currently used TKIs that are prescribed for which cancer type, together 
with their target kinases in tumour cells. The majority of the drugs are targeted at receptor tyrosine 
kinases for growth factors (EGF, FGF, PDGF, VEGF) or for differentiation/proliferation factors (Flt, 
Fms, Kit, Ret). Several of the drugs (in addition) target intracellular tyrosine kinases (ABL, B-Raf, 
Btk, Itk, MEK, SFK, Syk). Although affinities towards individual kinases will differ, essentially all TKIs 
have a more or less broad efficacy, which in some cases is intentional. For instance, both VEGF 
and PDGF are known to be important in tumour angiogenesis. Sunitinib, blocking signalling via 
both types of receptors, thus will have a broader action spectrum than vatalanib, targeting only 
VEGF receptors18. In general, the use of TKIs for treatment of specific tumours depends on the 
affinity for the targeted kinases19 and the pharmacokinetics at indicated dosages and treatment 
regimens20 (Table 2.1). As far as understood, the ultimate specificity is not strongly correlated with 
chemical structure or the subfamily of the targeted kinase18.
Receptor-linked tyrosine kinases are also abundantly expressed in non-tumour cells, 
and treatment with TKIs will inevitably have off-target effects, thus interfering with the normal 
function of non-diseased cells and tissues. This can explain side effects of treatment, varying from 
general complications as fatigue, diarrhoea, and nausea, to specific complications like hand-foot 
syndrome21. In spite of drug-to-drug variations, many TKIs can cause skin toxicity, even in >50% 
of patients22. For antiangiogenic TKIs, ‘blood-related’ side effects have been reported, such as 
hypertension, myelosuppression and bleeding23. Incidentally, also on-treatment cardiovascular 
events have been reported, for instance linked to affected vascular integrity of the endothelium24. 
TKI effects on the vessel wall comprise endothelial dysfunction and increased capillary leakage25, 
which may contribute to an increased bleeding tendency. Paradoxically, interfering with the 
integrity of endothelial cells can shift the haemostatic balance in favour of thrombosis, which 
might explain why treatment with TKIs can associate with arterial thromboembolic events in 
cancer patients25, 26.
Despite clinical benefit of the prescribed TKIs, some of the patients who initially respond 
to the therapy experience a relapse, e.g., due to acquired drug resistance of the tumour14. In such 
cases, the treatment schedule is adjusted, or a switch is made to an alternative TKI as a second- 
or third-line treatment (Table 2.1). In specific cases, several TKIs can be combined for effective 
blockade of one or two signalling pathways14, 21. Furthermore, chemotherapy or radiation therapy 
can be complemented with TKI treatment13.
Protein tyrosine kinases implicated in platelet activation
A global overview of platelet tyrosine kinases signalling underneath relevant receptors, as 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CLEC-2, C-type lectin-like receptor 2; GP, glycoprotein; SFK, Src family kinase; SLP76, Src homology 2 domain-containing 
leukocyte phosphoprotein
SFK Other 
GPVI Src, Fyn, Lyn, Fgr Btk, Syk, Tec Ca2+ mobilisa�on, integrin ac�va�on, 
 degranula�on
CLEC-2 Src, Fyn, Lyn Btk, Syk, Tec Ca2+ mobilisa�on, integrin ac�va�on, 
 degranula�on
GPIb-IX-V Src, Fyn, Lyn Btk Integrin ac�va�on





GPVI signalling. Collagen-induced platelet activation is established via the tyrosine 
kinase-linked receptor GPVI, a member of the immunoglobulin superfamily. GPVI is linked to 
the Fc receptor γ (FcRγ) chain, which contains two immunoreceptor tyrosine-based activation 
motives (ITAM) requiring phosphorylation to mediate platelet activation27. Ligand binding and 
dimerization of the GPVI-FcRγ complex leads to activation of the SFK isoforms Src, Fyn and Lyn, 
which in turn phosphorylate the FcRγ ITAM tyrosine residues to recruit and phosphorylate Syk1, 
28. The tyrosine kinases SFK and Syk furthermore phosphorylate downstream targets, including 
the transmembrane adapter linker for activated T cells (LAT) and the Src homology 2 domain-
containing leukocyte phosphoprotein (SLP76). The consequence is the formation of a large 
signalling complex, including LAT, SLP76, Btk, isoforms of phosphoinositide-3 kinase and Tec 
family kinases29. A key downstream event is the phosphorylation and activation of the second 
messenger-generating phospholipase (PLC)γ2, resulting in Ca2+ mobilisation and protein kinase 
C (PKC) activity. Further responses are integrin activation, thromboxane A2 release, granule 
secretion and phosphatidylserine exposure.
CLEC-2 signalling. A similar powerful activation pathway of platelets is induced via CLEC-2, a 
C-type lectin receptor also acting through tyrosine phosphorylation. Known ligands of this receptor 
are podoplanin (expressed in tumour tissue among others) and the snake venom rhodocytin. 
Signalling occurs through a so-called hemITAM motif30. The clustering of CLEC-2 induces more or 
less similar events as described for GPVI. Starting with the tyrosine phosphorylation of SFK and 
Syk, a signalling complex is formed including Tec family tyrosine kinases, with as result PLCγ2 and 
PI3K activation. Consequences are, again, integrin activation, granule release, and thromboxane 
A2 production
30.
GPIb-IX-V signalling. Interaction of vWF with the GPIb-IX-V receptor is one of the first 
steps in platelet tethering and adhesion under shear flow1. This interaction causes only weak 
signalling, e.g., leading to restructuring of the actin cytoskeleton, with under certain conditions 
phosphorylation of SFK (Src, Fyn, Lyn) and activation of PI3K isoforms1. Integrin αIIbβ3 activation 
and platelet spreading are a result of this.
Table 2.2. Protein tyrosine kinases implicated in platelet activation responses: global overview of tyrosine kinases 
implicated in signaling via key platelet receptors, as well as downstream platelet responses. Summarized from 1, 16, 18, 30
27
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Integrin-dependent signalling. Platelet integrins, in particular αIIbβ3, α2β1 and αƲβ3, regulate 
adhesion, aggregation and thrombus formation28. Especially regarding integrin αIIbβ3 (ligands: 
fibrinogen, vWF and other matrix proteins) much research has been performed to the outside-in 
signalling events triggered by the occupied, activated conformation. Several tyrosine kinases are 
implicated in this signalling pathway, including FAK, Pyk2, Src, SLP76 and Syk29, 31.
Effects of TKIs on platelet function
Tyrosine kinases are targeted by TKIs as treatment for cancer, where their most important 
effect is the prolongation of progression free survival. Given the presence of on-target or related 
off-target tyrosine kinases in megakaryocytes and platelets, it is to be expected that several TKIs 
















































































Figure 2.1. Heatmap of affinity profile of tyrosine kinase inhibitors (TKIs) with described targets that are known to 
be expressed in platelets.  Shown are normalized affinity-based dissociation constants (Kd) of the indicated TKIs 
determined for purified kinases18, 19, 33, 36, as far as they are present in platelets. Scaling is from 0 to 10, with the lowest Kd 
indicating the highest affinity (deep red is highest affinity = lowest Kd; white is lowest affinity = highest Kd; pink gradient 
represents intermediate Kd’s; gray values have not been described). The right column indicates increased bleeding risk 
(black, yes; white, no or unknown); see Table 2.1. 
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To provide an overview, we evaluated the inhibition profiles of TKIs (22 in total) against 
target protein tyrosine kinases that are known to be expressed in platelets32. Markedly, the 
majority of these TKIs demonstrated relatively low affinities for kinases with crucial roles in 
platelet activation processes (SFK, Syk, Btk, MEK and Eph isoforms), with as exceptions bosutinib, 
dasatinib, fostamatinib, nintedanib and sunitinib (Figure 2.1). For such an in vitro affinity-based 
analysis18, 19, 33, it should be realised that the presence of blood plasma and blood cells can 
profoundly change the bioavailability of a TKI, apart from its metabolic and pharmacokinetic 
profile. Markedly, bleeding symptoms have been reported for 11 of these TKIs. For individual TKIs, 
based on their known targets, we summarised in Table 2.3 which of these targets are expressed 
in platelets. Furthermore, we made an inventory of the published effects of these TKIs on platelet 
responses.
Ibrutinib is a covalently acting TKI that is targeted at the family members Btk and Tec, 
which probably explains the strong effects observed on platelets34. It is frequently used for the 
treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL). Emerging 
data suggest that ibrutinib could also be used to treat solid tumours35 and has been shown 
to inhibit several other kinases such as Itk, JAK3, Hck, Blk, EGFR, ErbB2 and ErbB436. Ibrutinib 
treatment is associated with a risk of bleeding34, 37, 38. Being the most investigated TKI with regard 
to platelets, ibrutinib has been demonstrated to potently inhibit collagen-induced responses of 
platelets from patients on-treatment39-44. Efficient inhibition by ibrutinib of the GPVI pathway 
(in response to collagen or collagen-related peptide) has been demonstrated to proceed via 
reduced PLCγ2 phosphorylation42. In treated patients, the suppression of collagen-induced 
platelet aggregation correlated with the occurrence of bleeding events42. Subsequent studies 
showed that ibrutinib suppressed multiple (mostly) GPVI-dependent platelet responses, including 
adhesion, spreading, calcium fluxes, secretion, phosphatidylserine exposure and clot retraction40, 
43. In addition, evidence was obtained for reduced αIIbβ3-dependent outside-in signalling, linked 
to thrombus instability in vitro40. Several studies confirmed that Btk can act as a central target of 
ibrutinib in GPVI-stimulated platelets, although downstream tyrosine kinases may be affected as 
well40, 42, 44. In vitro, ibrutinib was found to fully inhibit the tyrosine phosphorylation of Src and 
PLCγ242. Other affected events were the phosphorylation of Fyn, Lyn, Btk, Tec and Syk40, 44. Taken 
together, this pointed to a potent suppression of ibrutinib of the GPVI signalosome with as major 
target the Tec family kinases.
The second-generation drug, acalabrutinib, is a more selective, irreversible Btk inhibitor. 
In a clinical trial with patients with relapsed CLL, acalabrutinib showed promising safety and 
efficacy profiles, although some minor bleedings were still reported45. A recent study comparing 
treatment with ibrutinib or acalabrutinib indicated that both compounds impaired the platelet 
aggregation responses after collagen receptor stimulation46. Both drugs inhibited platelet Btk 
and Tec at physiological concentrations, while only ibrutinib inhibited SFK isoforms. This provided 
29








































































































































































































































































































































































































































































































































































































































































































































































































an explanation why only ibrutinib caused dysfunctional thrombus formation, in contrast to 
acalabrutinib46.
Imatinib, targeting the oncogenic kinase BCR-ABL, was the first tyrosine kinase inhibitor 
developed for chronic myeloid leukaemia (CML). Imatinib is known to block Kit and PDGF receptors, 
as well as Erk and Akt isoforms47. This TKI has been reported to evoke thrombocytopenia in 18% 
of the treated patients, with haemorrhages being reported as well48. Despite a high efficacy of 
imatinib, 15% of patients appear to develop clinical resistance and relapse after initial response 
to therapy.
Dasatinib and nilotinib have been developed as second generation BCR-ABL inhibitors for 
the treatment of CML. Two case reports showed that dasatinib could induce a bleeding diathesis 
correlated to platelet dysfunction, which was reversed upon cessation of the dasatinib intake49, 
50. Studies with blood from patients or healthy subjects showed an impairment of platelet 
aggregation by dasatinib given in vivo or in vitro51, 52. In particular, platelet aggregation in response 
to collagen, arachidonic acid and epinephrine was affected52, along with collagen-induced 
thrombus formation51, 53, thus suggesting interference with GPVI signalling and other pathways. 
The mechanism of dasatinib-induced inhibition in platelets was elucidated from changes in 
the protein phosphorylation profile after collagen stimulation. Herein, dasatinib appeared to 
interfere with SFK, PLC and PI3K activities51. Thrombocytopenia is a relatively common side 
effect of dasatinib treatment54. This is proposed to be due to reduced megakaryocytopoiesis, 
thus resulting in lower platelet production55. The combined quantitative (via megakaryocytes) 
and qualitative (via signalling) platelet dysfunction most likely is the reason of the relatively high 
bleeding incidence in dasatinib-treated patients. Compared to dasatinib, imatinib induces less 
antiplatelet activity and causes less bleeding at clinically achievable doses, likely due to the fact 
that it is less inhibitory for SFK isoforms. On the other hand, nilotinib is reported to potentiate 
thrombus formation and increase the risk of thrombosis56.
Ponatinib and bosutinib are third generation BRC-ABL inhibitors for the treatment of CML, 
which are applicable when patients develop resistance to imatinib. The use of ponatinib has been 
associated with bleeding diatheses, along with changes in platelet count and function, which thus 
may explain the impaired haemostasis57, 58. One study describes inhibiting effects of ponatinib, 
imatinib and nilotinib on platelet activation, secretion, and aggregation in response to collagen57. 
Herein, ponatinib appeared to be the most potent platelet inhibitor. Ponatinib increased PFA-100 
closure times, likely by suppressing ITAM signalling via several tyrosine kinases, including Src, 
Lyn, Syk, and Btk57, 58. In contrast, imatinib and nilotinib did not affect platelet granule secretion, 
procoagulant activity or aggregation, and only moderately reduced the tyrosine phosphorylation 
of Lyn and Btk, as compared to ponatinib57. Yet, whole blood thrombus formation was reduced 
by imatinib and ponatinib to a similar extent. For bosutinib (also targeting Src), bleeding has 
been reported as well59, although in patients it did not affect platelet aggregation in response to 
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several agonists52. In microfluidic whole blood testing of platelet thrombus formation, bosutinib 
was found to be less potent than dasatinib53. Overall, it appears that BCR-ABL inhibitors used for 
leukaemia treatment have an inhibiting effect on platelet functions, with the possible exception 
of nilotinib.
Sunitinib, sorafenib and pazopanib are multi-target TKIs used for the treatment of renal 
cell carcinoma, aiming to inhibit tumour angiogenesis via interference with the receptors for VEGF 
and PDGF. Such multi-target TKIs may potentially also inhibit tyrosine kinases present in platelets. 
For sunitinib and sorafenib, a meta-analysis of 23 trials (>6,500 patients) showed an increased 
incidence of bleeding events with 16.7% on all grades of bleeding, and a 2.4% probability of 
high-grade bleeding events60. For sunitinib, both quantitative and qualitative effects on platelets 
are reported. The compound can be taken up by platelets from healthy donors and renal cell 
carcinoma patients, and hence reduce the platelet functionality in a way depending on protein 
tyrosine phosphorylation61. In patients on-treatment, this is accompanied by a decrease in platelet 
count61, 62. For sorafenib, similarly to other TKIs used for treatment of renal cell carcinoma such as 
pazopanib, an increased risk of bleeding has also been observed63, but effects on platelet function 
have not been investigated.
Afatinib is used for the first-line treatment of particularly patients with non-small cell lung 
cancers64. It acts as an irreversible inhibitor of EGF and HER receptors. An increased bleeding risk 
of patients receiving afatinib has been linked to impaired platelet function and apoptosis65. In 
particular, afatinib impaired GPVI-induced platelet responses, including calcium fluxes, integrin 
activation, secretion, procoagulant activity and platelet aggregation (Table 2.3). On the other 
hand, thrombin-induced platelet responses were less strongly inhibited. Further investigation 
showed that the collagen-induced phosphorylation of Akt was decreased by afatinib65.
Cabozantinib, cediranib, dovitinib, lenvatinib, regorafinib and other TKIs co-target the 
receptor kinase Kit, which acts as a receptor for stem cell factor in megakaryocytopoiesis, 
regulating platelet production. The Kit receptor is known to signal via SFK, PI3K, Ras/MEK and 
JAK/STAT pathways66. In an analogous way, the thrombopoietin receptor Mpl signals via JAK2 
and Tyk2 as immediate effector kinases, resulting in the activation of STAT isoforms67. For these 
signalling pathways, key tyrosine kinases are also present in platelets and/or megakaryocytes 
(Table 2.2 and 2.3), which raises the possibility that Kit-targeted TKIs can also modulate platelet 
function as well as platelet count. So far, the signalling effects of these TKIs on platelets have not 
been investigated in detail. Cabozantinib intake has been associated with a higher bleeding risk63. 
Related drugs are ruxolitinib, pacritinib and lesaurtinib, which also target JAK1/2 and are usually 
prescribed for myeloproliferative disorders, such as essential thrombocythemia, characterised by 
an elevated platelet count (thrombocytosis). The latter compounds appear to lower (normalise) 
the concentration of circulating platelets68, most likely via inhibition of the thrombopoietin 
pathway in megakaryocytes. However, effects on platelet function are still unclear. It is known that 
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thrombopoietin potentiates agonist-induced platelet activation via JAK2 and Tyk2 signalling69. 
This indicates that this pathway is not strong enough to induce platelet activation on its own. 
Inhibition of JAK2 in platelets has been reported to only attenuate collagen-induced responses70.
For multiple prescribed TKIs with a broad target range, bleeding symptoms have not been 
reported (Table 2.1). Examples of these are fostamatinib, dovitinib and vantedanib, which based 
on their affinity profiles should affect SFK and/or MEK isoforms in platelets (Figure 2.1). In these 
cases, additional research is needed to verify effects on platelet count and activation, and to 
determine if there is a bleeding risk. Summarising the current knowledge of TKI effects on platelet 
activation responses, it appears that the majority of multi-target TKIs in particular suppresses 
GPVI-induced signalling pathways, but that they can also target kinase events downstream of 
other platelet receptors. As the inhibition of GPVI alone has been shown to prevent occlusive 
thrombus formation without causing bleeding71, it is most likely that the targeting of pathways 
downstream of additional receptors is responsible for an increased bleeding risk with these 
compounds.
Clinical implications of platelet inhibition with TKIs
Platelets are known to interact with cancer cells in the blood. Tumours exposed to the 
blood stream can activate platelets, while platelets can stimulate tumour angiogenesis, growth, 
and metastasis. The question has been raised whether and how interfering in the platelet-cancer 
loop via antiplatelet treatment may also influence cancer progression. Several studies have 
reported that aspirin or P2Y12 receptor inhibitors suppress tumour angiogenesis in vitro
72 and 
tumour growth in vivo73. A low daily aspirin intake has been associated with a reduced risk for the 
development of cancer as well as prevention of metastases74. The mechanism is not completely 
resolved, but it has been shown that inhibition of platelets by aspirin decreased their ability 
to stimulate cancer cell proliferation through modulation of the Myc oncoprotein75. For other 
antiplatelet drugs, clinical evidence of a beneficial effect on cancer is still lacking.
 Of growing interest is the recent finding that platelets are capable to sequester bioactive 
compounds from the plasma, including growth factors12, 76, 77 and RNA species7. In addition, 
platelets accumulate the anticancer drugs bevacizumab78 and sunitinib (in granules)61. Other 
TKIs can also be taken up by platelets, which usually is a requirement for interaction with the 
intracellular kinases. Whether these TKIs can also secondarily be released by platelets and, 
perhaps, then contribute to tumour inhibition is matter of speculation. Another consideration is 
that uptake of TKIs by platelets (e.g., in patients with thrombocytosis) can reduce the availability of 
the compounds for tumour inhibition. On the other hand, it is likely that a decreased aggregation 
tendency of platelets (as induced by TKIs) also lowers tumour-induced platelet activation, and 
thereby reduces metastasis of tumour cells. However, the evidence for such a mechanism is at 
best indirect, and further investigation here is required. Taken together, it appears that platelets 
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can interfere with drug effects in different ways and by different mechanisms, which should be 
taken into account upon therapeutic drug monitoring.
 Application of the TKIs axitinib, dasatinib, pazopanib, sorafenib and sunitinib ‒ all of 
which have indications may cause bleeding ‒ can lead to a reduction of the platelet concentration 
in blood (Table 2.3). In cancer patients, thrombocytosis has been associated with a worse 
overall prognosis, when compared to patients with a normal platelet count8, 9. In addition, in 
glioblastoma patients, who underwent concomitant radiotherapy and chemotherapy, a decrease 
in platelet count correlated with longer overall survival79. In renal cell carcinoma patients with 
metastasis, a reduction in platelet count after start of sunitinib treatment was associated with 
a better treatment outcome62. Although more research is needed, these studies suggest that 
platelet count can be used as one of the parameters to monitor anticancer treatment efficacy.
 Besides platelet count, also platelet function can be affected by many TKIs, as indicated 
in Table 2.3. This suggests that combined platelet count and function tests could be used in clinical 
practice to assess the risk of bleeding upon TKI treatment. For the availability of such (point-of-
care) tests, we like to refer to the expert literature80. In the future it may be possible to use flow-
based assays for this purpose. Our laboratory recently found that this method detects additive 
effects of low platelet count and impaired platelet functionality in patients with a bleeding 
phenotype81.
 It is known that cancer patients are at increased risk of thrombosis, also indicated as 
Trousseau’s syndrome82. As a consequence, many cancer patients have a history of cardiovascular 
disease and are treated with antiplatelet or anticoagulant drugs. When additional treatment with 
a TKI is started, the clinical problem of an enhanced bleeding risk may arise. Another treatment 
issue is that some oral anticoagulants and TKIs (ibrutinib for instance) have a common metabolic 
pathway (CYP3A4), which can affect the pharmacokinetics of either drug. These interactions 
between TKIs and antithrombotic treatments need to be further investigated.
Conclusions
Several of the TKIs used for the treatment of cancer can increase the risk of bleeding. 
For some but not all of these, the bleeding tendency is linked to a lowering of platelet count 
and/or an impairment of platelet function. Based on their binding profiles, some other TKIs are 
predicated to have an antiplatelet effect, although no bleeding side effects have been reported 
so far. For a third group of TKIs, no published data on platelets are available. Given the suspected 
role of platelets in tumour progression, platelet inhibition may be a clinically relevant side-effect 
of several TKIs. Together, the available knowledge asks for awareness of the potential antiplatelet 
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Pazopanib is an angiostatic tyrosine kinase inhibitor (TKI) presently used for cancer 
treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be 
accompanied by mild bleeding as an adverse effect. Given the role of protein tyrosine kinases 
in platelet activation processes, we investigated whether and how pazopanib can affect platelet 
functions in purified systems and during treatment of advanced RCC patients. In isolated 
platelets from healthy volunteers, pazopanib dose-dependently reduced collagen-induced 
integrin activation and secretion, as well as platelet aggregation. Pazopanib addition diminished 
glycoprotein (GP)VI-dependent tyrosine phosphorylation of multiple platelet proteins, including 
the tyrosine kinase Syk. Furthermore, pazopanib inhibited GPVI-induced Ca2+ elevation, resulting 
in reduced exposure of the procoagulant phospholipid phosphatidylserine (PS). Upon perfusion of 
control blood over a collagen surface, pazopanib inhibited thrombus size as well as PS exposure. 
Blood samples from ten RCC patients were also analysed before and after 14 days of pazopanib 
treatment as monotherapy. This treatment caused an overall lowering in platelet count, with three 
out of ten patients experiencing mild bleeding. Platelets isolated from pazopanib-treated patients 
showed a significant lowering of PS exposure upon activation. In addition, platelet procoagulant 
activity was inhibited in thrombi formed under flow conditions. Control experiments indicated 
that higher pazopanib concentrations were required to inhibit GPVI-mediated PS exposure in the 
presence of plasma. Together, these results indicated that pazopanib suppresses GPVI-induced 
platelet activation responses in a way partly antagonized by the presence of plasma. In treated 
cancer patients, pazopanib effects were confined to a reduction in GPVI-dependent PS exposure. 
Together with the reduced platelet count, this may explain the mild bleeding tendency observed 
in pazopanib-treated patients.
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Introduction
Tyrosine kinase inhibitors (TKIs) are widely approved drugs, aiming to target tyrosine kinase 
signalling pathways that regulate uncontrolled cellular growth and proliferation. Currently, several 
TKIs are in clinical use for the treatment of malignancies, such as lung, breast, kidney, and neuro-
endocrine pancreatic cancers as well as gastro-intestinal stromal tumours and chronic myeloid 
leukaemia1-3. Their common way of action is by competition with adenosine triphosphate (ATP) 
in the conserved catalytic binding site in the protein tyrosine kinase superfamily. In spite of this 
action mechanism, individual TKIs can target partially different spectra of intracellular tyrosine 
kinases, can have different pharmacokinetics, and vary in their adverse effects1. Commonly, TKIs 
are clinically applied as a multi-target therapy to intervene in tumour proliferation4, 5. Specific 
targets are the receptors for vascular endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF) and epidermal growth factor (EGF), which are all involved in (tumour) angiogenesis3, 
6. The expected effects are to reduce tumour lesions, delay disease development, and thus 
prolong the progression-free survival of patients7.
Platelets contain several protein tyrosine kinases as key signal transducers, which regulate 
the function of platelets in haemostasis8. Downstream of glycoprotein (GP)VI (collagen receptor), 
GPIb-IX-V (von Willebrand receptor) and CLEC-2 (podoplanin receptor), Src family tyrosine 
kinases control the signalling routes to most platelet responses8-10. Activation of GPVI also implies 
tyrosine phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) present 
on the Fc-receptor γ-chain, which is co-expressed with GPVI11. This results in activation of the 
protein tyrosine kinase Syk10, 12, and further downstream Bruton tyrosine kinase (Btk), culminating 
in the phosphorylation and activation of phospholipase Cγ2 (PLCγ2), an event required for 
integrin activation and granule secretion. A similar set of protein tyrosine kinases (Src-family 
kinases, Syk and JAK isoforms) is known to play a critical role in megakaryocyte development and 
thrombocytopoiesis13. 
Considering the role of protein tyrosine kinases in both platelet activation and platelet 
formation, it can be expected that treatment of patients with a broad-spectrum TKI affects 
haemostasis. Indeed, for several TKIs, anti-haemostatic effects have been reported, like anaemia, 
neutropenia, thrombocytopenia, and bleeding incidences14-19. In particular, the TKIs sunitinib, 
ibrutinib, and ponatinib may cause a bleeding risk that relates to impaired GPVI-induced signalling, 
platelet aggregation, and thrombus formation14, 15, 18. Also for other TKIs a decrease in platelet 
count has been described upon treatment18, 20-22. 
Pazopanib is currently used as a first-line therapy for advanced clear-cell renal cell 
carcinoma (RCC), the most common type of kidney cancer in adults. Pazopanib is aimed to target 
the VEGF and PDGF receptors, stem-cell factor receptor cKit and Flt-323. The inhibition of these 
receptors decreases tumour angiogenesis and growth, and hence prolongs patient survival24, 25. 
In vitro studies have indicated that pazopanib also inhibits several other tyrosine kinase-linked 
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receptors, including fibroblast growth factor receptor, IL-2 receptor inducible T-cell kinase 
(Itk), leukocyte-specific protein tyrosine kinase (Lck), and the glycoprotein receptor c-Fms24. In 
addition, other in vitro kinase targets of pazopanib have been described, of which ABL1, ABL2, 
FGR, Src, Fyn and Lck are present in platelets26, 27. Patients are commonly treated with a high daily 
dose of pazopanib (800 mg), resulting in a steady-state plasma concentration of up to 45 µg/mL 
after several weeks24. This treatment regimen can reduce the platelet count and lead to bleeding 
events24. Since effects of pazopanib on platelet function have not been reported, we aimed to 
investigate this in vitro and ex vivo, using blood from RCC patients and control subjects. 
Materials and Methods
Materials
Pazopanib (Votrient) was obtained from LC Laboratories (Woburn MA, USA). Arachidonic 
acid was obtained from Bio/DATA Corporation (Horsham PA, USA), fibrillar Horm type I collagen 
from Takeda (Hoofddorp, The Netherlands), thrombin from Enzyme Research Laboratories 
(South Bend IN, USA), thrombin receptor activating peptide 6 (TRAP-6) from Bachem (Bubendorf, 
Switzerland) and U46619 (thromboxane A2 receptor agonist) from Cayman Chemicals (Ann Arbor 
MI, USA). Fluorescein isothiocyanate (FITC)-labelled PAC-1 monoclonal antibody (mAb) against 
activated human integrin αIIbβ3 was from BD Bioscience (Franklin Lakes NJ, USA; nr. 340507), 
while FITC-labelled anti-human CD62 mAb was from Beckman Coulter (Sydney, Australia; nr. 
65050). Collagen-related peptide (CRP-XL) was obtained from the University of Cambridge 
(Cambridge, UK). 2Methylthio-adenosine-diphosphate (2Me-S-ADP), D-phenylalanyl-prolyl-
arginyl chloromethyl ketone (PPACK) and mouse anti-Syk antibody were purchased from Santa 
Cruz Biotechnology (Dallas TX, USA). Fibrinogen and unfractionated heparin were obtained 
from Sigma-Aldrich (Saint Louis MO, USA). FITC-labelled annexin A5 was from Pharmatarget 
(Maastricht, The Netherlands). Fura-2-AM was from Invitrogen (Carlsbad CA, USA); Pluronic F-127 
from Molecular Probes (Eugene OR, USA). For Western blotting, the following antibodies were 
used: mouse anti-phosphotyrosine mAb (clone 4G10) obtained from Millipore (Billerica MA, USA), 
rabbit anti-tubulin Ab from Abcam (Cambridge, UK), rabbit anti-phospho Syk Tyr525/526, HRP-
conjugated anti-rabbit-IgG from Cell Signalling, (Leiden, The Netherlands) and HRP-conjugated 
anti-mouse-IgG from VWR international (Amsterdam, The Netherlands).
Blood collection from patients and healthy volunteers
The study was approved by the medical ethics committee of the Maastricht University 
Medical Centre+ (MUMC+, The Netherlands). All participants provided written informed consent 
in accordance with the Declaration of Helsinki. Blood was obtained from healthy volunteers 
and ten patients diagnosed with metastatic renal cell carcinoma at the Department of Medical 
Oncology of MUMC+. Patients were included, if eligible for treatment with pazopanib as a single 
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agent (800 mg/day). Excluded were subjects who used anticoagulants or platelet inhibitory drugs. 
From healthy volunteers, one blood sample was collected, while the patients donated two blood 
samples: one day before and at 14 days after starting pazopanib treatment, i.e., when a steady-
state plasma concentration was reached24. Blood samples were collected from the antecubital 
vein into 3.2% trisodium citrate; the first 5 mL of blood was discarded after which 10 mL was 
collected.
Blood composition and platelet isolation
Haematological parameters, including platelet count, were determined with a Sysmex 
XP300 (Chuo-ku Kobe, Japan). Washed platelets were obtained as described28. In brief, platelet-
rich plasma (PRP) was collected after 15 minutes centrifugation at 240 g, followed by a washing 
step. Washed platelets were resuspended into Hepes buffer pH 7.45 [10 mM Hepes, 136 mM 
NaCl, 2.7 mM KCl, 2 mM MgCl2, 0.1% glucose and 0.1% bovine serum albumin (BSA)]. Platelet 
count was adjusted, as required for the particular assay.
Blood from healthy volunteers was used for in vitro experiments of pazopanib effects. 
Samples of whole blood, PRP or washed platelets were pre-incubated with pazopanib or vehicle 
(dimethylsulfoxide) for 10 minutes at 37°C.
Light transmission aggregometry
Aggregation of platelets, washed or in PRP (250x109 platelets/L) was measured using a 
Chronolog aggregometer (Havertown PA, USA) under constant stirring (37°C); pazopanib (5, 10 or 
30 μM) or vehicle was present as indicated. Aggregation responses were quantified as maximal 
amplitude in light transmission29. Aggregation of washed platelets was induced with collagen (1 
μg/mL), 2Me-S-ADP (1 μM) in the presence of fibrinogen (25 μg/mL), thrombin (1 nM), TRAP-
6 (10 μM), U46619 (1 μM), or arachidonic acid (10 μM). Aggregation of platelets in PRP was 
induced with collagen (1 μg/mL).
Flow cytometry
Washed platelets (100x109/L) were incubated for 10 minutes at 37°C with vehicle or 
pazopanib (10 μM). The cells in Hepes buffer pH 7.45 containing 2 mM CaCl2 were then stimulated 
with CRP-XL (1 μg/mL), 2Me-S-ADP (1 μM), or thrombin (1 nM). Using described flow cytometry 
procedures, integrin αIIbβ3 activation and P-selectin expression were determined with FITC-
conjugated PAC1 mAb (1:10) and FITC-conjugated anti-CD62P mAb (1:10), respectively30. For the 
measurement of PS exposure, platelets were stimulated with CRP-XL (5 μg/mL) and thrombin (4 




To assess PS exposure in the presence of plasma, platelet count of washed platelets or 
PRP were adjusted to 100x109 platelets/L. Washed platelet were diluted in Hepes buffer pH 7.45 
with 2 mM CaCl2; PRP was diluted with autologous plasma supplemented and 6.3 mM CaCl2 plus 
3.2 mM MgCl2. Washed platelets and PRP were mixed in various ratios to obtain 0, 10, 30, 50 and 
100% plasma. The mixed samples were preincubated with pazopanib (1, 5, 10, 30, 50, 75 or 100 
µM) or vehicle for 10 minutes at 37°C, and then activated with CRP-XL (5 µg/mL) and TRAP-6 (15 
µM) in the presence of PPACK (40 µM). Exposure of PS was determined after 60 minutes at 37°C 
with FITC-conjugated annexin A5 (1 μg/mL). Flow cytometric measurements were performed in 
duplicate using a BD Accuri C6TM flow cytometer and corresponding software (Erembodegem, 
Belgium).
Whole blood perfusion experiments
Whole blood perfusion experiments were performed as described before32. In short, citrate-
anticoagulated blood samples were incubated with pazopanib (30 μM) or vehicle for 10 minutes 
at room temperature. After recalcification in the presence of thrombin inhibitor (40 μM PPACK, 
6.3 mM CaCl2, 3.2 mM MgCl2, f.c.), the samples were perfused through a transparent parallel-
plate flow chamber, containing a coverslip coated with type I collagen (50 μg/mL) at a wall-shear 
rate of 1000 s-1. After 4 minutes, thrombi formed on coverslip were stained with FITC-conjugated 
annexin A5 (1 μg/mL in Hepes buffer pH 7.45, containing 2 mM CaCl2 and 1 U/mL heparin). At 
least 10 random brightfield and fluorescence images were captured with an EVOS microscope 
(Bothell WA, USA). Microscopic digital images were analysed for platelet deposition (% of surface 
area coverage, SAC), multilayer % SAC, integrated feature size and staining for PS (% SAC), using 
ImageJ 1.45s software (ImageJ ecosystem, from imagej.nih.gov/ij/). The integrated feature size 
is a parameter of platelet aggregation, taking into account the proportional contribution of large 
and small thrombi on microspots33. Further details of image analysis are described elsewhere34.
Cytosolic Ca2+ measurements
Washed platelets were incubated with Fura-2-AM (3 μM) in the presence of pluronic (600 
μM) for 45 minutes at 37°C. After another wash step, the Fura-2 loaded platelets (100x109/L) were 
used for cytosolic Ca2+ ([Ca2+]i) measurements, as described previously
35. In brief, using polystyrene 
cuvettes, platelets in suspension (0.5 mL) were pre-incubated with pazopanib (10 μM) or vehicle 
for 8 minutes at room temperature and 2 minutes at 37°C. After baseline measurement, CaCl2 (1 
mM) was added, followed by an agonist. Changes in Fura-2 fluorescence were measured by ratio 
fluorometry at dual excitation wavelengths of 340 and 380 nm and an emission wavelength of 
510 nm. After correction for background fluorescence, ratio values were converted into levels of 
[Ca2+]i. Maximal rises in [Ca
2+]i and [Ca
2+]i-time integrals (4 minutes) were determined
36.
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Western blotting
Washed platelets (500x109/L) were pre-incubated with pazopanib (10 or 30 µM) or vehicle 
and stimulated under stirring conditions with CRP-XL (5 μg/mL) or left unstimulated. Samples 
were lysed with NP40 lysis buffer, supplemented with a cocktail of phosphatase inhibitors, and 
protein content was determined using a BioRad protein assay (Hercules CA, USA). Platelet lysates 
were separated by polyacrylamide gel electrophoresis and subjected to standard western blotting. 
Blots were stained for tyrosine phosphorylation profile as described18, using anti-phosphotyrosine 
mAb 4G10 (1:2000) and secondary HRP-conjugated Ab (1:500). Specific phosphorylation of Syk 
was visualized, as described37, using anti-Syk Tyr525/526 mAb (1:1000) and secondary HRP-
conjugated secondary Ab (1:500). Total Syk was determined by reprobing with anti-Syk mAb 
(1:1000) and HRP-conjugated secondary Ab (1:1000). As a control for total platelet proteins, blots 
were also probed for α-tubulin (1:1000). The intensity of stained bands was analysed with ImageJ 
1.45s software.
Statistical analysis
Data were checked for Gaussian distribution using the Kolmogorov-Smirnov Normality test. 
Normally distributed data are presented as means ± SEM; data that are not normally distributed 
are presented as median ± interquartile ranges. Statistical significance between in vitro datasets 
(vehicle vs. pazopanib-treated samples) was determined using paired t-test. Paired datasets of 
the patients (before and after pazopanib therapy) were compared using the Wilcoxon matched-
pairs signed-rank test. When more than 2 conditions were compared, a one-way ANOVA was 
used. GraphPad Prism 5.0 software (La Jolla CA, USA) was used for statistical analyses. A P-value 
less than 0.05 was considered to be statistically significant.
Results
Pazopanib in vitro suppresses collagen- and ADP-induced platelet aggregation, secretion 
and PS exposure
Platelet activation in haemostasis involves multiple agonists and their receptors38. 
Adhesion of platelets to extracellular matrix proteins, like collagen, is followed by platelet 
activation (characterized by integrin αIIbβ3 activation and secretion), aggregation (via released 
ADP and thromboxane A2) and thrombus formation. Highly activated platelets also expose the 
procoagulant phospholipid PS, which promotes thrombin generation and fibrin formation39, 40. 
We first investigated the effect of pazopanib on the aggregation response of washed platelets 
to collagen (acting via GPVI) or ADP (acting via P2Y receptors). Dose-response curves indicated 
near-complete inhibition with either agonist already at a relatively low dose of 10 µM pazopanib 
(Figure 3.1A). In following experiments, the concentration of 10 µM appeared to suppress platelet 
aggregation with ADP, arachidonic acid and U46619 (thromboxane A2 analogue). On the other 
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hand, platelet aggregation induced by thrombin or the PAR1 receptor agonist, TRAP-6, was not 
affected by pazopanib at this dose (Figure 3.1B).
Subsequently, flow cytometry was used to determine the effects of pazopanib on specific 
platelet responses, i.e. integrin αIIbβ3 activation and α-granule secretion (P-selectin expression). 
Markedly, pazopanib at 10 µM strongly inhibited integrin activation and granule secretion induced 
by the GPVI receptor agonist (CRP-XL), with no or limited effect in response to ADP or thrombin 
stimulation (Figure 3.1C). Pazopanib also reduced CRP-XL plus thrombin-induced PS exposure by 



























































































































































































































Figure 3.1. Pazopanib inhibits collagen- and ADP-induced platelet aggregation, integrin activation, secretion and PS 
exposure. Washed platelets from healthy donors were incubated with 1, 10, or 30 μM pazopanib or vehicle (0.1% DMSO) 
for 10 minutes. (A) Representative aggregation curves and dose-response graphs of inhibition of aggregation (n = 4). 
Arrow indicates addition of (i) 1 μg/mL collagen or (ii) 25 μg/mL fibrinogen and 1 μM Me-S-ADP. (B) Aggregation of washed 
platelets in presence (black bars) or absence (white bars) of 10 μM pazopanib was induced by 1 μg/mL collagen, 1 nM 
thrombin, 10 μM TRAP-6, 1 μM Me-S-ADP in presence of 25 μg/mL fibrinogen, 30 μM arachidonic acid or 1 μM U46619. 
Histograms indicate maximal amplitude of aggregation (n = 6). (C) Platelets, pre-treated with vehicle or pazopanib (10 μM), 
were stimulated with 5μg/mL CRP-XL, 1μM Me-S-ADP or 1 nM thrombin for 10–20min, and analysed by flow cytometry (n 
= 6). Shown are percentages of platelets binding FITC-labelled PAC-1 monoclonal antibody against integrin aIIbb3 or FITC-
labelled anti-human CD62 mAb. (D) Platelets pre-treated with vehicle or pazopanib (10μM) were stimulated with 5 μg/
mL CRP-XL and 4 nM thrombin for 60 minutes, and analysed by flow cytometry (n = 6). Exposure of PS was determined 
by FITC-labelled annexin A5. Histogram shows percentages of platelets binding FITC-annexin A5. Data are means ± SEM, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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an efficient antagonist of platelet responses induced by GPVI agonists (collagen or CRP-XL), but is 
less effective in antagonizing responses induced by the G-protein coupled receptor agonists ADP, 
thromboxane A2 or thrombin.
Pazopanib inhibits phosphorylation of Syk, and reduces platelet Ca2+ responses
The decreased platelet responses to GPVI agonists suggested that pazopanib 
influences platelet signalling via the tyrosine kinase-operating ITAM pathway. To 
investigate this in more detail, we assessed the effect of pazopanib on protein 
tyrosine phosphorylation patterns of GPVI-stimulated platelets using western blotting. 
Pre-incubation of 500x109 platelets/L with 30 µM pazopanib (i.e., equivalent to 15 µM for 250x109 
platelets/L, used for aggregation experiments) strongly reduced the CRP-XL induced tyrosine 
phosphorylation of multiple proteins (Figure 3.2A). This suggested interference of pazopanib 
early in the GPVI signalling cascade. This was confirmed by the finding that pazopanib strongly 
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Figure 3.2. Pazopanib inhibits GPVI-induced protein tyrosine phosphorylation via Syk and cytosolic Ca2+ rises. (A,B) 
Representative western blots (n=4) with washed platelets (500×109/L) incubated with vehicle or pazopanib (10 or 30 μM) 
for 10 minutes, and stimulated with 5 μg/mL CRP-XL for 3 minutes. For comparison to Figure 1, pazopanib concentrations 
were re-calculated to match a platelet concentration of 250×109/L. (A) Protein tyrosine phosphorylation was visualized 
with 4G10 mAb. Total amount of protein was visualized by staining for a-tubulin. (B) Protein phosphorylation of Syk 
(Tyr525/526) and Syk, and parallel staining for a-tubulin. Shown is the ratio of phospho-Syk/total Syk assessed by gray 
intensity analysis (n=4). (C) Representative traces of changes in cytosolic Ca2+ of Fura-2-loaded platelets (100×109/L), pre-
incubated with vehicle or 10 μM pazopanib for 10 minutes, and stimulated with 1 μg/mL CRP-XL or 1 nM thrombin in the 
presence of 1 mM CaCl2. (D) Histograms show maximal rise in [Ca
2+]i and total [Ca
2+]i (area-under-curve, AUC) (n=5). Data 
are means ± SEM, **p<0.01, ***p<0.001.
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GPVI signalling via Syk results in elevation of intracellular Ca2+ levels ([Ca2+]i) as a prerequisite 
for integrin activation, secretion and PS exposure. To investigate this, platelets were loaded with 
the Ca2+ probe Fura-2, and agonist-induced responses were measured. In platelets stimulated 
with CRP-XL, the presence of pazopanib resulted in a reduction of the maximal (peak height) and 
total (area-under-curve) Ca2+ rises (Figure 3.2C-D). Pazopanib did however not influence [Ca2+]i 
elevation in response to thrombin stimulation (not shown). These results confirm that pazopanib 
interfered in the early GPVI-induced signalling cascade. 
Pazopanib affects thrombus size and PS exposure in whole blood under flow
Platelet activation via GPVI is an essential step in collagen-induced thrombus formation in 
whole blood under flow conditions41. This method was used to determine the effect of pazopanib 
on platelets in a whole blood environment. Pre-incubation of blood with 30 µM pazopanib 
resulted in a small, but significant decrease in platelet deposition compared to vehicle-treated 
blood (Figure 3.3A-B). Furthermore, the height of thrombi with multi-layered platelets was 
reduced with pazopanib (Figure 3.3C). The aggregate-reducing effect was confirmed by measuring 
the size distribution of thrombi (integrated feature size), which was significantly decreased after 
treatment of the blood with pazopanib (Figure 3.3D). Post-staining with fluorescently labelled 
annexin A5 indicated a lower PS exposure (Figure 3.3E), as in agreement with the flow cytometric 




























































































Figure 3.3. Pazopanib suppresses thrombus formation in whole blood perfused over collagen. Whole blood from 
healthy volunteers was perfused for 4 minutes at wall shear rate of 1,000 s−1 over microspots containing collagen-I. 
(A) Representative brightfield images (upper panel) and fluorescence images of PS exposure (lower panel) of control 
blood sample incubated with 30μM pazopanib. Bar=20 μm. (B–E) Quantification (n=6) of brightfield images of: platelet 
deposition (B), multilayered thrombus (C), cumulative size of thrombus (integrated feature size) (D), and fluorescence 
images of staining for PS exposure (E). Data are means ± SEM (n = 6), *p < 0.05, **p < 0.01.
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Pazopanib treatment of renal cell carcinoma patients moderately affects platelet 
functions
To investigate the clinical relevance of these findings, blood samples were obtained from 
ten patients diagnosed with metastatic RCC, and eligible for pazopanib treatment (Table 3.1). The 
patients (6 females) had a mean age of 69 (range: 51-88) years. Blood samples were collected at 
one day prior and at 14 days after the start of pazopanib treatment. Median platelet count in the 
patients’ blood before start of treatment was 230x109/L, while this moderately, but significantly 
reduced to 201x109/L after treatment (Figure 3.4A). Bleeding complications were reported for 
three patients, who all developed mild epistaxis (Table 3.1). 
Using washed platelets from patients before and after pazopanib treatment, aggregation 
was determined by light transmission aggregometry. Strikingly, no treatment effect could be 
observed upon collagen stimulation (Figure 3.4B). Flow cytometry was used to assess αIIbβ3 
integrin activation and secretion upon stimulation with CRP-XL, ADP or thrombin. Again, no effect 
of the treatment on these platelet responses could be observed (Figure 3.4C). On the other 
hand, platelet procoagulant activity, as determined from PS exposure in response to CRP-XL plus 
thrombin, was significantly decreased by 18% after treatment (Figure 3.4D). 
In whole blood flow experiments over collagen, parameters of thrombus formation were 
investigated before and after pazopanib treatment. Whereas platelet deposition and thrombus 
buildup were not affected in the post-treatment blood samples (Figure 3.5A-D), a significant 
reduction of 48% was seen in PS exposure in the post-treatment samples, as compared to pre-
treatment (Figure 3.5A, E).
Plasma impairs pazopanib effects on platelet function
In isolated platelets we observed a dose-dependent inhibiting effect of pazopanib 
on platelet function via the inhibition of tyrosine phosphorylation of Syk, and downstream 
intracellular Ca2+ signalling. This was accompanied by reduced integrin activation, secretion and PS 







day 14 (x109/L) Bleeding
1 56-60 238 183 No
2 61-65 222 212 No
3 71-75 175 107 Yes, epistaxis
4 61-65 212 189 No
5 66-70 217 219 Yes, epistaxis
6 81-85 443 288 Yes, epistaxis
7 66-70 402 130 No
8 51-55 295 249 No
9 76-80 274 276 No
10 81-85 179 139 No
Table 3.1. Characteristics of patients treated with pazopanib 800 mg/day.
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PS exposure. We hypothesized that the presence of plasma can interfere with the antiplatelet 
activity of pazopanib. To investigate this, experiments were performed with both PRP and washed 
platelets, which were incubated with different concentrations of pazopanib. In undiluted PRP, 
collagen-induced aggregation was not affected by pazopanib, whereas this response was strongly 
inhibited at 10 µM in washed platelets (Figure 3.6A). Pre-incubation of PRP with increasing doses 
of pazopanib until 20 µM did not inhibit PS exposure, in contrast to pre-incubation of washed 
platelets (Figure 3.6B). 
It has been described that pazopanib is highly bound by plasma proteins at concentration 
ranges of 10-100 µg/mL24. This corresponds with a concentration of 23-230 µM. Hence, also 










































































































































Figure 3.4. Treatment of carcinoma patients with pazopanib decreased platelet count and suppressed 
phosphatidylserine exposure in washed platelets. Blood from patients was collected the day before and at 2 weeks 
after pazopanib treatment. (A) Platelet count was measured in blood from RCC patients before and on treatment with 
pazopanib. Each dot represents a single patient. (B) Platelets were isolated and aggregation was induced by 1μg/mL 
collagen, 1μM Me-S-ADP (in the presence of 25μg/mL fibrinogen), or 1 nM thrombin. Histograms indicate maximal 
amplitude of aggregation (n = 6). (C) Platelets before and during treatment of patients were stimulated with 5μg/mL CRP-
XL, 1μM 2Me-S-ADP or 1 nM thrombin for 10–20min, and analyzed by flow cytometry (n = 10). Shown are percentages of 
platelets binding FITC-PAC1 mAb (aIIbb3 expression) or FITC-anti-CD62P mAb (P-selectin expression). (D) Patient platelets 
were stimulated with 5 μg/mL CRP-XL and 4 nM thrombin for 60min, and analyzed by flow cytometry (n = 6). Histogram 
shows percentages of platelets binding FITC-annexin A5 (PS exposure). Data are medians ± interquartile ranges, *p<0.05, 
**p<0.01.
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Figure 3.5. Treatment of pazopanib patients suppressed phosphatidylserine exposure upon thrombus formation on 
collagen. (A) Whole blood from patients was perfused for 4min at wall shear rate of 1,000 s−1 over a collagen surface. 
Shown are representative brightfield images (upper panel) and fluorescence images of PS exposure (lower panel) for 
blood samples taken before and after 2 weeks of pazopanib treatment. Bar=20 μm. (B–E) Quantification of brightfield 
images of platelet deposition (B), multilayered thrombus (C), cumulative size of thrombus (integrated feature size, IFS) 

















































































































































































Figure 3.6. Plasma suppresses effects of pazopanib on platelet activation in vitro. Washed platelets or PRP from healthy 
donors were incubated with 1, 5, 10, or 30 μM pazopanib or vehicle (0.1% DMSO) for 10 minutes. (A) Aggregation of 
platelets in buffer or PRP in response to 1 μg/mL collagen. (B) Exposure of PS measured in washed platelets or in PRP, 
stimulated with 5 μg/mL CRP-XL and 4 nM thrombin for 60 minutes, and analyzed by flow cytometry using FITC-labeled 
annexin A5. (C) Platelets reconstituted at different plasma concentrations were pre-incubated with pazopanib (1–100 
μM), and stimulated with 5 μg/mL CRP-XL plus 15 μM TRAP-6; PS exposure was quantified by flow cytometry using FITC-
labeled annexin A5 (PS exposure). Data are means ± SEM (n=3), *p<0.05, **p<0.01, ****p<0.0001.
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plasma concentrations (0, 10, 30, 50 or 100% plasma). It appeared that pazopanib treatment 
substantially suppressed PS exposure in response to CRP-XL plus TRAP-6 in the presence of low 
amounts of plasma (Figure 3.6C). However, at 100 µM pazopanib, PS exposure was still significantly 
reduced by 25% with 30-100% plasma (Figure 3.6C, p<0.01). This effect is comparable to the 
moderate inhibition of PS exposure in patients treated with pazopanib (see Figure 3.4D). These 
results suggest that the presence of plasma interferes with the incorporation of pazopanib into 
platelets. 
Discussion
In the present study, we demonstrate that the multi-target TKI pazopanib markedly 
reduces the collagen-induced activation responses of isolated platelets, including aggregation, 
PS exposure and Ca2+ signalling through inhibition of tyrosine kinases, including Syk. In blood 
samples from RCC patients treated with pazopanib, these effects were confined to a suppression 
of GPVI-mediated PS exposure, observed in isolated platelets as well as in whole blood thrombus 
formation under flow.
Several protein tyrosine kinases are known to contribute to platelet activation processes 
and haemostasis8, 10, 11. An activity-based kinase profiling already showed that pazopanib can target 
various tyrosine kinases that are highly expressed in platelets42. Here we confirm that, in washed 
platelets, the GPVI-dependent phosphorylation of multiple proteins, including Syk, is suppressed 
by pazopanib, in a way accompanied by reduced platelet activation processes. Syk is known to 
have multiple sites of phosphorylation which both regulate activity and serve as docking motifs 
for other proteins43. These sites include Tyr-348 and Tyr-352 within the SH2-linker region, Tyr-525 
and Tyr-526 within the activation loop of the kinase domain, Tyr-630 in the C terminus of Syk, 
and other sites such as Thr-384 and Ser-297. It has been shown that Tyr-525/526 is essential for 
Syk function44. Therefore, we selected this phosphorylation site to study the effect of pazopanib 
on platelet function. However, from the present data it cannot be concluded whether pazopanib 
inhibits Syk directly, or if its phosphorylation is reduced through inhibition of upstream tyrosine 
kinases. Most likely, it can be both as pazopanib has been shown to have affinity for multiple 
TKs in platelets. We have observed that the Syk inhibitor II completely inhibits PS-exposure in 
washed platelets37, which was much stronger than the inhibitory effect of pazopanib (Figure 
3.1D). Furthermore deficiency and selective inhibition of Syk has been shown to prevent platelet 
aggregation and activation in response to collagen-receptor stimulation in mice45. 
Interestingly, pazopanib also suppressed platelet responses to ADP, arachidonic acid and 
TxA2 analogue, while responses to thrombin were unaffected. In agreement with this is the recent 
finding that three tyrosine kinases are phosphorylated upon platelet activation with ADP using 
phosphoproteomics46. These are JAK3, Btk and TNK2, indicating TKs are involved in signalling 
underneath ADP. Whether TKs are also phosphorylated under AA and thromboxane A2 receptor 
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stimulation has not yet been investigated with phosphoproteomics, but this is not unlikely. 
Although it appears that the majority of the targets of pazopanib are underneath GPVI, these data 
indicate that pazopanib may also target kinase events downstream of other platelet receptors. 
Moreover, as it has been shown that inhibition of GPVI alone prevents occlusive thrombus 
formation without causing bleeding47, these results support the hypothesis that the targeting of 
pathways downstream of additional receptors may be responsible for the increased bleeding risk 
with pazopanib treatment.
Pazopanib is known to have an extremely high plasma protein binding compared to other 
TKIs24, 48. Therefore, we explored if the presence of blood plasma affected its inhibitory effect on 
platelet responses. Upon increasing plasma concentrations, it appeared that the inhibition of 
collagen-induced aggregation became lost at pazopanib concentrations up to 100 μM, whereas 
the inhibition of PS exposure was still present albeit diminished. Albumin, as a major plasma 
protein (about 55% of plasma proteins) present at 35-50 mg/mL49, is considered to be the main 
pazopanib-binding plasma component50. This is in agreement with the residual, but consistent 
inhibition of PS exposure observed in the platelets from patients treated with pazopanib, as well 
as in whole blood thrombus formation under flow.
Patients with advanced RCC are commonly treated with 800 mg pazopanib per day. 
The reported steady state, maximal concentration here is 45 µg/mL51, which corresponds to a 
concentration of 100 µM. In phase III trials, pazopanib effectively delays disease progression and 
reduces tumour lesions25, 52. In spite of the only partial response rate25, the affinity of pazopanib 
for VEGF and PDGF receptors is relatively high42, and likely is higher than that for the intracellular 
tyrosine kinases implicated in platelet activation. This may explain why the pazopanib dose used 
for effective cancer treatment does not completely abolish platelet activation processes, but only 
platelet procoagulant activity (PS exposure), i.e. a response that is most sensitive to inhibition of 
the cytosolic Ca2+ rises. 
We and others24 observed a moderate decrease in platelet count upon pazopanib 
treatment. This by itself is not expected to result in bleeding, with values still within the 
normal range of 150–400x109 platelets/L53. This effect may suggest interference in platelet 
formation (megakaryocytopoiesis). This has not been reported so far, but there is evidence that 
megakaryocytic signalling via Src family and Syk kinases is required for megakaryocyte migration, 
and platelet formation13.
The combination of a reduced platelet count and impaired PS exposure may explain the 
mostly minor bleeding events observed during pazopanib treatment. In the present study, this held 
for three out of ten patients, all experiencing epistaxis. This number is relatively high compared 
to a published clinical trial, reporting mild bleeding in only 13% of the patients24. However, we 
like to note that the power of our study is low. Mild bleeding has also been reported with the 
use of other TKIs in cancer therapy18, 19. Ibrutinib – affecting collagen- and von Willebrand factor-
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dependent platelet functions54 – can cause a risk of mild bleeding in about half of the treated 
patients, whilst 4-8% of these experiencing major haemorrhages14. Treatment with the drug 
ponatinib resulted in a prolonged PFA-100 closure times in patients’ blood samples, indicating 
a loss of platelet function15. Bleeding occurred here in about 10% of the patients, who however 
occasionally used other anticoagulants or antiplatelet drugs55. Treatment with the TKI dasatinib 
was associated with mild thrombocytopenia and an increased risk of bleeding, likely due to 
combined effects on megakaryocytes and platelets56. Also in the latter case, the patients’ platelets 
were less responsive to collagen stimulation, resulting in decreased thrombus formation57. To 
take this further, we recently reviewed how distinct TKIs inhibit platelet activation mechanisms, 
as well as the clinical consequences of antiplatelet effects due to TKI treatment58. Comparison of 
affinity profiles of TKIs for platelet targets, as well as literature regarding effects on platelet count, 
platelet function and bleeding, enabled us to distinguish three categories of TKIs. (i) For several 
TKIs the bleeding tendency is linked to a lowering of platelet count and/or an impairment of 
platelet function, (ii) other TKIs are predicated to have an antiplatelet effect, although no bleeding 
side effects have been reported so far, and (iii) for some TKIs no published data on platelets are 
available.
In comparison to pazopanib, treatment of RCC patients with sunitinib was found to result 
in a more profound inhibition of platelet activation18. Sunitinib is taken up by platelets, and can 
thus effectively reduce collagen-receptor induced aggregation and thrombus formation18. A 
comparative study of sunitinib versus pazopanib treatment indicated that both drugs provided 
a progression-free survival benefit when compared to placebo; however, pazopanib had a better 
safety and quality-of-life profile52. Sunitinib causes bleeding in up to 20% of patients, and life-
threatening bleeding in 3% of the patients16. As indicated above, for pazopanib these numbers are 
lower, but still non-negligible24. Accordingly treatment of metastatic RCC with either pazopanib 
or sunitinib should be accompanied by special attention of the haemostatic condition, especially 
when the patients are also treated with antiplatelet drugs. 
In summary, the present work demonstrates that platelet treatment with pazopanib 
in vitro results in strong inhibition of collagen-induced platelet activation, aggregation and PS 
exposure, whereas pazopanib treatment of RCC patients is restricted to inhibition of the platelet 
procoagulant activity. In combination with the reduction in platelet count, these effects are likely 
to contribute to the higher bleeding tendency in pazopanib treated RCC patients. Therefore, anti-
platelet effects of TKIs should be taken into account in therapy decisions for patients, especially 
when prescribed in combination with antiplatelet drugs.
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Background: Sunitinib is a multi-target tyrosine kinase inhibitor (TKI) used for cancer 
treatment. In platelets, sunitinib affects collagen-induced activation under non-coagulating 
conditions. We investigated (i) the effects of sunitinib on thrombus formation induced by other 
TK-dependent receptors, and (ii) the effects under coagulating conditions. Cardiovascular disease 
is a co-morbidity in cancer patients, resulting in possible aspirin treatment. Sunitinib and aspirin 
are associated with increased bleeding risk, and therefore we also investigated (iii) the synergistic 
effects of these compounds on thrombus and fibrin formation.
Methods: Blood or isolated platelets from healthy volunteers or cancer patients were 
incubated with sunitinib and/or aspirin or vehicle. Platelet activation was determined by TK 
phosphorylation, flow cytometry, changes in [Ca2+]i, aggregometry and whole blood perfusion 
over multiple surfaces, including collagen with(out) tissue factor (TF) was performed. 
Results: Sunitinib reduced thrombus formation and phosphatidylserine (PS) exposure 
under flow on collagen type I and III. Also, sunitinib inhibited GPVI-induced TK phosphorylation 
and Ca2+ elevation. Upon TF-triggered coagulation, sunitinib decreased PS exposure and fibrin 
formation. In blood from cancer patients more pronounced effects of sunitinib were observed 
in lung and pancreatic as compared to neuroglioblastoma and other cancer types. Compared to 
sunitinib alone, sunitinib plus aspirin further reduced platelet aggregation, thrombus formation 
and PS exposure on collagen under flow with(out) coagulation. 
Conclusions: Sunitinib suppresses collagen-induced procoagulant activity and delays fibrin 
formation, which was aggravated by aspirin. Therefore, we urge for awareness of the combined 
antiplatelet effects of TKIs with aspirin, as this may result in increased risk of bleeding.
Visual abstract
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Introduction
Treatment of cancer patients with sunitinib results in anticancer effects and improves 
progression free survival1, 2. Sunitinib is a broad-spectrum tyrosine kinase inhibitor (TKI), affecting 
not only tumour cells, but also the blood vessel wall3. A side effect of sunitinib treatment is mild 
bleeding (mainly epistaxis, and mucocutaneous and gastrointestinal bleeding, which occurs 
in approximately 19% of sunitinib-treated patients)3. Fortunately, in the majority of cases, the 
effects on haemostasis remain sub-clinical.
Platelets contribute to haemostasis by signalling pathways involving multiple protein 
tyrosine kinases (TKs) such as Syk, Btk and Src family kinases (SFKs)4. We and other authors 
have previously shown that sunitinib is sequestered by platelets, which affects collagen-induced 
platelet function under non-coagulating conditions5, 6. TKs do not only signal under the collagen 
receptor glycoprotein (GP)VI, but also under the receptors GPIb, CLEC-2 and integrins α6β1 and 
αIIbβ3 that bind von Willebrand factor (vWF), podoplanin, laminin and fibrinogen, respectively
4. 
The effects of sunitinib on thrombus formation stimulated via these receptors has not been 
studied. Furthermore, the question arises whether the suppression of collagen-induced thrombus 
formation is also present under physiological conditions of coagulation.  
The link between cancer and arterial thrombosis has been well-established7, 8. Cancer 
patients with a cardiovascular history receive treatment with anti-platelet drugs like aspirin to 
prevent recurrent events. Aspirin irreversibly inhibits platelet activation and is associated with an 
increased bleeding risk9 by preventing the formation of thromboxane A2 (TxA2)
10. TxA2 acts as an 
important soluble agonist released by platelets upon GPVI stimulation. In this respect, aspirin and 
other platelet-targeted pharmacologic treatments are under investigation as adjuvant anti-cancer 
therapy11, 12. The combined effects of these drugs on platelet function have not been investigated 
thus far. 
The aim of the present study was to further investigate the effect of sunitinib on thrombus 
formation by stimulation with multiple agonists, as well as under coagulating conditions stimulated 
by collagen plus TF. Furthermore, we assessed whether treatment with sunitinib in combination 
with aspirin increasingly inhibited collagen-induced thrombus formation as compared to either 
compound alone. The results indeed show an enhancing effect of this dual treatment of platelets 
with sunitinib and aspirin on collagen-induced platelet phosphatidylserine (PS) exposure and 
ensuing fibrin formation. Finally, platelet-dependent fibrin formation in whole blood from cancer 
patients was significantly inhibited by sunitinib. 
Materials and Methods
Materials
Sunitinib malate (Sutent) was provided by Pfizer (New York NY, USA). Aspirin, bovine 
serum albumin (BSA), D(+)-glucose, unfractionated heparin, and apyrase were purchased from 
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Sigma-Aldrich (Saint Louis MO, USA). The agonists collagen-related peptide crosslinked (CRP-XL) 
and Von Willebrand factor III (vWF-III) were obtained from CambCol Laboratories (Cambridge, 
UK), whereas thrombin was obtained from Enzyme Research Laboratories (South Bend IN, USA) 
and Horm collagen type I from Takeda (Hoofddorp, The Netherlands). 2-Methylthio-adenosine-
diphosphate (2MeS-ADP) and D-phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK) were 
obtained from Santa Cruz Biotechnology (Dallas TX, USA). Recombinant human TF (Innovin) 
was purchased from Dade Behring (Deerfield IL, USA). Laminin came from Octapharma (Berlin, 
Germany). Fura-2-AM was obtained from Invitrogen (Carlsbad CA, USA). Plastic syringes and 
fluorescein isothiocyanate (FITC)-labelled PAC1 monoclonal antibody (mAb) against activated 
human integrin αIIbβ3 were purchased from BD Bioscience (nr. 340507; Franklin Lakes NJ, USA), 
while FITC-conjugated α-fibrinogen mAb was purchased from DAKO (F0111; Santa Clara CA, USA). 
Alexa Fluor (AF) 647-labelled CD62-P mAb was obtained from Biolegend (London, UK), whereas 
the FITC-labelled anti-human CD62-P mAb was obtained from Beckman Coulter (nr. 65050; 
Sydney, Australia). 3,3-dihexyloxacarbocyanine iodide (DiOC6) was purchased from Anaspec 
(Reeuwijk, The Netherlands). FITC-conjugated annexin A5 was from Pharmatarget (Maastricht, 
The Netherlands). AF568-conjugated annexin A5 and AF647-labelled fibrinogen were purchased 
from Molecular Probes, Life Technologies (New York NY, USA). 
Blood collection and platelet isolation
With approval from the medical ethics committee from the Maastricht University Medical 
Centre+ (MUMC+) and informed consent in accordance with the Declaration of Helsinki, blood was 
collected from healthy volunteers. Furthermore, blood was collected from 11 patients diagnosed 
with several cancer types (lung, pancreas, neuroglioblastoma, ovarian or paraganglioma) at the 
University Hospital of Padua (Italy), also with approval of the local medical ethical committee and 
after informed consent. Blood was collected in 3.2% trisodium citrate tubes by venipuncture, 
after discarding the first 3 mL of blood. Platelets, plasma or serum were isolated from whole 
blood as described previously13. Whole blood or isolated platelets were incubated with either 
vehicle or sunitinib (10 or 30 µM as indicated) for 10 minutes at room temperature (unless stated 
otherwise) before measurements.
Flow cytometry
Washed platelets (100x109 platelets/L) were supplemented with 2 mM CaCl2 and 
stimulated by a combination of CRP-XL (5 μg/mL) and thrombin (4 nM) for 1 hour at 37°C. 
Phosphatidyl-serine (PS) exposing platelets were labelled with FITC-conjugated annexin A5 and 
measured by flow cytometry using a BD Accuri C6TM flow cytometer and accompanying software 
(Erembodegem, Belgium).
65
Sunitinib and aspirin in platelet-induced coagulation
4
Cytosolic Ca2+ measurements
Cytosolic Ca2+ ([Ca2+]i) measurements in Fura-2 loaded platelets (200x10
9 platelet/L) were 
performed as described using a Shimadzo RF-5001PC spectrofluorophotometer (Kyoto, Japan)14. 
Levels of [Ca2+]i were determined by the conversion of ratio values
15 with correction for background 
fluorescence and maximal values of [Ca2+]i (peak level) were used as output. 
Light transmission aggregometry
Washed platelets or PRP (250x109 platelets/L) were incubated with vehicle or sunitinib (10 
or 30 µM as indicated) for 10 minutes at 37°C. Where indicated, aspirin (100 µM) was incubated 
in PRP for 30 minutes at 37°C before further platelet isolation. Platelet aggregation was induced 
by collagen type I (5 µg/mL), 2MeS-ADP (1 µM) or thrombin (1 nM) and aggregation responses 
were measured using a Chronolog optical aggregometer (Havertown PA, USA) and maximum 
amplitude was quantified.
Pam-Gene kinase assay
Washed platelets (500x109 platelets/L) were pretreated with vehicle (control) or 30 μM 
sunitinib for 10 minutes at 37°C and were subsequently stimulated with 5 μg/mL CRP-XL in the 
presence of 2 mM CaCl2. Unstimulated, resting platelets served as control. After 90 seconds of 
stimulation, samples were lysed by adding 1:1 M-PER Mammalian Extraction Buffer containing 
Halt Phosphatase Inhibitor and EDTA-free Halt Protease Inhibitor Cocktail (1:100 each; Thermo 
Fischer Scientific). Samples were lysed for 15 minutes on ice and afterwards centrifuged for 15 
minutes at 10,000 g at 4°C. Supernatants were collected and protein content was quantified with 
a BioRad DC protein kit (Hercules CA,  USA). 
Tyrosine kinase profiles were determined using the PamChip® peptide tyrosine kinase 
microarray system on PamStation®12 (PTK; PamGene International, ´s-Hertogenbosch, The 
Netherlands). Each PTK-PamChip® array contains 144 individual phospho-site(s) that are peptide 
sequences derived from substrates for TKs. Each peptide on the chip builds a 15-amino acid 
sequence representing a putative endogenous phosphorylation site which functions as a TK 
substrate. The phosphorylation of the peptides is visualized by detection of the fluorescent signal 
which is emitted as a result of the binding of the FITC-conjugated PY20 anti-phosphotyrosine 
antibody. 
For the PTK assay, 7.5 µg of protein was applied per array (N=3  per condition) and carried 
out using the standard protocol supplied by Pamgene. All reagents used for PTK activity profiling 
were supplied by Pamgene International B.V. Initially, to prepare the PTK Basic Mix, the freshly 
frozen lysate was added to 4 µL of 10x protein PTK reaction buffer (PK), 0.4 µL of 100x BSA, 0.4 µL 
of 1 M dithiothreitol (DTT) solution, 4 µL of 10x PTK additive, 4 µL of 4 mM ATP and 0.6 µL of 
monoclonal anti-phosphotyrosine FITC-conjugate detection antibody (clone PY20). Total volume 
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of the PTK Basic Mix was adjusted to 40 µL by adding distilled water (H20). Before loading the PTK 
Basic Mix on the array, a blocking step was performed applying 30 µL of 2% BSA to the middle of 
every array and washing with PTK solution for PamChip® preprocessing. Next, 40 µL of PTK Basic 
Mix were applied to each array of the PamChips®. Then, the microarray assays were run for 94 
cycles. An image was recorded by a CCD camera PamStation®12 at kinetic read cycles 32–93 at 
10, 50 and 200 ms and at end-level read cycle at 10, 20, 50, 100 and 200 ms. The spot intensity 
at each time point was quantified (and corrected for local background) using the BioNavigator 
software version 6.3 (PamGene International, 's-Hertogenbosch, The Netherlands). Upstream 
Kinase Analysis (UKA)16, a functional scoring method (PamGene) was used to rank kinases based 
on combined specificity scores (based on peptides linked to a kinase, derived from 6 databases) 
and sensitivity scores (based on treatment-control differences).
Whole blood perfusion experiments with(out) coagulation and quantification
Whole blood perfusion experiments without coagulation were performed as described 
before17.  Platelet activation properties were determined by staining for integrin activation, 
P-selectin expression and PS exposure using FITC-conjugated α-fibrinogen mAb (1:80), AF647-
conjugated CD62-P (1:100), and AF568-conjugated annexin A5 (1:200). 
Whole blood perfusion experiments under coagulating conditions were performed as 
described before18. Platelet activation properties were determined by supplementing blood 
samples with AF647-fibrinogen (16.5 µg/mL f.c), DiOC6 (0.5 µg/mL f.c.), and AF568-Annexin A5 
(1:200).
Image capturing was performed using an EVOS microscope (Life Technologies, Carlsbad 
CA, USA). All images were analysed using specific (half-automated) scripts in the open-access Fiji 
software (Laboratory for Optical and Computational Instrumentation, University of Wisconsin-
Madison WI, USA) as described17. For comparative data analysis heatmaps were generated from 
the mean values per parameter for each surface, which were scaled to a range from 0-10 based 
on the highest value per parameter. In order to visualize effects more clearly, scaled data were 
subtracted from control data to obtain subtraction heatmaps. The effects in subtracted heatmaps 
were filtered based on significant differences or 1x standard deviation as indicated. 
Statistical analysis
Data are presented as mean ± SEM. GraphPad Prism 8.3.0 software (La Jolla CA, USA) 
was used for statistical analyses, using the paired and nonparametric Wilcoxon test to compare 
means of 2 parallel experimental conditions and one-way non-parametric Anova (Kruskal-Wallis) 
for experiments with more than 2 conditions. In case of multiple experimental conditions and 
timepoints, a nonparametric 2-way Anova was used. A p-value less than 0.05 was considered 
statistically significant in which * is p<0.05; ** is p<0.01 and *** is p<0.001.
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Results
Sunitinib reduces thrombus formation and PS exposure in whole blood under flow on 
collagen type I and III
To widely explore the multi-target inhibition of sunitinib on thrombus formation, we 
investigated thrombus formation induced by several TK-dependent receptors using multiple 
surfaces for coating in whole blood flow chamber experiments. First, we performed dose-
response studies with sunitinib and showed that approximately 3x higher concentration of this 
compound was required to inhibit aggregation induced by collagen (1 μg/ml) in the presence of 
plasma when compared to washed platelets (Suppl. Figure 4.1). This agrees with the knowledge 
that sunitinib is highly protein-bound1.We therefore assessed the effects on thrombus formation 
during whole blood perfusion under flow using 30 μM sunitinib. This dose is in range with the 
plasma concentrations observed in patients with higher peak levels of sunitinib19,but exceeded 
the therapeutic target levels1.
The flow studies were performed in a microspot setting, allowing the quasi-simultaneous 
measurement of sunitinib on adhesive surfaces consisting of collagen type I, collagen type III, 
vWF co-coated with rhodocytin, vWF co-coated with laminin, vWF co-coated with fibrinogen and 
vWF co-coated with ristocetin. Hence, roles of different platelet receptors, such as GPVI, CLEC-2, 
GPIb and integrin α6β1 and αIIbβ3, were investigated as described before
20-22. Captured microscopic 
images were analysed (Suppl. Figure 4.2), and a heatmap was generated for a more systematic 
analysis of the seven thrombus parameters, which were averaged and scaled per parameter 
(Figure 4.1). Parameters of thrombus formation were only consistently affected on GPVI-
dependent surfaces, i.e. collagen type I and III (Figure 4.1A, B). In the presence of sunitinib, these 
thrombi were smaller and less compact in structure as compared to the control condition (Suppl. 
Figure 4.2A and B, brightfield images). Quantification showed a reduction in platelet deposition, 
thrombus height and contraction (Figure 4.1). P-selectin exposure was significantly reduced in 
thrombi formed on collagen III and vWF co-coated with laminin, fibrinogen and ristocetin (Suppl. 
Figure 4.2B and 4.2C). Notably, thrombus parameters for CLEC-2, GPIb- and integrin αIIbβ3/α6β1-
dependent surfaces were not affected by sunitinib (Figure 4.1C-F, Suppl. Figure 4.2C-F), suggesting 
a mostly GPVI-specific effect. 
Sunitinib inhibits multiple tyrosine kinases, intracellular Ca2+ responses and PS exposure 
upon GPVI stimulation 
We have previously shown that overall tyrosine phosphorylation upon GPVI stimulation 
is inhibited by sunitinib5. To study the effect of sunitinib on GPVI-induced phosphorylation of 
multiple specific TKs simultaneously, we performed a PamGene kinase assay. We observed that 
in isolated platelets, in total 34 TKs were significantly phosphorylated by stimulation with CRP-XL, 
























































Figure 4.1. Sunitinib strongly reduces thrombus formation on GPVI-dependent surfaces, as compared to surfaces for 
CLEC-2, GPIb, integrin α6ß1 and αIIbß3. Whole blood from healthy volunteers was preincubated with vehicle (<0.1% DMSO) 
or sunitinib (30 µM) for 10 min and perfused for 3.5 minutes at a wall shear rate of 1,000 s-1 over coated microspots 
containing (A) collagen type I, (B) collagen type III and (C) vWF plus rhodocytin, (D) vWF plus laminin, (E) vWF plus 
fibrinogen and (F) vWF plus ristocetin. Subtraction heatmaps are shown representing significant effects of normalized 
values from the following parameters: platelet deposition (PltSac), morphological score (MoSc), multilayer deposition 
(MultiSac), multilayer score (MultiSc), contraction score (ContrSc), PS exposure deposition (PSSac) and P-selectin 
deposition (PselSac). Controls with addition of vehicle (<0.1% DMSO) were set at 0 for reference. Effects were filtered for 
significant changes (p<0.05). 
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relevant for GPVI signalling are Syk and the SFKs Src, Fyn, and Yes, which all show a high level 
of inhibition in the presence of sunitinib. Interestingly, the Focal Adhesion Kinases (FAK1 and 2) 
which signal mostly downstream of integrins23, as well as the Gas6 receptor Tyro3/Sky showed a 
similar pattern of regulation. Furthermore, also other non-GPVI-linked TKs were activated upon 
GPVI stimulation, most likely via agonists secreted from the α-granules. Overall, this assay clearly 
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Figure 4.2. Sunitinib inhibits GPVI-induced tyrosine kinase activity, Ca2+ responses and PS exposure in washed 
platelets. (A) Heatmaps visualize all tyrosine kinases that are significantly up- or downregulated in both comparisons 
(sorted alphabetically). Cut-off has been set at a median final score of at least 1.2. Colour indicator reflects the calculated 
median kinase statistic reflecting effect size and directionality (red: upregulated; blue: downregulated). (B) Representative 
curve of a calcium response of Fura-2 loaded platelets (200x109/L); arrow indicates addition of CRP-XL (5 µg/mL). Bar 
graphs show quantification of maximum (peak) level of the calcium response induced by CRP-XL (5 µg/mL) or thrombin 
(1 nM) of Fura-2 loaded platelets in presence (black bars) or absence of sunitinib (white bars). All data are represented as 
means + SEM (n=5-7), *p<0.05. (C) Isolated platelets from healthy volunteers were incubated with vehicle (<0.1% DMSO) 
or sunitinib (10 µM) for 10 minutes at RT. Platelets (100x10⁹/L) were activated in the presence (black bars) or absence of 
sunitinib (white bars) by CRP-XL (5 µg/mL) in combination with thrombin (4 nM) and incubated for 60 minutes at 37°C. PS 
exposure was detected by FITC-conjugated annexin A5 and measured by flow cytometry.
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GPVI signalling results in sustained elevation of intracellular calcium levels 
([Ca2+]i) upon stimulation, resulting in PS-exposure
24. In accordance with the effects on TK 
phosphorylation, also the Ca2+ increase in response to CRP-XL was nearly abolished in the presence 
of sunitinib (Figure 4.2B). Elevation in [Ca2+]i upon thrombin stimulation was not significantly 
affected. Also, platelet procoagulant activity (PS exposure), was inhibited by sunitinib in isolated 
platelets stimulated with CRP plus thrombin (Figure 4.2C). This was in agreement the reduction of 
PS exposure in whole blood under flow, only on collagen type I (Figure 4.1A). 
Considering that GPVI and CLEC-2 display many similarities in the downstream signalling 
pathways25,we additionally determined the effects of sunitinib on CLEC-2 dependent platelet 
activation. We observed that in isolated platelets, both rhodocytin-induced aggregation, as well 
as activation of integrin αIIbβ3 and expression of P-selectin were significantly reduced by sunitinib 
(Suppl. Fig 4.3A, B). Also, PS exposure as induced by rhodocytin plus thrombin was significantly 
reduced by sunitinib (Suppl. Fig. 4.3C). However, we did not observe an effect of sunitinib in 
whole blood thrombus formation on rhodocytin plus vWF (Fig. 4.1C, Suppl. Fig 4.2C), suggesting 
that CLEC-2-induced thrombus formation was not affected by sunitinib in whole blood. 
So far, all data showed that sunitinib most prominently reduced phosphorylation of TKs 
and rises of intracellular Ca2+ levels, resulting in inhibition of thrombus formation and PS exposure 
induced by the collagen receptor GPVI. Therefore, we used collagen type I for further experiments.
Aspirin enhances sunitinib-induced inhibition of platelet aggregation and thrombus 
formation
To investigate the combined effect of sunitinib and aspirin on platelet function, we started 
by measuring platelet aggregation. Sunitinib alone caused a minor inhibition (±14%) of the 
aggregation response induced by a high dose (5 μg/ml) of collagen, whereas aspirin inhibited this 
collagen-induced aggregation by ±70% (Figure 4.3A). The combination of sunitinib and aspirin 
reduced the aggregation response even further as compared to aspirin alone (>80%; Figure 4.3A). 
Similar results could be observed when platelets were stimulated with 2MeS-ADP (Figure 4.3B). 
However, both sunitinib and/or aspirin treatment did not affect the aggregation response elicited 
by thrombin (Figure 4.3C). 
 Next, we determined the effects of sunitinib and/or aspirin in whole blood thrombus 
formation over collagen type I. When aspirin was added in vitro, we only observed a significant 
effect on thrombus contraction, while other parameters were not affected (Figure 4.3D). No 
additional effects on thrombus formation in whole blood could be observed when both aspirin 
and sunitinib were added in vitro (Figure 4.3D). Subsequently, we obtained blood from healthy 
volunteers who had taken a single dose of aspirin (100 mg) one day before. Treatment with aspirin 
inhibited platelet deposition as compared to controls without aspirin intake (Figure 4.3E, Suppl. 
Figure 4.4). Addition of sunitinib to blood from aspirin-treated donors further enhanced the 
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effects that were observed with aspirin alone (Figure 4.3E). Especially thrombus height (multilayer) 
and PS exposure were reduced when both drugs were present, as compared to aspirin alone 
(Figure 4.3E). Altogether, these results suggest that dual treatment with anti-platelet therapy and 



























































































Figure 4.3. Aspirin enhances the effect of sunitinib in collagen-induced platelet aggregation and in ex vivo thrombus 
formation on collagen in whole blood after aspirin intake. Washed platelets (250x10⁹/L) were incubated with vehicle 
(<0.1% DMSO), aspirin (100 µM) and/or sunitinib (10 µM). Aggregation of washed platelets was induced by (A) 5 µg/mL 
collagen, (B) 1 µM 2MeS-ADP or (C) 1 nM thrombin. Data are represented as means + SEM (n=3), *p<0.05, ***p<0.001. 
(D, E) Whole blood from healthy volunteers was preincubated with vehicle (<0.1% DMSO), sunitinib (30 µM) and/or 
aspirin (100 µM) for 10 min. Recalcified whole blood was perfused over a collagen surface at 1000 s-¹ for 3.5 minutes, 
followed by perfusion with buffer supplemented with AF568-annexin A5 and AF647-α-CD62P to detect PS exposure and 
P-selectin expression, respectively. (D) Subtraction heatmaps representing the significant effects of normalized values 
of the parameters. Controls with addition of vehicle (<0.1% DMSO) were set at 0 for reference. Effects were filtered for 
significant alterations by addition of sunitinib and/or aspirin. (E) Subtraction heatmaps representing the significant effects 
of normalized values of parameters as for supplemental Figure 4.4B. Healthy controls were set at 0 for reference to aspirin 
intake or aspirin intake with in vitro addition of sunitinib. Effects were filtered for significant changes of the different 
platelet parameters (p≤0.05). 
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Figure 4.4. Aspirin partially enhances the inhibiting effect of sunitinib in platelet-dependent fibrin formation under 
flow. Citrated whole blood of healthy volunteers with single dose of aspirin was treated in vitro with vehicle (<0.1% 
DMSO) or sunitinib (30 µM) for 10 min followed by addition of DiOC6 (platelet deposition), AF568-annexin A5 (PS-
exposure) and AF647-α-fibrinogen (fibrin). Blood was co-perfused with CaCl2/MgCl2 over collagen type I at a wall shear 
rate of 1000 s-1. (A) Representative brightfield and fluorescence images taken after 10 minutes of blood perfusion. (B) 
Kinetic analysis of brightfield images of (i) platelet deposition (PltSac), (ii) morphological score (MoSc), (iii) multilayer score 
(MultiSc), and (iv) contraction score (ContrSc) and of fluorescence images of (v) DiOC6 platelet deposition (DiOC6Sac), 
(vi) PS exposure (PSSac), (vii) fibrin deposition (FibrinSac), (viii) fibrin score (FibrinSc) and (ix) time to fibrin (TTF). Data are 
represented as means + SEM (n=6), *p<0.05, **p<0.01. (C) Heatmap representing the significant effects of normalized 
values of parameters analysed in B. Healthy controls were set at 0 for reference to aspirin intake or aspirin intake with 
in vitro addition of sunitinib. Effects were filtered for significant changes of the different platelet parameters (p≤0.05). 
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Aspirin enhances sunitinib effects on thrombus fibrin formation
As we observed that the exposure of procoagulant PS was reduced by sunitinib (plus 
aspirin), we further investigated whether these effects extended to conditions of thrombin 
generation and fibrin formation. Hence, we assessed the kinetics of platelet-fibrin thrombus 
formation under flow on a collagen surface co-coated with TF18. Recalcified whole blood was 
labelled with DiOC6, AF568-Annexin A5 and AF647-fibrinogen, and was perfused over a 
microspot consisting of collagen type I plus TF. Using control blood samples, we observed time-
dependent increases in platelet deposition and thrombus formation in time, with the start of 
fibrin formation after 7-8 minutes (Figure 4.4A). Preincubation of blood with sunitinib did not 
affect the parameters of platelet deposition and thrombus size in time, but sunitinib significantly 
reduced PS exposure with a concomitant delay in fibrin formation (Suppl. Figure 4.5).  Of note, 
sunitinib did not affect thrombin generation under static conditions, as measured with the 
calibrated automatic thrombogram26 in PRP stimulated with collagen (data not shown). Markedly, 
using blood from aspirin-treated healthy volunteers, we observed a reduction in thrombus size, 
height and density as compared to healthy volunteers without aspirin intake (Figure 4.4A, B). 
Furthermore, a slight decrease in PS exposure as well as a delay in fibrin formation was observed 
upon aspirin intake (Figure 4.4). These effects were further reduced by in vitro addition of sunitinib 
(Figure 4.4C). Especially, effects on thrombus height, contraction, PS exposure and time to fibrin 
generation were increased upon dual treatment with aspirin and sunitinib as compared to aspirin 
alone. Together, these results suggest that sunitinib reduces GPVI-induced activation of platelets 
resulting in decreased PS exposure and thereby delaying the time for fibrin to be formed, which 
is enhanced by aspirin intake. 
Sunitinib reduces platelet-dependent fibrin formation under flow in whole blood from 
cancer patients 
Previously, we demonstrated that sunitinib reduced thrombus formation and PS exposure 
in whole blood from renal cell carcinoma (RCC) patients under non-coagulating conditions5. To 
explore whether sunitinib could also reduce platelet-dependent fibrin formation under flow in 
blood from cancer patients, we obtained blood from 11 patients diagnosed with lung, pancreatic 
and (neuro)glioblastoma cancer (Suppl. Table 4.1). Sunitinib has been reported to be used as 
a (combination) therapeutic strategy for these types of cancer27-29. As a proof-of-principle, we 
preincubated recalcified whole blood from these patients with vehicle or sunitinib followed by 
labelling with DiOC6, AF568-Annexin A5 and AF647-fibrinogen. Upon perfusion of the vehicle-
treated blood over collagen co-coated with TF, we observed increases in platelet deposition and 
thrombus formation in time, with a median start of fibrin formation after 7-8 minutes, comparable 
to healthy controls (Suppl. Figure 4.6A, B). Three patients were treated with anticoagulant 
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Figure 4.5. Sunitinib reduces platelet-dependent fibrin formation under flow in whole blood from cancer patients. 
Citrated whole blood from cancer patients (suppl. Table I) was treated in vitro with vehicle (<0.1% DMSO) or sunitinib 
(30 µM) for 10 min, followed by addition of DiOC6 (platelet deposition), AF568-annexin A5 (PS-exposure) and AF647-
α-fibrinogen (fibrin). Blood was co-perfused with CaCl2/MgCl2 over collagen type I plus TF at a wall shear rate of 1000 
s-1. (A) Endpoint analysis of brightfield images of (i) platelet deposition (PltSac), (ii) morphological score (MoSc), (iii) 
multilayer score (MultiSc), and (iv) contraction score (ContrSc) and of fluorescence images of (v) DiOC6 platelet deposition 
(DiOC6Sac), (vi) PS exposure (PSSac), (vii) fibrin deposition (FibrinSac), (viii) fibrin score (FibrinSc) and (ix) time to fibrin 
(TTF). Data are represented as median ± interquartile range (n=9-11). Each dot represents an individual cancer patient 
(colour-coding in Suppl. Table 4.1), *p<0.05. (B) Subtraction heatmap representing the overall effect of sunitinib in 
cancer patients. The effects of normalized values of parameters during time are based on the analysis of Suppl. Figure 7. 
Vehicle treated blood of cancer patients was set at 0 for reference to in vitro addition of sunitinib. Effects were filtered for 
significant changes between the different platelet parameters (p≤0.05). (C) Subtraction heatmap of the effect of sunitinib 
per cancer type. Effects were filtered for changes greater than the 1x SD range of the different platelet parameters. 
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compared to the patients without this treatment. Preincubation of blood with sunitinib showed 
a trend in overall inhibition of thrombus size and height in time, as well as a reduction in PS 
exposure with a significant delay in fibrin formation (Figure 4.5A and Suppl. Figure 4.6A, B). To 
visualize the overall effects of sunitinib in blood from cancer patients, we generated a heatmap 
(Figure 4.5B). This heatmap clearly shows that sunitinib inhibits platelet PS-exposure and fibrin 
formation, but also some effects on thrombus formation parameters can be observed. We 
included patients with different types of cancer, which this may result in different cancer-specific 
responses. Therefore, we also generated a heatmap with the patients averaged per cancer type 
(Figure 4.5C). This heatmap shows that in lung and pancreatic cancer, more pronounced effects 
of sunitinib were observed on thrombus formation parameters (i.e. height, size and contraction) 
as compared to neuroglioblastoma and other cancer types. This variable response to sunitinib 
treatment was even more pronounced when a heatmap was generated per patient (suppl. Figure 
4.6C). This heatmap shows that the effects of sunitinib on thrombus and fibrin formation under 
flow varied more between individual patients than between the types of cancer. Overall, in 6 of 
the 9 patients were sunitinib was added we observed clear inhibition of thrombus formation 
and/or PS exposure and/or fibrin generation. This suggested that the in vitro inhibitory effects of 
sunitinib were more pronounced in cancer patients (Figure 4.5C and suppl. Figure 4.6C) than in 
healthy controls (Suppl. Figure 4.5). 
Discussion
In the present study we further explored the multi-target inhibition of sunitinib on 
thrombus formation, by investigating thrombus formation by stimulation with multiple agonists, 
as well as under coagulating conditions stimulated by collagen plus TF. We observed that sunitinib 
predominantly inhibited collagen-induced exposure of phosphatidylserine, resulting in delayed 
fibrin formation. Furthermore, we found an enhancing effect of dual treatment of platelets with 
sunitinib and aspirin in these processes. Finally, platelet-dependent fibrin formation in whole 
blood from cancer patients was significantly inhibited by sunitinib. 
We have previously reported that platelets sequester sunitinib in vitro as well as in cancer 
patients and that this uptake inhibits platelet function in response to collagen5. As sunitinib is a 
multi-target TKI and TKs do not only signal under the collagen receptor GPVI, but also under the 
receptors GPIb, CLEC-2 and integrins α6β1 and αIIbβ3
21, we investigated the effects of sunitinib on 
thrombus formation in whole blood perfused over multiple agonists. However, sunitinib did not 
affect thrombus formation on CLEC-2, GPIb- and integrin αIIbβ3/α6β1-dependent surfaces, which 
pointed to GPVI as the main signalling pathway inhibited by this TKI. We did observe that sunitinib 
inhibited CLEC-2-induced aggregation and activation responses in isolated platelets. This is in line 
with the many similarities in the downstream signalling pathways underneath GPVI and CLEC-225. 
The inhibiting effects of sunitinib on CLEC-2-induced thrombus formation were however absent in 
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whole blood. This may be explained by a stronger dependence on Syk of CLEC-2 signalling, while 
GPVI signalling is more dependent on Src25. Inhibition of Src by sunitinib upon GPVI stimulation 
was more pronounced as compared to inhibition of Syk (Figure 4.2A), suggesting that the effects 
of sunitinib on CLEC-2 signalling may be less prominent, especially in whole blood conditions. 
Furthermore, we noted that higher collagen doses overrule the inhibiting effects of sunitinib at 
10 μM. Hence, a higher concentration of sunitinib may be required to inhibit platelet activation 
at higher agonist concentrations. A possible role for integrin α2β1, the other collagen receptor on 
platelets, should be mentioned here as well, as this receptor also signals via Src and Syk kinases30. 
It has been shown that integrin α2β1 has a supporting role with regard to platelet activation and 
contributes to stable thrombus formation on collagen31. As we have shown that sunitinib strongly 
reduced phosphorylation of Syk and Src, the inhibiting effects observed in thrombus formation 
on collagen may be partly due to inhibition of integrin α2β1 signalling. In addition, thrombus 
formation under flow on collagen type III was reduced by sunitinib treatment, although not as 
strong as compared to thrombus formation on collagen type I. Together, this is consistent with 
the multi-target nature of sunitinib as a broad-spectrum protein TKI, having lower affinity for 
multiple TKs rather than high affinity for one specific signalling protein32, 33. This also explains why 
the effects of sunitinib on platelet activation are not as strong as compared to specific inhibitors 
of Syk or Src34, 35. 
We showed that in total 34 TKs were activated upon GPVI stimulation, which were 
subsequently inhibited in the presence of sunitinib. Several TKs could be directly linked to GPVI 
signalling, such as Syk and the SFKs, but most TKs were most likely activated by agonists secreted 
from the α-granules upon GPVI stimulation, such as fibrinogen, activating FAK1/2 via integrin 
αIIbβ3
23, as well as Gas6, activating Tyro3/Sky. As platelets contain many bioactive molecules in their 
granules, most likely also the other non-ITAM-linked TKs that showed phosphorylation upon GPVI 
stimulation, have been activated via similar secondary events. As we have shown that platelet 
secretion is inhibited by sunitinib5, the inhibiting effects of sunitinib on non-GPVI-linked TKs may 
also be due to reduced secretion of secondary mediators. Prolonged elevation of intracellular 
calcium levels is a prerequisite for platelet PS exposure, a hallmark of procoagulant activity24. The 
observed effects of sunitinib on intracellular calcium rises in response to GPVI stimulation fits with 
the currently observed reduction in TK phosphorylation and agrees with previously shown effects 
on collagen-induced tyrosine phosphorylation of multiple proteins5. This implies interference 
of sunitinib early in the signalling cascade used by the collagen receptor GPVI, e.g. with TKs in 
the GPVI signalosome or with Syk as a central regulator of collagen-induced platelet activation. 
In agreement, another study reported that collagen-induced tyrosine phosphorylation of c-Src 
is reduced in platelets treated with sunitinib6. Others have shown that also in cardiomyocytes 
sunitinib treatment results in reduced calcium responses accompanied with decreased sarcomere 
shortening36. We showed that sunitinib reduced platelet PS exposure in isolated platelets in vitro, 
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as well as during whole blood thrombus formation under flow in the presence and absence of 
coagulation. This reduction in platelet procoagulant activity upon sunitinib treatment resulted in 
delayed and reduced fibrin clot formation. An earlier study with other TKIs has also demonstrated 
that platelet tyrosine phosphorylation is required for procoagulant activity and fibrin formation37.
As both aspirin and sunitinib are associated with increased bleeding risk3, 9, we investigated 
if the combination of these drugs could reinforce the inhibiting effects on platelets. We observed 
that indeed this aspirin-sunitinib combination resulted in stronger inhibition of collagen-induced 
platelet aggregation as compared to either compound alone. However, in whole blood perfusion 
experiments (with and without coagulation) we did not observe these additive effects when 
aspirin and sunitinib were added in vitro. In contrast, platelet deposition and thrombus height 
were reduced in blood from aspirin-treated donors as compared to controls without aspirin 
intake. Moreover, addition of sunitinib further enhanced the effects that were observed with 
aspirin alone, accompanied by further reductions in PS exposure and fibrin formation. In an 
earlier study from our group with patients suffering from peripheral artery disease (PAD), no 
effects of aspirin intake were observed on thrombus formation under flow as compared to 
healthy controls without aspirin intake38. This could be due to the increased platelet reactivity 
observed in these PAD patients, that was counterbalanced by the aspirin intake. In contrast, 
in this study in vitro addition of aspirin to blood from healthy volunteers did reduce thrombus 
formation and PS exposure under flow38, which was also observed by others39, 40. The present 
findings are compatible to the variable effects of aspirin intake alone on thrombus formation, 
while the combination of aspirin with other anti-platelet drugs causes a marked reduction41-45. 
Furthermore, a recent study has shown concomitant effects of aspirin and ibrutinib on collagen-
induced aggregation46. Altogether, these results suggest that dual treatment with anti-platelet 
therapy and TKIs increase the inhibition of platelet function.
In the present study we included a limited number of cancer patients, who suffered from 
different cancer types. Also, we added the sunitinib in vitro, which may be a limitation to the 
current study. The effects of sunitinib on platelet-dependent coagulation in blood from patients 
treated with sunitinib requires further study. Also, the combined effects of sunitinib and aspirin or 
other anti-platelet drugs on platelets from patients on treatment in relation to bleeding should be 
further investigated. Despite these limitations, we clearly observed in this proof-of-principle study 
that the in vitro inhibitory effects of sunitinib on thrombus size and height under coagulating 
conditions were more pronounced in several individual cancer patients as compared to healthy 
controls. It is known that cancer patients have a procoagulant phenotype47, 48, and therefore 
platelets from cancer patients may be more sensitive to inhibitory compounds as compared to 
platelets from healthy individuals. We also observed more pronounced effects of sunitinib on 
thrombus formation parameters in lung and pancreatic cancer as compared to neuroglioblastoma 
and other cancer types. It has been reported that tumour-induced changes in platelet proteins 
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and mRNA are tumour-type specific49, 50, hence we hypothesize that these specific tumour-
induced changes may influence the platelet response to inhibiting drugs. 
Altogether, we conclude that sunitinib inhibited GPVI-induced phosphorylation of TKs (a.o. 
Syk and Src), with subsequent reduction of Ca2+ elevation, resulting in reduced platelet activation 
and PS-exposure. This was accompanied by delayed and reduced formation of fibrin, all of which 
were aggravated in the presence of aspirin. This asks for awareness among clinicians for the 
combined antiplatelet effects of TKIs together with anti-platelet drugs.
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Supplemental Figure 4.1. Inhibition of aggregation with sunitinib is stronger in washed platelets compared to PRP. 
Washed platelets or PRP (250x10⁹/L) from healthy volunteers was incubated with vehicle (<0.1% DMSO) or sunitinib (10 
or 30 µM) for 10 minutes at 37°C. Shown are the percentages of aggregation of washed platelets (left) or PRP (right) in 
absence (white bar) or presence of sunitinib (grey / black bars) in response to collagen (1 µg/mL). Data are represented as 










1 Female 71 Lung NA NA 164
2 Male 72 Lung Pembrolizumab Aspirin (100) 105
3 NA NA Lung NA NA 203
4 Male 76 Neuroglioblastoma - - 118
5 Female 45 Neuroglioblastoma - - 93
6 Male 81 Neuroglioblastoma - Fondaparinux (5) 62
7 Male 76 Pancrea�c - - 248














10 Female 61 Ovarian
Male 67 Pancrea�c - 198
Supplemental Table 4.1. Characteristics of cancer patients
























Vehicle Sunitinib Vehicle Sunitinib
Collagen type I Collagen type III
vWF + Ristocetin




























01020304050 Platelet deposition (%SAC)
*
012345 Morphological score (0-5)
0510152025 Multilayer (%SAC)
*
0123 Multilayer score (0-3)
*
0123 Contraction score (0-3)
*
0510152025 PS exposure (%SAC)
01020304050 P-selectin (%SAC)
*
01020304050 Platelet deposition (%SAC)
**




0123 Multilayer score (0-3)
**
0123 Contraction score (0-3)
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Supplemental Figure 4.3. Sunitinib inhibits CLEC-2 induced aggregation and activation in washed platelets. (A) Washed 
platelets (250x10⁹/L) from healthy volunteers were incubated with vehicle (<0.1% DMSO) or sunitinib (10 or 30 µM) for 
10 minutes at 37°C. Shown are the percentages of aggregation in the absence (white bar) or presence of sunitinib (black 
bars) in response to rhodocytin (1 µg/mL). (B) Washed platelets (100 x 109/L) were pre-incubated with vehicle (<0.1% 
DMSO) or sunitinib (10 µM) and stimulated rhodocytin (1 µg/mL) for 15 minutes and simultaneously stained for activated 
integrin αIIbβ3 and α-granule secretion (P-selectin). Histograms show the percentages of platelets binding FITC-labelled 
PAC-1 monoclonal antibody or AF647-labelled anti-human CD62 mAb. (C) Isolated platelets from healthy volunteers were 
incubated with vehicle (<0.1% DMSO) or sunitinib (10 µM) for 10 minutes at 37°C. Platelets (100x10⁹/L) were activated in 
the presence (black bars) or absence of sunitinib (white bars) by rhodocytin (5 µg/mL) in combination with thrombin (4 
nM) and incubated for 60 minutes at 37°C. PS exposure was detected by FITC-conjugated annexin A5 and measured by 
flow cytometry. Data are represented as means + SEM (n=4-6), *p<0.05.
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Supplemental Figure 4.4. Aspirin intake enhances the effect of sunitinib in ex vivo thrombus formation on collagen 
in whole blood. Recalcified whole blood of healthy volunteers or healthy volunteers with single dose of aspirin was 
treated in vitro with vehicle or sunitinib (30 µM) for 10 min. Subsequently, blood was perfused over a collagen surface at 
1000 s-¹ for 3.5 minutes, followed by perfusion with buffer supplemented with AF568-annexin A5 and AF647-α-CD62P to 
visualize PS exposure and P-selectin expression, respectively. (A) Representative brightfield and fluorescent images. (B) 
Quantification of brightfield images of (i) platelet deposition, (ii) morphological score, (iii) multilayer (%SAC), (iv) multilayer 
score, (v) contraction score, and fluorescence images of (vi) PS exposure and (vii) P-selectin expression of vehicle (white 
bar), aspirin intake (dark grey bars), or aspirin intake with in vitro sunitinib (black bar). Data are represented as means + 




































Supplemental Figure 4.5. The effects of sunitinib on platelet-dependent fibrin formation under flow. Whole blood from 
healthy volunteers was preincubated with vehicle (<0.1% DMSO) or sunitinib (30 µM) for 10 min. Subsequently, the blood 
was supplemented with DiOC6, AF568-annexin A5 and AF647-α-fibrinogen to visualize platelet deposition, PS-exposure 
and fibrin formation, respectively. Blood samples were co-perfused with CaCl2/MgCl2 over collagen type I co-coated with 
TF microspot at a wall shear rate of 1000 s-1. Subtraction heatmaps representing the significant effects of normalized 
values of the parameters. Controls with addition of vehicle (<0.1% DMSO) were set at 0 for reference. Effects were filtered 
for significant alterations by addition of sunitinib (p≤0.05). 
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Supplemental Figure 4.6. Sunitinib reduces platelet-dependent thrombus-fibrin formation under flow in whole blood 
from cancer patients. Citrated whole blood from cancer patients (suppl. Table I) was treated in vitro with vehicle (<0.01% 
DMSO) or sunitinib (30 µM) for 10 min, followed by addition of DiOC6 (platelet deposition), AF568-annexin A5 (PS-
exposure) and AF647-α-fibrinogen (fibrin). Blood was co-perfused with CaCl2/MgCl2 over collagen type I co-coated with 
TF at a wall shear rate of 1000 s-1. (A) Representative brightfield and fluorescent images taken after 10 min of flow. (B) 
Kinetic analysis of brightfield images of (i) platelet deposition (PltSac), (ii) morphological score (MoSc), (iii) multilayer score 
(MultiSc), and (iv) contraction score (ContrSc) and of fluorescence images of (v) DiOC6 platelet deposition (DiOC6Sac), (vi) 
PS exposure (PSSac), (vii) fibrin deposition (FibrinSac), and (viii) fibrin score (FibrinSc). Data are represented as median ± 
interquartile range (n=9-11), *p<0.05, **p<0.01. (C) Subtraction heatmap representing the effect of sunitinib in individual 
cancer patients. Vehicle treated blood of cancer patients was set at 0 for reference to in vitro addition of sunitinib. Effects 
were filtered for changes greater than the 1x SD range of the different platelet parameters.
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Quantitative and qualitative changes in 
platelet traits of sunitinib-treated patients with 
renal cell carcinoma in relation to circulating 
sunitinib levels: a proof-of-concept study
Tullemans BME,  Brouns SLN, Swieringa F, Sabrkhany S, van 
den Berkmortel FWPJ, Peters NJB, de Bruijn P, Koolen SLW, 





Background: Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer 
treatment, but may also affect platelet count and function with possible hemostatic consequences. 
Here, we investigated how patient treatment with the TKI sunitinib affected quantitative and 
qualitative platelet traits as a function of the sunitinib level and the occurrence of bleeding. 
Methods: Blood was collected from 20 metastatic renal cell carcinoma (mRCC) patients 
before treatment, and at 2 weeks, 4 weeks and 3 months after sunitinib administration. We 
measured blood cell counts, platelet aggregation, and the concentrations of sunitinib as well as 
its N-desethyl metabolite in plasma, serum and isolated platelets. Progression of disease (PD) and 
bleeding were monitored after 3 months.
Results: In sunitinib-treated mRCC patients, concentrations of (N-desethyl)sunitinib 
in plasma and serum were highly correlated. In the patients' platelets the active metabolite 
levels were relatively increased as compared to sunitinib. On average, a sustained reduction in 
platelet count was observed on-treatment, which was significantly related to the inhibitor levels 
in plasma/serum. Principal component and correlational analysis showed that the (N-desethyl-)
sunitinib levels in plasma/serum were linked to  a reduction in both platelet count and collagen-
induced platelet aggregation. The reduced aggregation associated in part with reported bleeding, 
but did not correlate to PD. 
Conclusions: The sunitinib-induced reduction in quantitative and qualitative platelet traits 
may reflect the effective sunitinib levels in the patient. These results may serve as a proof-of-
principle for other TKI-related drugs, where both platelet count and functions are affected, which 
could be used therapeutic drug monitoring. 
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Introduction
In the past two decades, over 40 tyrosine kinase inhibitors (TKIs) have been developed 
and approved for the treatment of many cancer types1. The majority of these drugs target the 
receptor-linked tyrosine kinases for growth factors, e.g., receptors for vascular endothelial growth 
factor, and/or differentiation/proliferation factors (e.g., Flt, Fms, Kit, and Ret). Several other TKIs 
target intracellular tyrosine kinases (Abl, B-Raf, Btk, Itk, Src-family kinases and Syk). However, in 
spite of the intended specific targets, most TKIs used for treatment also have broad off-target 
effects, invariably affecting a range of protein tyrosine kinases. It is debated whether these off-
target effects help to improve progression-free survival (PFS) and overall survival (OS) of the 
treated patients2. 
Until shortly, the survival of metastatic clear cell renal cell carcinoma (ccRCC) patients 
was poor with a 5-year survival rate of 12%3. However, in recent years treatment options have 
increased by the availability of immune- and targeted therapies, using anti-PD1 and anti-CTLA4 
antibodies, as well as new TKIs. Randomized controlled trials testing the targeted therapies showed 
an overall improvement in response rates, PFS and OS, especially for the intermediate and poor 
risk groups4-7. For the favorable risk patients, it appeared that sunitinib, a broad-spectrum TKI, was 
superior to the immuno-agents nivolumab/ipilimumab, and was equivalent to pembrolizumab 
plus axitinib4, 5. Therefore, sunitinib has become a mainstay not only for first-line treatment in this 
particular risk group, but also in second line treatment after nivolumab/ipilimumab. 
Upon activation of platelets via non-G-protein coupled receptors, tyrosine phosphorylation, 
via Src-family kinases and Syk, is one of the key signal transduction mechanisms8. Especially, 
platelet activation via the collagen receptor glycoprotein (GP) VI fully relies on this tyrosine kinase 
pathway. Clinical studies have shown that several TKIs, next to affecting platelet function, also 
affect platelet count.  Both effects on platelets can contribute to the increased bleeding risk, 
regularly observed in patients treated with TKIs1, 9. Also for sunitinib treatment, mild bleeding 
diathesis has been described as a side effect. This was observed as epistaxis, or mucocutaneous 
and gastrointestinal bleeding, which occurred in approximately 19% of the sunitinib-treated 
patients10. 
Recently, we have demonstrated a rapid uptake of sunitinib by platelets, which was 
accompanied by a reduced collagen receptor-induced aggregation, secretion of α-granules and 
thrombus formation under flow conditions, both in vitro and ex vivo in RCC patients on treatment11. 
Furthermore, we and others have shown that the platelet concentration decreases upon sunitinib 
treatment11-13, an effect that has been postulated as a prognostic factor for the sunitinib treatment 
response in RCC12. However, to which extent these sunitinib effects are related to each other and 
to the circulating sunitinib concentration and/or bleeding is unclear. 
In the present study with 20 patients, we investigated as a proof-of-concept with regards to 
other TKIs, whether the effects of sunitinib on quantitative (count) and qualitative (aggregation) 
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platelet traits is associated with the circulating inhibitor level. Furthermore, we set out to deduce 
how this relates to reported bleeding symptoms. 
Materials and Methods
Materials
Sunitinib malate (Sutent) was provided by Pfizer (New York NY, USA). Bovine serum 
albumin (BSA), D(+)-glucose, and apyrase were purchased from Sigma-Aldrich (Saint Louis MO, 
USA). Horm collagen type I was from Takeda (Hoofddorp, the Netherlands). Ilomedin (iloprost) 
injection fluid was obtained from Bayer (Mijdrecht, the Netherlands).
Study population and blood collection
The study was performed in accordance with the declaration of Helsinki and approved 
by the local medical ethical committee of Maastricht University Medical Center+ (MUMC+). Full 
informed consent was obtained from all participants. Blood samples were collected from 20 
patients diagnosed with metastatic renal cell carcinoma (mRCC) at the Department of Medical 
Oncology of MUMC+ (Maastricht, the Netherlands), Zuyderland Medical Centre (Sittard-Geleen, 
the Netherlands) and SJG Hospital (Weert, the Netherlands). Blood was also collected from 10 
healthy donors of similar age and gender. Patients were included, when eligible for treatment 
with sunitinib as a single agent (50 mg/day) with a treatment schedule of 4 weeks on and 2 weeks 
off medication. Patient blood samples were collected at four different timepoints: (i) before start 
with sunitinib, and after (ii) 2 weeks, (iii) 4 weeks and (iv) 3 months of sunitinib administration.
Blood samples were obtained from the antecubital vein. At each timepoint; 10 ml was 
collected using a vacuum container containing 3.2% trisodium citrate, and a second blood sample 
of 10 ml was collected in a Clot Activator Tube (CAT) Serum Separator (Greiner Bio-One, Alphen 
a/d Rijn, the Netherlands). Blood cell counts and haematological parameters were assessed in 
patient and healthy control samples, using a Sysmex XP300 (Kobe, Japan).
Reporting of bleeding
Patients were asked to fill out a self-assessment bleeding form after 2 weeks, 4 weeks and 
3 months of sunitinib administration, as was used earlier14. The physicians provided additional 
information with regards to bleeding. Any bleeding was scored as 1, no bleeding was scored as 0.
Response evaluation
A response to sunitinib treatment was defined as partial response (PR), stable disease (SD) 
or progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) 
1.1 guidelines, based on a CT scan performed 3 months after initiating sunitinib, as compared 
to the CT scan prior to treatment. For some of the 20 patients, values were only collected at 
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timepoints 0 and 2 weeks. Missing values at 4 weeks and/or 3 months were due to dose 
reduction (in 3 patients, after severe side effects of medication), hospital admission as a result of 
thrombocytopenia requiring blood transfusion (2 patients) or death (4 patients). 
Platelet isolation
Platelets were isolated from whole blood, as described previously15. Platelet-rich plasma 
(PRP) was isolated from citrate-anticoagulated blood by centrifugation at 240 g for 15 minutes. 
The PRP was supplemented with 1:10 acidic citrate dextrose (ACD; 80 mM trisodium citrate, 52 
mM citric acid and 180 mM glucose) and centrifuged for 2 minutes at 2,230 g. The supernatant 
plasma was retained in case of patient samples, and was further processed as described below. 
The platelet pellet was resuspended into Hepes buffer pH 6.6 (10 mM Hepes, 136 mM NaCl, 2.7 
mM KCl and 2 mM MgCl2) supplemented with 5 mM glucose and 0.1% bovine serum albumin 
(BSA). After addition of 1:15 ACD and 1 U/mL apyrase, the platelets were centrifuged for 2 
minutes at 2,230 g, followed by resuspension into Hepes buffer pH 7.45 with 5 mM glucose and 
0.1% BSA. Platelet count was determined using a Sysmex XP300 (Kobe, Japan) and adjusted as 
stated per assay.
Patient blood sample preparations
Serum was isolated from CAT tubes by centrifugation at 2,200 g for 10 minutes at room 
temperature. Both serum and plasma (obtained from PRP) were centrifuged a second time at 
22,500 g for 5 minutes to remove possible debris. The collected plasma and serum samples were 
frozen, and stored at –80°C until further use.
 Isolated platelets (250x109 platelets/L) were incubated for 5 minutes at room temperature 
with 50 nM iloprost, and centrifuged for 2 minutes at 2,230 g. Supernatant was discarded, and 
the pellet was frozen and stored at -80°C until further use. 
Light transmission aggregometry
Washed platelets (250x109 platelets/L) were incubated for 5 minutes at 37°C before 
stimulation. Aggregation response was induced by addition of 1 µg/mL collagen type I, except 
for patients with anti-platelet drugs where aggregation was induced by 5 µg/mL collagen. The 
collagen concentration was kept the same at all timepoints per patient. Platelet aggregation 
was recorded using a Chronolog optical aggregometer (Havertown PA, USA), and maximum 
aggregation amplitude was quantified at 8 minutes after collagen addition.  
Pharmacokinetic analysis of sunitinib in plasma and serum samples
Sunitinib and the N-desethyl metabolite (SU12662) were quantified, as described 
previously16 in plasma, serum and platelet pellets obtained from patients after 2 and 4 weeks on 
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sunitinib treatment. The concentration of either compound in isolated platelets was corrected for 
the number of platelets in the pellet, and normalized to ng per 2.5x108 platelets.
Statistical analysis
Data are presented as median ± interquartile ranges. Datasets within patients were 
compared using the Wilcoxon matched pairs test, whereas comparisons to controls were 
determined using the Kruskal-Wallis test. Correlation analysis was performed using a nonparametric 
Spearman correlation (2-tailed) using GraphPad Prism 8 software. To identify associations within 
the dataset, variables were quantile normalized and a rotated principal component analysis, 
based on an eigenvalue over 1, was performed using the statistical package for social sciences 
(SPSS version 24). A P-value less than 0.05 was considered to be statistically significant.
Results
Patient demographics and clinical characteristics
In the present study, 20 patients were included with mRCC, who were eligible for treatment 
with 50 mg sunitinib per day with a treatment schedule of 4 weeks on and 2 weeks off medication 
(Table 5.1). Median age of the mRCC patients was 65 years (range: 52-83). Of the patients, 6 were 
females (median age 65; range: 59-83) and 14 were male (median age 65.5; range: 52-80). All 
patients presented with ccRCC, except for two patients who were diagnosed with papillary RCC. 
Three patients required dose reduction of sunitinib during the study follow-up, due to side effects 
(Table 5.1). Four of the patients additionally received daily aspirin as an anti-platelet drug, one 
of whom received heparin during the 3-month follow-up. Two patients received the cholesterol-
lowering drug atorvastatin, which can also affect platelet function17, 18. Furthermore, 10 healthy 
individuals were included with similar median age of 63.5 (range: 53-85), of whom 3 were female.
Plasma and serum levels of sunitinib and N-desethyl-sunitinib are highly correlated, 
while platelets take up more N-desethyl-sunitinib as compared to sunitinib 
Sunitinib and its active metabolite N-desethyl-sunitinib were determined in both 
plasma and serum from mRCC patients after 2 and 4 weeks of treatment. The concentration 
of N-desethyl-sunitinib appeared to be significantly lower in serum and plasma than that of 
sunitinib (Figure 5.1A vs 5.1B, plasma P<0.0001 and serum P<0.0006). Comparison of plasma and 
serum levels of sunitinib or N-desethyl-sunitinib did not show marked differences at 2 or 4 weeks 
(Figure 5.1A, B). On the other hand, the concentration of sunitinib, but not of its metabolite, was 
slightly, but significantly, decreased after 4 weeks in both plasma and serum, as compared to 2 
weeks on treatment (Figure 5.1A). This is compatible with a 14-days peak level upon sunitinib 
administration, after which this reduced to a steady-state level. 
Because platelets are known to sequester sunitinib, we also measured the concentrations 
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of sunitinib and the active metabolite in isolated platelets from mRCC patients. Markedly, 
the concentration of the metabolite was significantly higher in platelets after 2 and 4 weeks 
on treatment, as compared to that of sunitinib (Figure 5.1C). This contrasted to the lower 
concentration of the metabolite in the plasma and serum samples, suggesting a preferential uptake 
of the metabolite by platelets. Furthermore, the concentrations of sunitinib and metabolite after 
2 and 4 weeks of treatment showed strong correlations between the plasma, serum and platelet 
samples (r>0.67033, P<0.01). 
Prolonged changes in platelet count by sunitinib treatment of mRCC patients are related 
to inhibitor levels in plasma and serum
Whole blood cell counts, haemoglobin and haematocrit were determined in blood 
samples from mRCC patients at four time points (Figure 5.2), i.e., the day before start of sunitinib 
treatment, after 2 and 4 weeks (1 treatment cycle) and after 3 months (2 complete cycles). 
Before start of sunitinib treatment, no significant differences were observed in these parameters 















































































Figure 5.1. Comparison of sunitinib and N-desethyl-sunitinib levels in plasma, serum and isolated platelets from mRCC 
patients on 2 and 4 weeks on treatment. The concentration of sunitinib (A) and N-desethyl-sunitinib (B) were measured in 
plasma and serum samples obtained from mRCC patients at 2 and 4 weeks of sunitinib treatment. (C) The concentrations 
of both compounds were determined in isolated platelets, normalized to ng per 2.5x108 platelets. Individual dots in the 
scatterplots represent one patient, for color coding see Table 5.1. Lines and error bars represent median ± interquartile 
range (n=14-20). *P<0.05. **P<0.01, ***P<0.001
97
Changes in platelet traits and circulating levels of sunitinib-treated patients
5
between patients and healthy controls (Figure 5.2). However, after 2 weeks of treatment platelet 
counts were decreased (>10%) in 15 patients (range: 17-87% reduction), while 5 patients showed 
no decrease or even an increase (5-10%, Figure 5.2A). Seven of the patients who presented a 
reduced platelet count showed an even further reduction after 4 weeks, which effect for six of 
them persisted for 3 months. The median platelet concentration of all patients increased after 3 
months as compared to 4 weeks, yet was still lower than before the start of treatment (Figure 
5.2A). In total, fifteen patients had a platelet count between 24-148x109/L (Table 5.1), which was 
below the normal range (150-400x109/L, according to the Dutch Society of Hematology, NVH). Of 
note, 5 patients presented with formal thrombocytopenia (<50x109 platelets/L) after 2-4 weeks 
of treatment. White blood cell (WBC) counts decreased (>10%) in 13 patients (range: 19-60% 
reduction) after 2 weeks of sunitinib treatment (Figure 5.2B), which decrease persisted in most 
patients for 3 months. According to the Common Terminology Criteria 7 patients presented with 
grade 2 neutropenia during the study period with no more than 3 patients per time point. No 




































































































































































































































Figure 5.2. Treatment of mRCC patients with sunitinib decreases platelet count and other hematological parameters 
over time. Blood was collected from 10 healthy controls and 20 mRCC patients the day before, after 2 weeks, 4 weeks 
and 3 months on sunitinib treatment. Hematological parameters were measured in whole blood. Scatterplots show (A) 
platelet count, (B) white blood cell count (WBC), (C) red blood cell count (RBC), (D) hemoglobin concentration (HGB) and 
(E) hematocrit levels (HCT). Individual dots in the scatterplots represent one patient, for color coding see Table 1. Lines 
and error bars represent median ± interquartile range (n=10-20). *P<0.05. **P<0.01, ***P<0.001.
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blood cell count (RBC) and hemoglobin were slightly, but significantly increased (Figure 5.2C-D). 
After 4 weeks and 3 months, these values were decreased, as well as the hematocrit (Figure 5.2E).
We examined whether the concentrations of (N-desethyl-)sunitinib were correlated with 
the reduction in platelet count. The levels of either compound in plasma and serum appeared to 
be correlated with the count reductions after 2 weeks treatment (Table 5.2, Figure 5.3A), and for 
the metabolite this correlation was even stronger after 4 weeks (Table 5.2). For the compound 
levels in platelets, we noticed a borderline significant negative correlation (Table 5.2, Figure 5.3B). 
Together, these data suggested that the changes in platelet count are related to the sunitinib 
levels in plasma and serum, thereby possibly reflecting the effective sunitinib dose in the patient. 
Plasma 78.5 (60.5-108.3) n=14 61.4 (55.3-81.8) n=3 -0.4966 0.0443*
Serum 80.6 (57.4-104.3) n=14 64.0 (55.4-69.4) n=3 -0.5221 0.0336*
Pellet 0.29 (0.18-0.54) n=12 0.20 (0.00-0.28) n=3 -0.4480 0.0960
Plasma 56.0 (43.0-73.5) n=14 - n=0 -0.4066 0.1505
Serum 59.3 (40.3-81.0) n=14 - n=0 -0.3846 0.1755
Pellet 0.18 (0.09-0.28) n=13 - n=0 -0.2707 0.3701
Plasma 26.0 (21.0-35.3) n=14 21.6 (14.8-23.2) n=3 -0.7353 0.0011**
Serum 26.2 (18.6-34.3) n=14 18.6 (16.1-20.3) n=3 -0.6152 0.0100*
Pellet 0.43 (0.35-0.67) n=12 0.27 (0.00-0.56) n=3 -0.5147 0.0517
Plasma 24.0 (17.0-31.5) n=14 - n=0 -0.7099 0.0058**
Serum 22.3 (17.5-30.7) n=14 - n=0 -0.7143 0.0054**
Pellet 0.39 (0.15-0.73) n=13 - n=0 -0.5557 0.0515
Week 2 -9.8 (-24.3 - -1.9) n=11 -5.7 (-6.6 - 35.6) n=3 0.6249 0.0192*
Week 4 -7.1 (-44.7 - 4.4) n=13 - n=0 0.1099 0.7231
Month 3 -6.6 (-17.3 - 0.3) n=10 -17.6 (-18.1 - -17.1) n=2 -0.5515 0.1049
Correla�on 


























Change in platelet count
IQR: interquartile range; ΔPlt count = Platelet count at indicated timepoint on treatment – platelet count before treatment. 
Negative value (-ΔPlt) indicates a reduction in platelet count; Positive value (+ΔPlt) indicates an increase in platelet count. 
Correlations are based on all changes in platelet count.
Table 5.2. Concentrations of (N-desethyl-)sunitinib in plasma and serum correlate with changes in platelet count and 















































r = -0.4480, p = 0.096
r = -0.5147, p = 0.052

























L) r = -0.4966, *p = 0.044r = -0.5221, *p = 0.034
r = -0.7353, **p = 0.001
r = -0.6152, *p = 0.010
(A) (B)
Figure 5.3. Concentrations of (N-desethyl-)sunitinib correlate with the reduction in platelet count. (A) Correlations 
between the concentration of sunitinib and N-desethyl-sunitinib in plasma and serum and difference in platelet count (ΔPlt 
count = Plt count at 2 weeks on treatment – platelet count before treatment). (B) Correlation between the concentration 
of sunitinib and N-desethyl-sunitinib in isolated platelets (normalized to ng/2.5x108 platelets) and difference in platelet 
count. 
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Comparative changes in quantitative and qualitative platelet traits by sunitinib 
treatment of mRCC patients
For adequate dosing, the collagen concentration required for maximal platelet aggregation 
was determined using washed patient platelets before the sunitinib treatment. Either 1 or 5 µg/
mL collagen was used, dependent on intake of aspirin or atorvastatin (see Table 5.1). This dose 
was maintained for all follow-up measurements per patient. Platelet aggregation responses 
on treatment were compared to pre-treatment measurements for each patient. This resulted 
in an overall decrease in aggregation (range: 5-45% decrease) in 10 mRCC patients after 2 
weeks sunitinib treatment (Figure 5.4A), despite of the observed variation between patients. 
Platelet aggregation was continued to be decreased in 10 patients (in 7 patients >10%) after 4 
weeks, while in 5 patients there was no decrease or even increased aggregation as compared 
to pre-treatment. Altogether, on average no differences in aggregation were observed after 4 
weeks. After 3 months, again no differences in aggregation were observed, due to substantial 
variation. Remarkably, platelets from 6 patients showed a long-term reduction (>10% decrease) 
in collagen-induced aggregation until 3 months, while platelets from other patients were not or 
only minimally affected during this time-period (Figure 5.4A). The five mRCC patients who were 
treated with both sunitinib and aspirin and/or atorvastatin, revealed no significant differences in 
platelet aggregation, as compared to patients on sunitinib monotherapy.  
We investigated whether an observed reduction in platelet aggregation was correlated 
to a reduction in platelet count at all time points (Table 5.2). It appeared that the difference in 
platelet count (ΔPlt = Platelet count at 2 weeks on treatment - platelet count before treatment) 
correlated with the difference in aggregation (ΔPlt aggregation = maximum amplitude at 2 weeks 
on treatment - maximum amplitude before treatment) at two weeks on treatment only (Table 5.2, 
Figure 5.4B). Next, we compared the reduction in platelet aggregation with the inhibitor levels 
in plasma, serum and platelets, though no correlation was observed between these parameters 
(Figure 5.4C). 
To further unravel the relationship between the quantitative and qualitative platelet traits 
and sunitinib levels in patients, we performed a principal component analysis (PCA). The resulting 
heatmap (Figure 5.4D) indicates which parameters tended to cluster together per component. 
Four components were uncovered, which combined accounted for 95% of the variance of this 
data.  It is observed that the parameters contributing to component 1 (C1) included aggregation, 
count and platelet concentration of (N-desethyl-)sunitinib at 2 and 4 weeks. C2 was composed 
of the parameters of plasma, serum and platelet levels of (N-desethyl-)sunitinib, and C3 showed 
the related count levels and metabolite concentrations in plasma and serum at 2 and 4 weeks. 
C4 revealed an association of aggregation and sunitinib levels in plasma and serum at 4 weeks. 
Altogether, this PCA underlined that the (N-desethyl-)sunitinib levels in either serum or plasma 















































































































































































































































r = -0.6249, *p = 0.019
Figure 5.4. Platelet aggregation is reduced in RCC patients after 2 weeks of sunitinib treatment and correlates with 
reduction in platelet count. Blood was collected from 10 healthy controls and 20 RCC patients the day before, after 
2 weeks, 4 weeks and 3 months on sunitinib treatment. (A) Light transmission aggregometry was induced in isolated 
platelets (250x109/L) by collagen type I. Scatterplots indicate percentage of aggregation normalized to aggregation pre-
treatment. Circles indicate platelets from patients treated with sunitinib, stimulated with 1 µg/mL collagen; diamonds 
indicate platelets from patients treated with sunitinib and anti-platelet drugs, stimulated with 5 µg/mL collagen. Individual 
dots in the scatterplots represent one patient, for color coding see Table 5.1. Lines and error bars represent median 
± interquartile range (n=10-20), *P<0.05. (B) Correlation between difference in platelet count (ΔPlt count = Plt count 
at 2 weeks on treatment – platelet count before treatment) and difference in platelet aggregation (ΔPlt aggregation = 
Maximum amplitude at 2 weeks on treatment – maximum amplitude before treatment). Individual dots in the scatterplots 
represent one patient, for color coding see Table 5.1. (C) Correlation of significant R values for (changes in) platelet count, 
change in aggregation response and (N-desethyl-)sunitnib concentration parameters, with a highly negative correlation in 
green, a highly positive correlation in orange and no correlation in white.
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suggesting that the quantitative and qualitative platelet traits were jointly affected by the relative 
exposure to this TKI.
Changes in quantitative and qualitative platelet traits by sunitinib treatment of mRCC 
patients in relation to reported bleeding and disease progression
Of the 20 mRCC patients treated with sunitinib, 9 reported bleeding complications during 
the 3-month follow-up. Events included minor nose bleeds (epistaxis) or bleeding gums (gingivitis), 
blood in urine (haematuria), stool (gastrointestinal bleeding) or mucus (haemoptysis) (Table 5.1). 
Figure 5.4. Continued.  (D) Rotated component matrix determined by principal component analysis. Heatmap shows 
relative contribution of parameters to the four components (C1-4) with an eigenvalue over 1. Heatmap was filtered to only 
include values greater than 0.4 or less than -0.4 as important contributors to the determined component. Colors refer to a 




to componentParameter Sample Timepoint C1 C2 C3 C4
Aggregation 2 weeks
∆ Aggregation 2 weeks
Count 4 weeks
N-des-sunitinib Pellet 4 weeks
∆ Count 2 weeks
Sunitinib Pellet 4 weeks
Sunitinib Plasma 2 weeks
N-des-sunitinib Pellet 2 weeks
Sunitinib Pellet 2 weeks
N-des-sunitinib Plasma 2 weeks
N-des-sunitinib Plasma 4 weeks
Sunitinib Serum 2 weeks
∆ Count 4 weeks
Count 2 weeks
Count at start
N-des-sunitinib Serum 2 weeks
N-des-sunitinib Serum 4 weeks
Sunitinib Plasma 4 weeks
Sunitinib Serum 4 weeks
Aggregation 4 weeks
∆ Aggregation 4 weeks
Week 2 132.5 (75.8-229.8) n=9 164.0 (119.0-194.8) n=8 -0.0515 0.8498
Week 4 78.5 (49.0-202.0) n=7 132.3 (98.4-155.0) n=8 0.0201 0.9508
Month 3 162.5 (104.5-255.8) n=4 161.5 (137.8-202.0) n=5 -0.3651 0.3786
Week 2 -10.7 (-29.6 - 4.0) n=6 -3.8 (-6.7 - 0.8) n=6 0.2612 0.4072
Week 4 -3.8 (-5.7 - 12.2) n=4 -24.0 (-62.3 - -7.8) n=8 -0.6680 0.0206*
Month 3 -10.2 (-22.1 - 12.7) n=4 -6.8 (-12.0 - -4.8) n=5 0.02623 0.9516
Progression % - 10.0 (0.0 - 31.3) n=4 0 (-22.3 - 14) n=8 -0.2500 0.4285
Correla�on












Table 5.3. Reported bleeding correlates with platelet aggregation in RCC patients at 4 weeks on treatment.
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Interestingly, of the 5 patients who were on dual treatment of sunitinib and aspirin, only 1 patient 
(also treated with heparin) reported bleeding events during the first cycle of sunitinib treatment. 
We analysed whether the altered platelet count correlated with the reported bleeding. As 
shown in Table 5.3, this was not the case. On the other hand, we observed that platelet function, 
as measured by collagen-induced aggregation, was negatively correlated with bleeding at 4 weeks 
on-treatment (Table 5.3), although the number of patients included in this analysis was relatively 
small (n=4-8). At the other time points this correlation was not observed. 
After three months on treatment, CT scans were evaluated for cancer response in 15 
patients (Table 5.1). In 5 of these patients progression of the disease was established, with an 
average of 23% increase in tumor size. In the other 10 patients no progression was observed (Table 
5.1). In this limited group of patients, no correlation was observed between disease progression 
and reduction in blood cell counts or platelet aggregation (Suppl. Table 5.1). 
Discussion
In the present study with patients treated with sunitinib for mRCC, we observed that 
changes in platelet count were related to the inhibitor levels in plasma and serum. The reduction 
in platelet count may thus reflect the effective sunitinib levels in the patient, which may be used for 
therapeutic drug monitoring19. Furthermore, we observed a strong correlation between effects on 
platelet count and collagen-induced platelet aggregation, regardless of the treatment time point. 
This pointed to a common effect of this TKI on quantitative and qualitative platelet traits, which 
was confirmed by PCA. Next to RCC, sunitinib is approved for the treatment of gastrointestinal 
stromal tumor (GIST) and pancreatic neuroendocrine tumors. Furthermore, phase 3 clinical trials 
with sunitinib have been completed with positive outcome for non-small cell lung cancer20, 21. 
Hence, the results of the present study may also be applicable to other cancer types. In addition, 
platelet traits have been reported to be affected by other TKIs used for treatment of a large 
variety of malignancies1, 9. Also, other anti-cancer drugs can be taken up by platelets22. Therefore, 
the results of the present study with sunitinib may serve as a proof-of-concept with regards to 
platelet trait effects of other drugs. 
We observed that the patients on-treatment who showed a stronger inhibition in platelet 
aggregation (at normalized platelet count), also displayed a lower platelet count in whole blood. 
This can be explained by two separate mechanisms elicited by sunitinib, being (i) an effect on 
megakaryocyte level, culminating in a lower platelet count, and (ii) an effect on platelet function 
(aggregation), likely via an impaired tyrosine kinase-mediated signaling. Regarding the first 
mechanism, sunitinib may affect megakaryocytes or precursor cells directly in the bone marrow 
via interference in the proliferation of megakaryocytes and the production of proplatelets, 
which processes are dependent on tyrosine kinase activity23. Alternatively, the effects on 
megakaryocytes may be indirect via altered thrombopoietin production. Tumors can stimulate 
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platelet production via de secretion of various cytokines, especially interleukin-6, which can 
in turn enhance thrombopoietin expression in the liver24. A direct effect of sunitinib on tumor 
proliferation may result in reduced levels of thrombopoietin and thereby lowering of the platelet 
count. Besides platelet count, we confirmed that sunitinib also reduced the WBC count (up to 
grade 2) in the mRCC patients. Furthermore, also the RBC count, and hemoglobin and hematocrit 
levels were affected upon sunitinib treatment. These results point to an effect of sunitinib on 
different hematopoietic cell populations in the bone marrow. Other studies with larger patient 
numbers indeed concluded that a reduced neutrophil count could be a predictor of PFS and OS 
probability13, 25. With regard to RBCs, sunitinib has been reported to affect erythropoiesis in both 
directions, resulting in either anemia26 or in erythrocytosis27. Markedly, in our small patient group, 
we observed a transient increase in RBC count, hemoglobin and hematocrit during the first cycle 
of sunitinib treatment, as reported previously and explained by cycling kinetics during the dosing 
schedule28.
Regarding the second mechanism of sunitinib affecting tyrosine kinase-mediated platelet 
signaling, we observed that collagen-induced platelet aggregation was reduced in mRCC patients 
after 14 days of sunitinib treatment. Others have shown that this inhibition was already present 
after 24 hours of sunitinib treatment29. Besides aggregation, sunitinib also inhibits collagen-
induced thrombus formation, exposure of phosphatidylserine under flow, as well as α-granule 
secretion11, 29. As discussed before, the protein tyrosine kinases that are affected by sunitinib are 
c-Src29, as well as other kinases expressed in platelets (e.g., Axl, CSF and Itk)1. 
As platelets are able to take up sunitinib11, we hypothesized that this affects the outcome 
of sunitinib plasma measurements. Therefore, we compared the concentrations of sunitinib and 
N-desethyl-sunitinib (active metabolite of sunitinib) in plasma, serum and isolated platelets from 
mRCC patients at 2 and 4 weeks of treatment. The concentration of N-desethyl-sunitinib was 
much lower than sunitinib in both serum and plasma, which is in line with previous results30. 
Furthermore, there was no difference between serum and plasma levels of either sunitinib or 
N-desethyl-sunitinib at 2 or 4 weeks of sunitinib administration. Honeywell et al. also reported 
no differences for sunitinib in plasma as compared to serum for 5 patients on sunitinib treatment 
after 24 hours and 3 weeks31. In contrast, another study demonstrated lower concentrations 
of sunitinib in plasma as compared to serum in patients treated with sunitinib29. These studies 
demonstrated a high variation in sunitinib plasma concentrations, which could only partly be 
explained by patient- or medication-related factors32. This highlights the importance for further 
research of therapeutic drug monitoring for individual dosage adjustments, especially in cases 
of toxicity19. Interestingly, the concentrations of the active metabolite were significantly higher 
in isolated platelets from mRCC patients at 2 and 4 weeks as compared to that of sunitinib itself. 
The only difference between the two molecules is an ethyl (CH2-CH3) group that is removed from 
sunitinib by cytochrome P45033. As this enzyme not present in platelets, these results suggest 
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preferential uptake of the metabolite by these cells. Overall, we concluded that although the 
concentration of the active metabolite in platelets was higher, the uptake of sunitinib in platelets 
did not affect the sunitinib concentration in plasma versus serum. The serum concentration of 
N-desethyl-sunitinib negatively correlated with platelet count at 4 weeks of treatment, suggesting 
that higher platelet counts result in a lower concentration of metabolite present in serum. 
Together with the observation that metabolite concentrations in isolated platelets were higher, 
this may suggest that platelets do not secrete sunitinib after uptake. 
Mild bleeding was reported in 9 of the 20 investigated cancer patients on sunitinib. No 
correlation existed between the platelet count at any time point on treatment and the occurrence 
of bleeding during the 3-month study period. This agrees with earlier reports that showed that 
the platelet count is a poor predictor for bleeding34, 35.  Hence, the reported bleeding events 
may be explained by an accompanying inhibition of platelet activation by sunitinib. We observed 
a correlation between platelet aggregation responses and bleeding during sunitinib treatment, 
meaning that stronger reduction in collagen-induced platelet aggregation was observed in patients 
that reported bleeding episodes. Of note, only a small number of patients was included in this 
analysis, and at no other time points a correlation was observed between platelet aggregation 
and reported bleeding. Also, Walraven et al. did not observe this correlation between bleeding 
and platelet aggregation after 3 weeks of treatment in 5 patients29. As normal platelet functions 
can be considered to be required for effective control of hemostasis, correlations between 
bleeding and TKI-induced effects on platelet function should be investigated in larger clinical 
studies. Of note, in patients treated with sunitinib, also endothelial dysfunction and increased 
capillary leakage can be induced by treatment with sunitinib36, which may also play a role in the 
increased bleeding tendency. Paradoxically, interfering with endothelial cell integrity can also shift 
the hemostatic balance in favor of thrombosis, and treatment with sunitinib and other TKIs have 
also been associated with an increase in arterial thromboembolic events in RCC patients36, 37.
A correlation between platelet count and disease progression in this study could not be 
observed due to a relatively small number of patients. However, it has already been demonstrated 
in large, retrospective patient studies that a decrease in platelet count following sunitinib 
treatment more likely resulted in a response to therapy and longer OS in mRCC12 and GIST13. 
In the present study we clearly showed that a reduction in platelet count is accompanied by an 
inhibition of platelet aggregation, which were correlated to the (N-desethyl-)sunitinib levels in 
either serum or plasma of mRCC patients (component 1 of the PCA). Altogether this suggested 
that both quantitative and qualitative platelet traits were linked to the exposure to this TKI.
Renal cancer is a disease of the elderly, with most patients being diagnosed between 65 
and 7438, 39. Older cancer patients generally have more comorbidities, especially cardio-vascular 
disease, and therefore often receive anti-coagulant or anti-platelet drugs. In the present study, 
five patients were treated with sunitinib in combination with aspirin and/or atorvastatin, both 
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affecting platelet functions17, 18, 40. In our tests, this did not result in significant differences in 
platelet aggregation as compared to patients on sunitinib without comedication. One explanation 
may be an increased platelet reactivity observed in cancer patients41, which compensates for the 
intake of the anti-platelet drugs. On the other hand, a recent study has shown combined effects 
of ibrutinib and aspirin on collagen-induced aggregation42. Therefore, the effects of dual anti-
platelet and TKIs treatments on the inhibition of platelet function should be further investigated.
Our study encounters some limitations. Due to the limited number of patients and some 
missing values, no (clear) correlations were observed between platelet count and function on 
the one hand and bleeding and disease progression on the other hand. Also, only one platelet 
function test could be performed due to the limited amount of blood obtained from the patients. 
Out of multiple function tests, we opted for light transmission aggregometry as this is still the gold 
standard for platelet function testing. Due to ethical restrictions, the relation between platelet 
dysfunction after sunitinib treatment and abnormal (pro)platelet formation from megakaryocytes 
in the bone marrow could not be assessed. For the TKI dasatinib it has been reported that it 
promoted megakaryocyte differentiation, while it impaired migration and proplatelet formation43. 
The effects of TKI treatment on megakaryocyte proliferation and function should therefore be 
investigated in future studies.
In summary, in this study with mRCC patients treated with sunitinib a strong correlation was 
found between the effects on platelet count and inhibition of aggregation as well as (N-desethyl)
sunitinib levels in plasma and serum. The effects on count and function may thus reflect the 
relative exposure of the patient to sunitinib. This pointed to an association between the effect 
of this TKI on quantitative and qualitative platelet traits. These results may serve as a proof-of-
principle with regards to other drugs, indicating that TKI treatment can affect both platelet count 
and function, which could be used as a measure for relative drug exposure and therapeutic drug 
monitoring.
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Week 2 -87.5 (-189.9 - -36.8) n=8 -36.5 (-60.3 - 24.8) n=4 0.4609 0.1535
Week 4 -143.3 (-194.6 - -45.1) n=8 -73.0 (-147.0 - -8.8) n=5 0.2535 0.4351
Month 3 -77.8 (-137.8 - -8.6) n=8 4.5 (-42.5 - 51.5) n=2 0.4352 0.2667
Week 2 -1.68 (-4.04 - -0.08) n=8 -0.68 (-2.05 - 1.26) n=4 0.4104 0.198
Week 4 -3.65 (-5.03 - -2.02) n=8 -2.65 (-3.18 - -0.83) n=5 0.4655 0.1181
Month 3 -3.70 (-5.70 - -1.35) n=8 0.65 n=1 0.5477 0.2222
Week 2 0.21 (0.20 - 0.33) n=8 0.25 (-0.07 - 0.41) n=4 0.1282 0.7152
Week 4 -0.06 (-0.17 - 0.18) n=8 0.08 (-0.01 - 0.35) n=5 0.3803 0.2222
Month 3 -0.93 (-1.73 - -0.50) n=8 -0.87 n=1 0.1369 0.8889
Week 2 -7.7 (-24.0 - -1.2) n=8 -5.7 n=1 0.0688 1.0000
Week 4 -24.0 (-60.2 - -4.2) n=8 -6.6 (-72.1 - 7.3) n=4 0.2132 0.6095
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Supplemental Table 5.1. No correlation of disease progression with changes in blood cell counts and platelet 
aggregation in mRCC patients 
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All irreversible Bruton tyrosine kinase (Btk) inhibitors, including ibrutinib and acalabrutinib 
induce platelet dysfunction and increased bleeding risk. New reversible Btk inhibitors were 
developed, like MK-1026. The mechanism underlying increased bleeding tendency with Btk 
inhibitors remains unclear. We investigated the effects of ibrutinib, acalabrutinib and MK-1026 
on platelet function in healthy volunteers, patients and Btk-deficient mice, together with off-
target effects on tyrosine kinase phosphorylation. All inhibitors suppressed GPVI- and CLEC-2-
mediated platelet aggregation, activation and secretion in a dose-dependent manner. Only 
ibrutinib inhibited thrombus formation on vWF-co-coated surfaces, while on collagen this was 
not affected. In blood from Btk-deficient mice, collagen-induced thrombus formation under flow 
was reduced, but preincubation with either inhibitor was without additional effects. MK-1026 
showed less off-target effects upon GPVI-induced TK phosphorylation as compared to ibrutinib 
and acalabrutinib. In ibrutinib-treated patients, GPVI-stimulated platelet activation and adhesion 
on vWF-co-coated surfaces were inhibited, while CLEC-2 stimulation induced variable responses. 
The dual inhibition of GPVI and CLEC-2 signalling by Btk inhibitors might account for the increased 
bleeding tendency, with ibrutinib causing more high-grade bleedings due to additional inhibition 
of platelet-vWF interaction. As MK-1026 showed less off-target effects and only affected activation 
of isolated platelets, it might be promising for future treatment.
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Introduction
Ibrutinib, an irreversible Bruton’s tyrosine kinase (Btk) inhibitor, is widely used to treat 
multiple haematological malignancies1-5. Ibrutinib treatment shows high response rates and 
improved progression-free survival, with decreased toxicity when compared to conventional 
treatment options1-6. However, ibrutinib is prescribed life-long (or until progression) and requires 
side effect management. These toxicities are responsible for discontinuation in up to 20% of 
patients6-9. A prominent side effect of ibrutinib is bleeding, with over 50% of patients experiencing 
bleeding events within 3 years, ranging from mild mucocutaneous bleeding to life-threatening 
haemorrhage3, 6, 8, 10. Studies have suggested that ibrutinib-associated bleeding tendency is caused 
by interference with platelet GPVI signalling pathway through off-target effects on Src kinases11, 12.
Recently, multiple other Btk inhibitors have been developed, including the irreversible 
Btk inhibitor acalabrutinib and the reversible Btk inhibitor MK-1026 (formerly known as ARQ-
531)13, 14. Opposed to data suggesting that acalabrutinib shows less off-target effects, it still 
causes an increased bleeding tendency in patients, albeit showing mainly mild bleeding15. 
Studies investigating GPVI inhibitors as potential antithrombotic drugs have shown that 
inhibition on receptor level does not impair haemostasis16. Also, GPVI-deficient patients exhibit 
only a mild bleeding diathesis17 and many potential patients are undiagnosed as they remain 
asymptomatic18. In agreement, studies in mice have shown that GPVI deficiency alone does not 
impair haemostasis19-21, while combined GPVI and CLEC-2 deficiency does21. Furthermore, Btk was 
shown to be involved in GPIb-vWF mediated platelet adhesion, as well as integrin αIIbβ3 outside-in 
activation which were inhibited by ibrutinib6, 22, 23. Therefore, the current mechanism of increased 
bleeding tendency in patients using Btk inhibitors is still unclear and underlines the importance 
for treatment decisions and the development of novel Btk inhibitors. We therefore investigated 
the effect of multiple Btk inhibitors on platelet function pathways in healthy volunteers, patients 
and Btk knock-out (KO) mice. 
Materials and Methods
Materials and methods are available in Supplemental Data.
Results
Ibrutinib and acalabrutinib inhibit platelet activation and aggregation by GPVI and 
CLEC-2 in a dose-dependent manner
Treatment with ibrutinib, but also acalabrutinib, can increase bleeding tendency6, 15. To 
assess the underlying pathways, we investigated platelet activation mediated by multiple agonists 
in presence of ibrutinib or acalabrutinib.
Both ibrutinib and acalabrutinib inhibited aggregation of washed platelets and platelet-
rich plasma induced by 1 µg/ml collagen in a dose-dependent manner (Fig 6.1A). In isolated 
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platelets, a significant inhibition was observed at 1 µM and higher for both compounds (Fig 6.1Ai). 
In the presence of plasma, a higher concentration of 5-10 µM was required to significantly inhibit 
collagen-induced platelet aggregation (Fig 6.1Aii). The IC50 values for ibrutinib and acalabrutinib 
were 7.7 and 6.0 times lower in washed platelets as compared to PRP (Suppl Table 6.1). At a higher 
collagen concentration, aggregation was not affected by either inhibitor. (Suppl Fig 6.1Aii). CLEC-
2-induced platelet aggregation was also inhibited by both acalabrutinib and ibrutinib in a similar 
dose-dependent manner (Fig 6.1B). GPVI-induced integrin αIIbβ3 activation, P-selectin expression, 







































































































































































































Figure 6.1. Ibrutinib and acalabrutinib inhibit GPVI- and CLEC-2-induced platelet activation and aggregation in a 
dose-dependent manner. Washed platelets (Ai, B) or PRP (Aii) (250x109/L) from healthy volunteers were incubated 
with different concentrations of acalabrutinib or ibrutinib for 10 minutes at 37°C. Shown are dose-response curves of 
aggregation induced by collagen type I (A, 1 µg/ml) or rhodocytin (B, 1 µg/ml) in presence of acalabrutinib (lime circles) 
or ibrutinib (green circles) normalised to control. (C) Washed platelets (100x109/L) were pre-incubated with different 
concentrations of acalabrutinib or ibrutinib and stimulated with collagen-related peptide (CRP-XL, 5 µg/mL) for 15 
minutes and simultaneously stained for activated integrin αIIbβ3 (i) and α-granule secretion (P-selectin, ii). Dose response 
curves show the percentages of platelets binding FITC-labelled PAC-1 monoclonal antibody or AF647-labelled anti-human 
CD62 mAb normalized to control expression. (D) Platelets pre-treated with different concentrations of acalabrutinib or 
ibrutinib were stimulated using both CRP-XL (5 µg/mL) and thrombin (4 nM) for 60 minutes at 37°C and PS-exposure was 
determined by flow cytometry. Histogram shows percentage of platelets binding FITC-labelled annexin A5 normalized to 
control expression. (E) Fura-2-loaded platelets (200x109/L) pre-incubated with vehicle, acalabrutinib (1 µM) or ibrutinib (1 
µM) were stimulated with CRP-XL (10 µg/mL) in presence of 2 mM CaCl2. Histograms show (i) maximal rise in [Ca
2+]i and 
(ii) slope. Data are shown as means ± SEM (n=6-7). * p<0.05, ** p<0.01 vs control (vehicle).
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concentrations of ibrutinib (<1 µM) resulted in significant inhibition as compared to acalabrutinib 
(Fig 6.1C-D). The IC50 values of ibrutinib for the inhibition of integrin αIIbβ3 activation, P-selectin 
expression and PS exposure were 5.0, 8.2 and 2.2 times lower, respectively, than for acalabrutinib 
(Suppl. Table 6.1). Furthermore, both compounds did not alter the peak level of intracellular Ca2+ 
elevations, but the slope of this response was reduced in ibrutinib-treated platelets (Fig 6.1E). 
Aggregation induced by the P2Y12 agonist 2MeS-ADP, the thromboxane A2 analogue 
U46619, and thrombin (Suppl Fig 6.1A) as well as ristocetin remained unaffected in presence 
of Btk inhibitors (Suppl Fig 6.1B). ADP-stimulated αIIbβ3 activation and α-granule secretion 
were mildly inhibited by both Btk inhibitors (Suppl Fig 6.1C). No effects on αIIbβ3 activation or 
α-granule secretion were observed upon thrombin activation (Suppl Fig 6.1C). Altogether, these 
results suggest that ibrutinib and acalabrutinib inhibit both GPVI- and CLEC-2-mediated platelet 
aggregation, albeit lower concentrations of ibrutinib were required. This might explain the 
increased bleeding tendency seen with both inhibitors.
Ibrutinib, but not acalabrutinib, impairs thrombus formation in whole blood on surfaces 
co-coated with vWF
We for the first time investigated the effects of ibrutinib and acalabrutinib on whole 
blood thrombus formation under flow, simultaneously over multiple surfaces24. This allowed 
systematic analysis of platelet activation and thrombus formation on collagen type I and III and 
vWF co-coated with laminin, rhodocytin, ristocetin or fibrinogen. In the presence of plasma, 
concentrations higher than 3.3 µM were required to significantly inhibit collagen-induced 
aggregation (Fig 6.1A). Considering previous in vitro studies, as well as plasma concentrations of 
ibrutinib and acalabrutinib in patients for inhibition of B-cell carcinomas15, 25, we selected 1 µM to 
inhibit washed platelets and 5 µM to inhibit platelets in the presence of plasma. 
Microscopic visualization of platelet adhesion, activation and thrombus formation on 
collagen showed that neither of the two inhibitors affected these processes, except for reduced 
PS-exposure by ibrutinib (Fig 6.2A). This was confirmed by image analysis resulting in five 
thrombus parameters (P1-P5) and three activation markers (P6-8, Suppl Fig 6.2). To systematically 
summarize the effects on all parameters, cumulative histograms were generated showing that 
ibrutinib, but not acalabrutinib, reduced PS-exposure on collagen type I and III (Fig 2B, P8). Upon 
blood perfusion over surfaces that trigger GPIb alone (vWF+ristocetin) or in combination with 
CLEC-2 (vWF+rhodocytin), α6β1 (vWF+laminin) or αIIbβ3 (vWF+fibrinogen), only ibrutinib decreased 
almost all parameters of thrombus formation (Fig 6.2B, Suppl Fig 6.2). In comparison to control, 
thrombi were smaller and less compact in structure with ibrutinib and showed reduced expression 
of activated integrin αIIbβ3 and P-selectin (α-granule release) (Suppl Fig 6.2). These results show 
that, in contrast to acalabrutinib, platelet adhesion to surfaces co-coated with vWF was strongly 
impaired by ibrutinib. 
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Figure 6.2. Ibrutinib, but not acalabrutinib, affected thrombus formation in whole blood perfused over six different 
surfaces. Pre-incubated blood samples from healthy donors with vehicle (<0.1% DMSO), acalabrutinib (5 µM) or ibrutinib 
(5 µM) were recalcified in presence of PPACK. Blood was perfused for 3.5 minutes at a wall shear rate of 1,000 s-1 over six 
different surfaces. After perfusion, thrombi were stained with AF568-annexin A5, FITC-α-fibrinogen and AF647-α-CD62P 
to detect PS-exposure, integrin αIIbβ3 activation and P-selectin expression. (A) Representative images of thrombi formed 
on collagen type I and vWF co-coated with rhodocytin. (B) Histograms show the cumulative representation of scaled 
values from 0-10 for each parameter over different surfaces consisting of (i) collagen type I, (ii) collagen type III, (iii) vWF 
co-coated with laminin, (iv) vWF co-coated with rhodocytin, (v) vWF co-coated with ristocetin and (vi) vWF co-coated 
with fibrinogen in presence of acalabrutinib or ibrutinib. Colours reflect the adhesion parameters (P1-2; black, grey), 
aggregation parameters (P3-5; shades of green), and activation parameters (P6-8; yellow, orange and red). * p<0.05, ** 
p<0.01, *** p<0.001 vs vehicle.
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Effects of ibrutinib and acalabrutinib on wild-type and Btk-deficient mouse platelets
To further examine the effects of ibrutinib and acalabrutinib on platelets, thrombus 
formation and platelet activation were determined in blood from WT and Btk-KO mice. Blood 
samples were incubated with ibrutinib or acalabrutinib before perfusion over collagen type I. In 
control conditions (vehicle), thrombus formation was reduced in blood from Btk-KO mice with 
regard to platelet deposition, multilayer formation (P1-2, P5) and PS-exposure (P8, Fig 6.3A-
B, Suppl Fig 6.3A). In WT blood, presence of acalabrutinib gave a similar inhibitory pattern of 
thrombus formation (Fig 6.3A, C). Comparable to human blood, incubation of WT mouse blood 
with ibrutinib resulted in limited effects on thrombus formation, only a decrease in PS-exposure 
was observed (Fig 6.3A, C, Suppl Fig 6.3A). When Btk inhibitors were pre-incubated in blood from 
Btk-KO mice, no additional inhibition on thrombus formation was observed (Figure 6.3A, C, suppl 
Fig 6.3A). The only observed effect, was a reduction in P-selectin expression in the presence of 
ibrutinib, as compared to vehicle, in Btk-KO mice (Figure 6.3A, C, Suppl Fig 6.3).
GPVI-induced platelet activation by CRP-XL was strongly reduced in Btk-KO platelets 
as compared to WT with regard to αIIbβ3 activation, α-granule release and PS-exposure, as 
determined by flow cytometry (Fig 6.3D-E). This was in agreement with the results obtained from 
whole blood perfusion experiments. Interestingly, αIIbβ3 activation and P-selectin expression were 
also moderately reduced in Btk-KO mice upon PAR4 stimulation, while activation with ADP was 
not affected (Suppl Fig 6.3B-C). When blood was preincubated with Btk inhibitors, we observed 
significant reduction of all platelet activation markers in WT platelets upon GPVI stimulation (Fig 
6.3D-E). In platelets from Btk-KO mice, both inhibitors did not further reduce αIIbβ3 activation and 
P-selectin expression regardless of the agonist. We only observed significant reduction of PS-
exposure in Btk-KO platelets in the presence of ibrutinib, as compared to vehicle (Fig 6.3E).
Overall, preincubation of whole blood from Btk-KO mice with acalabrutinib and ibrutinib 
did not result in major additional effects on thrombus formation on collagen under flow, as well 
as on platelet activation.
Btk inhibitors reduce GPVI-induced phosphorylation of multiple platelet tyrosine kinases
To evaluate off-target effects of the Btk inhibitors, we performed a PamGene kinase assay 
to visualize which tyrosine kinases were regulated upon platelet stimulation via GPVI, as well as 
those tyrosine kinases that were subsequently influenced upon pre-incubation of the platelets 
with 1 µM ibrutinib or acalabrutinib. We observed that in isolated platelets, in total 73 tyrosine 
kinases were significantly phosphorylated by stimulation with CRP65, of which were significantly 
inhibited by ibrutinib and acalabrutinib preincubation (Fig 6.4). Median kinase statistics showed 
that ibrutinib inhibited tyrosine phosphorylation of these proteins on average 4.4-fold, while 
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Figure 6.3. Acalabrutinib and ibrutinib reduced thrombus formation and PS-exposure in whole blood under flow, as 
well as activation of isolated platelets from WT but not Btk-KO mice. Pooled citrated whole blood samples from two WT 
or Btk-KO mice were pre-incubated with vehicle (<0.1% DMSO), acalabrutinib (5 µM) or ibrutinib (5 µM) in the presence of 
PPACK and fragmin for 10 minutes at 37°C. After incubation, blood samples were recalcified and perfused for 3.5 minutes 
at a wall shear rate of 1,000 s-1 over a collagen type I surface. Thrombi were post-stained with FITC-labelled anti-CD62P 
mAb, PE-labelled JonA mAb and AF647-labelled Annexin-A5 to detect P-selectin expression, integrin activation and PS-
exposure respectively. (A) Representative brightfield and fluorescence images from thrombus formation in blood from WT 
and Btk-KO mice for each inhibitor. (B) Histograms show the cumulative representation of scaled values from 0-10 for each 
parameter on a collagen type I surface of thrombus formation in WT and Btk-KO mice blood samples. Colours reflect the 
adhesion parameters (P1-2; black, grey), aggregation parameters (P3-5; shades of green), and activation parameters (P6-
8; yellow, orange and red). (C) Histograms of cumulative scaled values of multiple parameters in WT or Btk-KO mice with 
addition of vehicle (<0.1% DMSO), acalabrutinib or ibrutinib. (D) Platelet activation in whole blood induced by CRP-XL (1 
µg/mL). Histograms show the percentages of platelets binding PE-labelled JON/A monoclonal antibody against activated 
αIIbβ3 integrin or BB700-labelled CD62P mAb in WT and Btk-KO mice. (E) PS-exposure of platelets induced by CRP-XL (1 µg/
mL). Histogram shows percentage of platelets binding FITC-labelled lactadherin. Data are shown as means ± SEM (n=6-8). 
* p<0.05. ** p<0.01, *** p<0.001 vs vehicle or otherwise indicated.
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In comparison to these irreversible inhibitors, we investigated if the reversible Btk 
inhibitor MK-102614 showed a more favourable anti-platelet effect. First, we evaluated which 
platelet tyrosine kinases were affected by this compound upon GPVI stimulation. Only 18 tyrosine 
kinases were significantly inhibited by MK-1026 (Fig 6.4). Median kinase statistics showed that 
MK-1026 inhibited tyrosine phosphorylation of these proteins on average 0.52-fold, which was 
8.3-fold lower as compared to ibrutinib. As expected, all three inhibitors significantly inhibited 
the phosphorylation of Btk, and ibrutinib and acalabrutinib also inhibited Tec. Furthermore, 
ibrutinib and acalabrutinib also inhibited the phosphorylation of Src family kinase (SFKs) and 
other downstream proteins as previously described11, 12. 
These results show that ibrutinib and acalabrutinib showed the same off-target effects on 
GPVI-induced tyrosine kinase phosphorylation in platelets, although the effects of acalabrutinib 
were less strong. The reversible inhibitor MK-1026 appeared to have less off-target effects in 
platelets upon GPVI stimulation, in combination with a less strong inhibition profile as compared 
to the irreversible inhibitors.
The reversible Btk inhibitor MK-1026 shows only limited anti-platelet effects in human 
and mouse platelets in vitro
As we demonstrated that irreversible inhibition of Btk can impair platelet function, we 
also investigated the effects of the reversible Btk inhibitor MK-1026 on platelet function. First, we 
performed collagen- and rhodocytin-induced dose-response aggregation experiments in PRP and 
washed platelets. Similar to the irreversible Btk inhibitors, MK-1026 inhibited platelet aggregation 
(with more prominent effects in washed platelets compared to PRP) at multiple concentrations 
induced by both agonists (Fig 6.5A). GPVI-induced integrin αIIbβ3 activation, P-selectin expression, 
and PS-exposure were also dose-dependently reduced by MK-1026 (Fig 6.5B). The calculated 
IC50 values for MK-1026 in the presence of plasma were similar as for acalabrutinib (Suppl Table 
6.1). Based on these results, in combination with reported in vivo plasma concentrations26, we 
selected 5 µM for further experiments. Aggregation induced by ADP and U46619 were slightly 
but significantly reduced at this concentration of MK-1026, while responses to thrombin and 
ristocetin were unaffected (Suppl Fig 6.4A-B). Integrin αIIbβ3 activation and P-selectin expression 
were not inhibited by MK-1026 in platelets stimulated with ADP or thrombin (Suppl Fig 6.4C). 
Also, MK-1026 did not alter platelet adhesion and thrombus formation on six different surfaces, 
as seen with acalabrutinib (Fig 6.5D, Suppl Fig 6.5). 
We also investigated the effects of MK-1026 using blood from Btk-KO mice. Similarly as 
for acalabrutinib and ibrutinib, we did not observe additional inhibition of whole blood thrombus 
formation on collagen with MK-1026 in blood samples from WT or Btk-KO mice (Fig 6.6A-B, Suppl 
Fig 6.6A). Also, no inhibitory effect of MK-1026 was found upon platelet activation or PS-exposure 
from WT or Btk-KO mice with CRP-XL, ADP or PAR4 agonist (Fig 6.6C-D, Suppl Fig 6.6B-C). 
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Figure 6.5. Effects of MK-1026 on aggregation and activation of isolated platelets in response to several agonists as 
well as whole blood thrombus formation under flow. (A) PRP or washed platelets (250x109/L) from healthy volunteers 
were incubated with different concentrations of MK-1026 for 10 minutes at 37°C. Shown are dose-response curves of 
aggregation induced by (i) collagen type I (1 µg/mL), or (ii) rhodocytin (1 µg/mL) in the presence of MK-1026 normalised 
to control expression. (B) Washed platelets (100x109/L) were pre-incubated with different concentrations of MK-1026 
and stimulated with collagen-related peptide (CRP-XL, 5 µg/mL) for 15 minutes and simultaneously stained for activated 
integrin αIIbβ3 and α-granule secretion (P-selectin). Histograms show the percentages of platelets binding FITC-labelled 
PAC-1 monoclonal antibody or AF647-labelled anti-human CD62 mAb normalized to control expression. (C) Platelets pre-
treated with different concentrations of MK-1026 were stimulated using both CRP-XL (5 µg/mL) and thrombin (4 nM) for 
60 minutes at 37°C and PS-exposure was determined by flow cytometry. Histogram shows percentage of platelets binding 
FITC-labelled annexin A5 normalized to control expression. Data are shown as means ± SEM (n=6-7). (D) Pre-incubated 
blood samples from healthy donors with vehicle (<0.1% DMSO) or MK-1026 (5 µM) were recalcified in the presence of 
PPACK. Blood was perfused for 3.5 minutes at wall shear rate of 1,000 s-1 over six different coated surfaces. Thrombi were 
post-stained with AF568-annexin A5, FITC-α-fibrinogen and AF647-α-CD62P to detect PS-exposure, integrin activation 
and P-selectin expression. Cumulative histograms represent the scaled values (0-10) for each of the parameters. Colours 
reflect the adhesion parameters (P1-2; black, grey), aggregation parameters (P3-5; shades of green), and activation 
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These data show that the reversible Btk inhibitor MK-1026 inhibited GPVI- and CLEC-2-
mediated aggregation of washed platelets, but did not impair platelet adhesion or activation in 
whole blood perfused over collagen.
(B)
(C)
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Figure 6.6. Thrombus formation, platelet activation and PS-exposure in blood from WT and Btk-KO mice was 
unaffected by MK-1026. Pooled citrated whole blood samples from two WT or Btk-KO mice were pre-incubated with 
vehicle (<0.1% DMSO) or MK-1026 (5 µM) in the presence of PPACK and fragmin for 10 minutes at 37°C. After incubation, 
blood samples were recalcified and perfused for 3.5 minutes at a wall shear rate of 1,000 s-1 over a collagen type I surface. 
Thrombi were post-stained with FITC-labelled anti-CD62P mAb, PE-labelled JON/A mAb and AF647-labelled Annexin-A5. 
(A) Representative brightfield and fluorescence images from thrombus formation in blood from WT and Btk-KO mice. 
(B) Histograms of cumulative scaled values of multiple parameters in WT or Btk-KO mice with addition of vehicle (<0.1% 
DMSO) or MK-1026. Colours reflect the adhesion parameters (P1-2; black, grey), aggregation parameters (P3-5; shades of 
green), and activation parameters (P6-8; yellow, orange and red). (C) Platelet activation in whole blood induced by CRP-
XL (1 µg/mL). Histograms show the percentages of platelets binding PE-labelled JON/A monoclonal antibody or BB700-
labelled CD62P mAb in WT and Btk-KO mice. (D) PS-exposure of platelets induced by CRP-XL (1 µg/mL). Histogram shows 
percentage of platelets binding FITC-labelled lactadherin. Data are shown as means ± SEM (n=6-8). * p<0.05, ** p<0.01, 
*** p<0.001.
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Ibrutinib inhibits thrombus formation under flow on multiple surfaces and GPVI-induced 
platelet activation responses in patients 
Next, we assessed which platelet activation pathways were altered in patients using 
ibrutinib. Sixteen patients were included, of which 7 did not receive ibrutinib and 9 were treated 
with 420-560 mg ibrutinib once a day (Table 6.1). Baseline characteristics were largely similar 
between groups. Importantly, none of the patients were thrombocytopenic, except one patient 
with a platelet count of 50x109/L (Table 6.1). Of the ibrutinib-treated patients, 66% (6/9) reported 
bleeding symptoms with a median ISTH-BAT score of 2 (range 1-7, Table 6.1). Of patients without 
ibrutinib treatment, none reported bleeding symptoms. 
 Whole blood from patients was perfused over collagen type I or vWF plus rhodocytin 
or laminin. No differences in thrombus formation were observed between patients without 
ibrutinib and healthy controls (Suppl Fig 6.7). On collagen, treatment with ibrutinib reduced 
thrombus contraction and height (multilayer) compared to non-treated patients. Furthermore, 
αIIbβ3 activation, P-selectin expression and PS-exposure were significantly reduced (Fig 6.7A, Suppl 
Fig 6.7A). For thrombi formed on vWF plus rhodocytin or laminin, αIIbβ3 activation and α-granule 
secretion were reduced upon ibrutinib treatment (Fig 6.7A, Suppl Fig 6.7B-C). 
 Aggregation of isolated platelets from ibrutinib-treated patients showed on average 
no significant inhibition upon stimulation with any agonist (Fig 6.7B). However, platelets from 
5 ibrutinib-treated patients were highly nonresponsive to collagen stimulation, while platelets 
from 2 patients responded normally to collagen. Also, with rhodocytin, platelets from 4 patients 
receiving ibrutinib did not aggregate, while platelets from 4 patients showed normal aggregation. 
When platelet activation was examined by flow cytometry, αIIbβ3 activation and P-selectin 
expression were inhibited in CRP-XL-stimulated platelets from all ibrutinib-treated patients (Fig 
6.7C). Upon ADP stimulation, platelets from patients on treatment showed a slight increase in 
αIIbβ3 activation, while no effects on secretion were observed (Fig 6.7C). PS-exposure by thrombin 
plus CRP-XL, was unchanged for all patients’ platelets (Fig 6.7D).
As 66% of our patients reported bleeding symptoms, we compared patients with significant 
bleeding (>2 ISTH-BAT score) with patients with no/mild bleeding (0-1 ISTH-BAT score). Generally, 
no significant changes were observed in platelet aggregation and thrombus formation in patients 
with or without bleeding (Suppl Fig 6.8). 
In summary, platelets from patients on ibrutinib treatment displayed inhibition of 
activation by GPVI as well as reduced adhesion and thrombus formation under flow over collagen 
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Figure 6.7. Ibrutinib inhibits whole blood thrombus formation under flow on multiple surfaces and GPVI-induced 
platelet aggregation and activation responses in patients. Citrated whole blood was collected from healthy volunteers 
and 16 patients with(out) ibrutinib treatment. (A) Whole blood from healthy controls and patients was perfused for 3.5 
minutes at a wall shear rate of 1,000 s-1 over coated microspots containing collagen type I, vWF co-coated with rhodocytin 
or vWF co-coated with laminin. Subtraction heatmap representing the effect of ibrutinib treatment in individual patients. 
Average values obtained with blood of patients without ibrutinib treatment was set at 0 for reference. Effects were filtered 
for changes greater than the 2x SD range of the different platelet parameters. (B) Light transmission aggregometry was 
induced in isolated platelets (250x109 /L) by collagen (1 µg/mL), rhodocytin (1 µg/mL), 2MeS-ADP (1 µM), U46619 (1 
µM) or thrombin (1 nM). Scatter plots show the percentage of aggregation of healthy controls (white circles), patients 
(grey circles) or patients receiving ibrutinib (black circles). Each circle represents one individual. (C, D) Washed platelets 
(100x109 /L) were stimulated with collagen-related peptide (CRP-XL, 5 µg/mL) or 2MeS-ADP (1 µM) for 15 minutes and 
analysed by flow cytometry. Shown are percentages of platelets binding FITC-labelled PAC1 mAb against integrin αIIbβ3 
(C) and AF647-labelled CD62P mAb for α-granule secretion (D), respectively. (E) PS-exposure was stimulated using both 
CRP-XL (5 µg/mL) and thrombin (4 nM) for 60 minutes at 37°C. Scatter plots show the percentage of platelets binding FITC-




Due to their promising effects on progression-free survival, Btk inhibitors are increasingly 
prescribed in haematological malignancies4, 5. Btk inhibitors require lifelong treatment, and the 
high percentage of discontinuation due to side effects (including bleeding tendency) stresses the 
importance of understanding and managing these6-8. We found that ibrutinib and acalabrutinib 
inhibit both GPVI- and CLEC-2-mediated platelet aggregation in a dose-dependent manner. Also, 
all inhibitors dose-dependently impaired GPVI-induced αIIbβ3 activation and α-granule secretion. 
Ibrutinib reduced thrombus formation on surfaces co-coated with vWF, but not on collagen. 
Moreover, we are the first to study the effects on platelet function of MK-1026, a reversible Btk 
inhibitor.
Other studies investigating effects of Btk inhibitors on platelet function have described 
different findings. Several papers have shown inhibition of the GPVI pathway by ibrutinib or 
acalabrutinib, either directly via Btk or due to off-target effects on Src kinases or other downstream 
proteins11, 12, 23, 27-31. Others have implicated that GPIb-29, 32 or αIIbβ3-mediated signalling
28, 31 were 
affected by ibrutinib. In agreement, in the present study ibrutinib also inhibited thrombus 
formation on ristocetin and fibrinogen co-coated with vWF. Levade et al. have also shown that 
ibrutinib affected platelet adhesion to vWF only under flow, but did not assess acalabrutinib22. 
Furthermore, we found that both ibrutinib and acalabrutinib impaired GPVI-mediated aggregation, 
but not platelet adhesion on collagen under flow. Previous studies found conflicting results with 
regards to the effects of ibrutinib on collagen adhesion, with some who did find inhibition12,33 and 
others that could not34. A possible explanation for this is that platelet adhesion to collagen is also 
regulated by integrin α2β1, which does not signal via Btk
34. Our data now directly compared the 
differences between ibrutinib and acalabrutinib in whole blood thrombus formation under flow 
on six different surfaces, and shows for the first time that ibrutinib, but not acalabrutinib impairs 
platelet adhesion surfaces co-coated with vWF. This might play a role in the increased incidence 
of major bleeding seen in ibrutinib treatment compared to acalabrutinib.
Although GPVI is important for platelet adhesion and activation on collagen, recent studies 
have shown that GPVI inhibitors do not impair haemostasis16. GPVI-deficient patients exhibit only 
a mild bleeding diathesis17 and GPVI depletion in mice did not increase bleeding tendency19,20. 
Therefore, the bleeding tendency seen with Btk inhibitors cannot solely be mediated by GPVI. 
Depletion of both GPVI and CLEC-2 from mouse platelets did impair haemostasis21. In line with 
this, we found that Btk inhibitors inhibited both GPVI- and CLEC-2-mediated aggregation. 
Only few studies have investigated Btk-KO mice or X-linked agammaglobulinemia (XLA) 
patients, a Btk deficiency in humans. Btk-KO mice showed impaired GPVI, CLEC-2 and GPIb 
signalling35-38. In line with this, we found decreased GPVI-induced platelet granule secretion and 
thrombus formation in Btk-KO mice. XLA patients demonstrated impaired GPVI- or CLEC-2-induced 
PLCγ2 phosphorylation and platelet aggregation39, 40. As compared to XLA patients, ibrutinib has 
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similar effects on GPVI, CLEC-2 and GPIb signalling. However, XLA patients are not associated with 
an increased bleeding risk12. This suggests that Btk inhibitors affect other targets, most notably 
Tec, which can substitute for Btk35 and is also inhibited by ibrutinib and acalabrutinib12. Also, off-
target effects on Src kinases have been implicated in the  bleeding tendency11, 12. We assessed off-
target effects on GPVI-induced tyrosine kinase phosphorylation in platelets by using the PamGene 
assay. These results showed that ibrutinib and acalabrutinib showed the same off-target effects, 
although the effects of acalabrutinib were less strong. Importantly both inhibitors had an off-target 
effect on Tec and Src kinases, questioning the previous conclusions that these were responsible 
for the increased severe bleeding seen with ibrutinib compared to acalabrutinib. 
When comparing results found in vitro in human and mice, we found that in human 
samples, Btk inhibitors did not alter collagen-mediated adhesion under flow in agreement with 
Zheng et al.31, whereas in mice, Btk inhibition (either by KO mice or acalabrutinib) reduced this 
response. Btk-dependent signalling is completely absent in KO mice, and therefore, this may 
result in stronger effects as compared to pharmacological inhibition. Btk proteins display 99.4% 
similarity between human and mice41, so a species-dependent interaction with an inhibitor cannot 
explain the observed differences. A possibility could be different bioavailability between mouse 
and man. Ibrutinib and acalabrutinib are highly plasma protein-bound in human blood, 97.3% 
and 97.5%, respectively42, 43, while acalabrutinib was reported to have lower protein binding in 
mouse blood (75.4%)43. This may contribute to the more pronounced effects of acalabrutinib in 
mouse blood as compared to human blood. We also observed different results between human 
and mouse platelets with MK-1026 (same concentration) in flow cytometric experiments. This 
may be explained by the use of murine whole blood in these experiments. Mouse blood contains 
~three times more platelets as compared to human blood, and plasma proteins are also likely to 
bind MK-1026. Altogether, this may explain the absent effect of MK-1026 on platelet functions of 
wild-type mice.
As our data propose a direct role for Btk in impaired platelet function, we tested the 
reversible Btk inhibitor MK-1026. MK-1026 showed promising effects on ibrutinib resistant CLL 
cells in vitro and is currently being tested in clinical trials14. In the PamGene kinase assay MK-
1026 appeared to have less off-target effects in platelets upon GPVI stimulation, in combination 
with a less strong inhibition profile as compared to the irreversible inhibitors. MK-1026 reduced 
GPVI- and CLEC-2-mediated aggregation, as well as GPVI-induced platelet activation in washed 
platelets, largely similar to acalabrutinib. In human and mouse blood, MK-1026 did not impair 
collagen-induced thrombus formation under flow, in contrast to acalabrutinib which did affect this 
response in mouse blood. Hence, this reversible inhibitor had less inhibitory effects on platelets 
as compared to ibrutinib, in agreement with a recent study31. Hence, MK-1026 could be expected 
to show a slightly reduced or comparable bleeding tendency compared to acalabrutinib.
The present dose-response experiments, in line with previous studies11, 33, show that at 
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similar dose, ibrutinib is a more effective platelet inhibitor compared to other Btk inhibitors. This 
has been attributed to the inhibition of drug efflux pumps by ibrutinib33. We observed that higher 
concentrations of inhibitors are required to inhibit platelet aggregation in the presence of plasma, 
as compared to washed platelets. This in line with previous observations with other TKIs44, 45. This 
is most likely caused by binding of ibrutinib and acalabrutinib to albumin46-48. It has been reported 
that prolongation of the incubation time lowered the IC50 values of ibrutinib and acalabrutinib 
for GPVI-mediated aggregation49. However, in that study a much lower collagen concentration 
was used, which may be more sensitive to longer incubation with low doses of inhibitors. 
Furthermore, that study did not include CLEC-2-dependent platelet responses49. Although 
inhibitor concentration could play a role in the extent of inhibition, we showed that ibrutinib and 
acalabrutinib influence additional platelet pathways as compared to MK-1026, suggesting that 
the extent of Btk inhibition might not be the reason for the increased bleeding tendency. 
Previous studies assessing which platelet pathways are involved in bleeding tendency 
in patients using ibrutinib found conflicting results. Some showed a correlation with collagen-
induced aggregation12, 22, 50, and some with platelet adhesion to collagen12, whereas others could 
not find this22. Bleeding tendency was also associated with adhesion to vWF under flow22 and 
one study found a correlation with ristocetin-induced platelet aggregation32, which another study 
could not replicate28. Ibrutinib can also induce shedding of GPIbα, GPIX and integrin αIIbβ3 in 
patients, but the correlation with bleeding remains unknown51.
A recent study assessed platelet parameters in patients with CLL and mantle cell lymphoma 
(MCL)52, showing correlations between bleeding tendency, thrombocytopenia and decreased 
ADP-induced platelet aggregation. However, a drawback of this study was that a large patient 
proportion was thrombocytopenic, which can directly influence platelet aggregation, as platelet 
concentration in PRP was not reported to be adjusted. This impaired the establishment if ibrutinib 
or platelet count affected aggregation response. In our patients with (in general) normal platelet 
counts, we also observed significant differences in platelet responses to several stimuli of patients 
using ibrutinib. Furthermore, 66% of the included patients with ibrutinib treatment reported 
bleeding symptoms. Although we could show that in patients, similar to healthy volunteers, 
ibrutinib inhibited GPVI signalling, with variable effects on CLEC-2, as well as reduced thrombus 
formation to surfaces co-coated with vWF, this could not differentiate for the bleeding tendency. 
Generally, the patients showed a large variation in measurement outcomes, which might be 
influenced by clinical factors. However, with patients on ibrutinib treatment, we have directly 
compared whole blood thrombus formation under flow on multiple surfaces, including vWF plus 
rhodocytin and laminin, which has not been reported with ibrutinib-treated patients thus far.
In conclusion, the present work demonstrated that ibrutinib, acalabrutinib and MK-1026 
inhibited GPVI- and CLEC-2-mediated platelet aggregation, but only ibrutinib also inhibited GPVI-
induced platelet activation and thrombus formation on surfaces co-coated with vWF. The novel 
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reversible BTK inhibitor MK-1026 might therefore be promising for future treatment in patients 
at risk for bleeding.
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Acalabrutinib was obtained from Selleckchem (Houston, TX, USA), MK-1026 (formerly 
ARQ-531) was a provided by ArQule, Inc., a wholly-owned subsidiary of Merck & Co. (Kenilworth 
NJ, USA) and ibrutinib was purchased from Toronto Research Chemicals (North York, Canada). 
Bovine serum albumin (BSA), D(+)-glucose, unfractionated heparin and apyrase were purchased 
from Sigma-Aldrich (Saint Louis MO, USA). Low molecular weight heparin (Fragmin®) was from 
Prizer (Capelle a/d IJssel, The Netherlands). Horm® collagen type I came from Takeda (Hoofddorp, 
The Netherlands), whereas the agonists collagen-related peptide crosslinked (CRP-XL) and von 
Willebrand factor III (vWF-III) were obtained from CambCol Laboratories (Cambridge, UK). 
Thrombin was from Enzyme Research Laboratories Inc (South Bend, IN, USA) and protease-
activated receptor 4 activating peptide (PAR4-AP) was obtained from Bachem (Bubendorf, 
Switzerland). U46619 (thromboxane A2 receptor agonist) came from Cayman Chemicals (Ann 
Arbor MI, USA). 2-Methylthio-adenosine-diphosphate (2MeS-ADP) and D-phenylalanyl-prolyl-
arginyl chloromethyl ketone (PPACK) were obtained from Santa Cruz Biotechnology (Dallas TX, 
USA). Laminin was purchased from Octapharma (Lachen, Switzerland), whereas rhodocytin 
was purified from Calloselasma rhodostoma venom as described previously1. Fura-2-AM was 
obtained from Invitrogen (Carlsbad CA, USA). Fluorescein isothiocyanate (FITC)-labelled PAC1 
monoclonal antibody (mAb) against activated human integrin αIIbβ3 were purchased from BD 
Bioscience (nr. 340507; Franklin Lakes NJ, USA). FITC-conjugated α-fibrinogen mAb was purchased 
from DAKO (F0111; Santa Clara CA, USA). Alexa Fluor (AF)568 and AF647-conjugated annexin A5 
were purchased from Molecular Probes, Life Technologies (New York NY, USA). AF647-labelled 
CD62-P mAb was obtained from Biolegend (London, UK). FITC-conjugated annexin A5 was from 
Pharmatarget (Maastricht, The Netherlands), whereas FITC-conjugated lactadherin came from 
Haematologic Technologies (Essex Junction VT, USA). FITC-labelled rat anti-mouse CD62P mAb 
and phycoerythrin (PE) labelled rat anti-mouse JON/A mAb were obtained from Emfret Analytics 
(Würzburg, Germany). 
Blood collection and platelet isolation from healthy volunteers and patients
With approval from the medical ethics committee from the Maastricht University Medical 
Centre+ (MUMC+), blood was collected from healthy volunteers. Furthermore, blood was collected 
from patients diagnosed with chronic lymphocytic leukaemia (CLL), mantle cell lymphoma and 
Waldenstroms macroglobulinemia with or without ibrutinib treatment at the Catharina Hospital 
in Eindhoven (the Netherlands) with approval of the local medical ethical committee. This study 
was performed in accordance with the declaration of Helsinki and informed consent was obtained 
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from all participants. Blood was collected in 3.2% trisodium citrate tubes by venipuncture, after 
discarding the first 3 mL of blood. Blood cell counts and haematological parameters were assessed 
of all blood samples using a Sysmex XP300 (Kobe, Japan). Patients characteristic and ISTH-BAT 
score2 were acquired for each patient. 
Platelet-rich plasma (PRP) or platelets were isolated from whole blood as described 
previously3, 4. Washed platelets were resuspended in Hepes buffer, pH 7.45 (10 mM Hepes, 136 
mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 1 mg/mL glucose, and 1 mg/ml BSA). Platelet concentrations 
were adjusted as stated per assay.
Blood collection from animals
Specific-pathogen-free Btk-KO mice5 and littermate controls (wild-types, WT) were housed 
in the Animal Research Institute Amsterdam facility under standard care. Studies were reviewed 
and approved by the Central Authority for Scientific Procedures on Animals (CCD) and the Animal 
Welfare Body (IvD) of the Academic Medical Centre, University of Amsterdam (ID number: 17-
4125-1-80). The animal care and use protocol adhered to the Dutch Experiments on Animals Act 
(WOD) and European Directive of 22 September 2010 (Directive 2010/63/EU) in addition to the 
Directive of 6 May 2009 (Directive 2009/41/EC).
Only male mice between 8 and 12 weeks of age were used for experiments. Citrated blood 
was drawn from WT and Btk-KO mice from the vena cava inferior under full anaesthesia induced 
by intraperitoneal injection of ketamine (125 mg/kg bodyweight) and dexmedetomidine (300 µg/
kg bodyweight). After blood collection mice were sacrificed by severing the diaphragm.  
Whole blood thrombus formation under flow
Thrombus formation under flow with human blood was performed as described 6. 
Briefly, glass coverslips were coated with 3 microspots of collagen type I (100 µg/mL), collagen 
type III (100 µg/mL), vWF (50 µg/mL) co-coated with laminin (100 µg/mL), vWF co-coated with 
rhodocytin (250 µg/mL), vWF co-coated with ristocetin (250 µg/mL), or vWF co-coated with 
fibrinogen (250 µg/mL), and mounted in a parallel plate flow chamber. Citrated blood samples 
from healthy donors were incubated with vehicle or 5 µM of Btk inhibitor (acalabrutinib, ibrutinib 
or MK-1026) for 10 minutes at room temperature. Blood samples from CLL patients were used 
directly. Whole blood from healthy volunteers or CLL patients was recalcified in the presence of 
PPACK (40 µM), and perfused at a wall shear rate of 1000 s-1 for 3.5 minutes. Platelet activation 
properties were determined by post-perfusion with Hepes buffer (with additional 2 mM CaCl2 and 
1 U/mL heparin) containing FITC-conjugated α-fibrinogen mAb (1:80), AF647-conjugated CD62-P 
(1:100), and AF568-conjugated annexin A5 (1:200).
Thrombus formation under flow with mouse blood was performed as described7. Glass 
coverslips were coated with collagen type I (100 µg/mL) and blood samples, in the presence of 
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PPACK (57.1 µM) and Fragmin (35.7 µM), were incubated with 5 µM Btk inhibitor (acalabrutinib, 
ibrutinib or MK-1026) for 10 minutes at 37°C. Next, the blood samples were recalcified and 
perfused at a shear rate of 1000 s−1 for 3.5 minutes. To measure platelet activation status, thrombi 
were post-stained with Tyrode Hepes buffer, pH 7.45 (5 mM Hepes, 136 mM NaCl, 2.7 mM KCl, 
0.42 mM NaH2PO4, 1 mg/mL glucose, 1 mg/ml BSA, 2 mM CaCl2, 2 mM MgCl2 and 1 U/mL heparin) 
containing PE-labelled Jon-A (1:20) and FITC-conjugated anti-P-selectin mAb (1:40) and AF647-
labelled Annexin-A5 (1:200). 
For both human and mouse experiments, brightfield and fluorescent images were captured 
using an EVOS microscope (Bothel, WA, USA). Images were analysed using specific scripts in the 
open-access Fiji software (Laboratory for Optical and Computational Instrumentation, University 
of Wisconsin-Madison, WI, USA) as described6, 8. Values for the following parameters of thrombus 
formation and platelet activation were obtained: morphological score of platelet adhesion and 
thrombus formation (P1; scale 0-5), surface area coverage of adhered platelets (P2; %SAC), 
platelet aggregate contraction score (P3; scale 0-3), platelet aggregate multilayer score (P4; 
scale 0-3), coverage of multi-layered platelet aggregation (P5; %SAC), integrin αIIbβ3 activation 
(P6; %SAC), P-selectin expression (P7; %SAC) and PS exposure (P8; %SAC). For comparative data 
analysis, cumulative histograms were generated of scaled values from 0-10 for each parameter. 
For patient data subtraction heatmap representing the effect of ibrutinib treatment in individual 
patients. Average values obtained with blood of patients without ibrutinib treatment was set at 
0 for reference. Effects were filtered for changes greater than the 2x SD range of the different 
platelet parameters.
Light transmission aggregometry
Isolated platelets (250x109 platelets/L) from healthy volunteers were incubated with 
vehicle or 3.3 µM of Btk inhibitor (acalabrutinib, ibrutinib or MK-1026) for 10 minutes at 37°C, 
whereas platelets from CLL patients were used directly after preheating to 37°C for 10 minutes. 
Aggregation response was induced by collagen type I (1 µg/mL), 2MeS-ADP (1 µM), U46619 
(1 µM), rhodocytin (1 µg/mL) or thrombin (1 nM). Platelet aggregation was recorded using a 
Chronolog optical aggregometer (Havertown PA, USA) and maximum amplitude was quantified at 
8 minutes after agonist addition. 
Flow cytometry
Washed platelets (100x109 platelets/L) from healthy volunteers or CLL patients were 
supplemented with 2 mM CaCl2. Samples from healthy volunteers were incubated with vehicle or 
1 µM of Btk inhibitor (acalabrutinib, ibrutinib or MK-1026) for 10 minutes at room temperature, 
whereas patient samples were used directly. Platelets were stimulated by CRP-XL (5 μg/mL), 2MeS-
ADP (1 μM), or thrombin (1 nM) for 15 minutes at RT. Activation of integrin αIIbβ3 and P-selectin 
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expression were determined using FITC-conjugated PAC1 mAb (1:20) and AF647-conjugated 
CD62-P mAb (1:40) respectively. For measuring phosphatidyl-serine (PS) exposure platelets were 
activated with a combination of CRP-XL (5 μg/mL) and thrombin (4 nM) for 1 hour at 37°C and 
labelled with FITC-conjugated annexin A5. Flow cytometry was performed in duplicates using a 
BD Accuri C6TM flow cytometer and accompanying software (Erembodegem, Belgium).
Platelet activation in whole blood from WT and Btk-KO mice was performed using pooled 
blood samples (5 µl), in the presence of PPACK (57.1 µM) and Fragmin (35.7 µM), incubated with 
5 µM Btk inhibitor (acalabrutinib, ibrutinib or MK-1026) for 10 minutes at 37°C. Platelets were 
then stimulated for 30 minutes at room temperature with control buffer (PBS), CRP-XL (1 μg/ml), 
2MeS-ADP (1 μM) or PAR4-AP (0.1 mg/ml). Platelet activation was assessed by flow cytometry 
using APC-conjugated anti-CD61, BB700-labelled anti-CD62P, PE-conjugated JON/A and FITC-
labelled lactadherin. The labelling was terminated by addition of 40 volumes of buffer. Analysis 
was carried out immediately by flow cytometry using a CytoFLEX (Beckman Coulter, Brea, CA) 
until 10,000 CD61+ events were recorded. All stimulations and staining were done in duplicate. 
Compensation settings were validated using single-stained controls. Percentage of positivity 
was determined using unstimulated controls. Data analysis was done using FlowJoTM v10 (BD 
Biosciences, San Jose, CA).
Cytosolic Ca2+ measurements 
Washed platelets (200x109 platelets/L) were loaded with Fura-2 acetoxymethyl ester and 
changes in cytosolic Ca2+ ([Ca2+]i) were measured in 96-well plates using a FlexStation 3 (Molecular 
Devices, San Jose, CA, USA) as described9,10. In brief, platelet suspension was preincubated with 
vehicle or 1 µM Btk inhibitor (acalabrutinib, ibrutinib or MK-1026) for 10 minutes at RT. Fura-2 
loaded platelets in presence of CaCl2 were stimulated by CRP-XL (10 µg/mL). Changes in Fura-2 
fluorescence were measured in duplicate and ratio values were calculated and are presented as 
[Ca+]i in nM.
PamGene kinase assay 
Washed platelets (500x109  platelets/L) were pretreated with vehicle (control) or 1 μM 
ibrutinib, acalabrutinib or MK-1026 for 10 minutes at 37°C and were subsequently stimulated 
with 5 μg/mL CRP-XL in the presence of 2 mM CaCl2. Unstimulated, resting platelets served as 
control. After 90 seconds of stimulation, samples were lysed by adding 1:1 M-PER Mammalian 
Extraction Buffer containing Halt Phosphatase Inhibitor and EDTA-free Halt Protease Inhibitor 
Cocktail (1:100 each; Thermo Fischer Scientific). Samples were lysed for 15 minutes on ice and 
afterwards centrifuged for 15 minutes at 10,000g at 4°C. Supernatants were collected and protein 
content was quantified with a BioRad DC protein kit (Hercules CA, USA).
Tyrosine kinase profiles were determined using the PamChip® peptide tyrosine kinase 
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microarray system on PamStation®12 (PTK; PamGene International, ´s-Hertogenbosch, The 
Netherlands). Each PTK-PamChip® array contains 144 individual phospho-site(s) that are peptide 
sequences derived from substrates for TKs. Each peptide on the chip builds a 15-amino acid 
sequence representing a putative endogenous phosphorylation site which functions as a TK 
substrate. The phosphorylation of the peptides is visualized by detection of the fluorescent signal 
which is emitted as a result of the binding of the FITC-conjugated PY20 anti-phosphotyrosine 
antibody. 
For the PTK assay, 7.5 µg of protein was applied per array (N=4 per condition) and carried 
out using the standard protocol supplied by Pamgene. All reagents used for PTK activity profiling 
were supplied by Pamgene International B.V. Initially, to prepare the PTK Basic Mix, the freshly 
frozen lysate was added to 4 µL of 10 x protein PTK reaction buffer (PK), 0.4 µL of 100 x bovine 
serum albumin (BSA), 0.4 µL of 1 M dithiothreitol (DTT) solution, 4 µL of 10 x PTK additive, 4 µL 
of 4 mM ATP and 0.6 µL of monoclonal anti-phosphotyrosine FITC-conjugate detection antibody 
(clone PY20). Total volume of the PTK Basic Mix was adjusted to 40 µL by adding distilled water 
(H20). Before loading the PTK Basic Mix on the array, a blocking step was performed applying 30 µL 
of 2% BSA to the middle of every array and washing with PTK solution for PamChip® preprocessing. 
Next, 40 µL of PTK Basic Mix were applied to each array of the PamChips®. Then, the microarray 
assays were run for 94 cycles. An image was recorded by a CCD camera PamStation®12 at kinetic 
read cycles 32–93 at 10, 50 and 200 ms and at end-level read cycle at 10, 20, 50, 100 and 200 ms. 
The spot intensity at each time point was quantified (and corrected for local background) using the 
BioNavigator software version 6.3 (PamGene International, 's-Hertogenbosch, The Netherlands). 
Upstream Kinase Analysis (UKA)11, a functional scoring method (PamGene) was used to rank 
kinases based on combined specificity scores (based on peptides linked to a kinase, derived from 
6 databases) and sensitivity scores (based on treatment-control differences).
Statistical analysis
Data for healthy volunteers are shown as mean ± standard error of mean (SEM), whereas 
CLL patients are presented as median ± interquartile ranges. GraphPad Prism 8.3.0 software (La 
Jolla, CA, USA) was used for statistical analysis. For healthy donor and CLL patient samples a 
non-parametric and unpaired t-test (Mann-Whitney) was used to compare vehicle and inhibitor 
treatment in vitro, whereas for mouse samples statistics were calculated using a one-way 
non-parametric Anova (Kruskal-Wallis) to compare WT versus Btk-KO samples, as well as the 
comparison between vehicle and inhibitor treatment in both WT and Btk-KO mice. A p-value less 
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Supplemental Table 6.1. IC50 values (µM) of Btk inhibitors for inhibition of GPVI- and CLEC-2 induced platelet 
aggregation and activation in presence (PRP) or absence of plasma (WP).






Ibru�nib 3.31 0.425 0.170 0.196 0.176 0.332
Acalabru�nib 9.85 1.635 1.275 0.982 1.439 0.723













































































































































Supplemental Figure 6.1. Platelet aggregation and activation of blood samples from healthy volunteers with ibrutinib 
and acalabrutinib, as well as dose-response of collagen-induced aggregation. (A) Washed platelets (250x109/L) from 
healthy volunteers were incubated with vehicle, ibrutinib (3.3 µM) or acalabrutinib (3.3 µM). Aggregation was induced 
by (i) 2MeS-ADP (1 µM), (ii) collagen type I (5 µg/mL), (iii) thrombin (1 nM) or (iv) U46619 (1 µM). Aggregation responses 
were measured during 8 minutes. (B) PRP (250x109/L) was incubated with vehicle, ibrutinib (5 µM) or acalabrutinib (5 
µM) for 10 minutes at 37°C and stimulated with ristocetin (2 mg/mL). Aggregation responses were measured during 8 
minutes. (C) Washed platelets (100x109/L) were stimulated with 2MeS-ADP (1 µM) or thrombin (1 nM) for 15 minutes and 
analysed by flow cytometry. Shown are percentages of platelets binding FITC-labelled PAC1 mAb against integrin αIIbβ3 and 
AF647-labelled CD62P mAb for α-granule secretion, respectively. Data are shown as means ± SEM (n=5-6). * p<0.05, ** 
p<0.01, *** p<0.001 vs vehicle.
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Supplemental Figure 6.2. Thrombus formation under flow with blood from healthy donors in presence of acalabrutinib 
or ibrutinib over multiple microspots. (A) Representative brightfield and fluorescence images and (B) quantification of 
control (vehicle, white bars), acalabrutinib (5 µM, grey bars) or ibrutinib (5 µM, black bars) over (i) collagen type I, (ii) 
collagen type III, (iii) vWF co-coated with rhodocytin, (iv) vWF co-coated with laminin, (v) vWF co-coated with ristocetin 
and (vi) vWF co-coated with fibrinogen. P1 = morphological score of platelet adhesion and thrombus formation, P2 = 
surface area coverage of adhered platelets, P3 = platelet aggregate contraction score, P4 = platelet aggregate multilayer 
score, P5 = coverage of multi-layered platelet aggregation, P6 = integrin αIIbβ3 activation, P7 = P-selectin expression and P8 





























































































































































































































































































































































































































































































































































































































































Supplemental Figure 6.3. Thrombus formation and platelet activation with blood of WT or Btk-KO mice. Citrated 
whole blood from WT or Btk-KO mice pre-incubated with control (vehicle, white bars), acalabrutinib (5 µM, grey bars) or 
ibrutinib (5 µM, black bars) was perfused for 3.5 minutes at a wall shear rate of 1,000 s-1 over a collagen type I surface. (A) 
Quantification of brightfield and fluorescence images. (B-C) Platelet activation in whole blood induced by (B) 2MeS-ADP 
(1 µM) or (C) PAR4AP (100 µg/mL). Histograms show the percentages of platelets binding PE-labelled JON/A monoclonal 
antibody or PerCP-labelled CD62P mAb in WT and Btk-KO mice. Data are presented as means ± SEM (n=5-6), * p<0.05, ** 
p<0.01 vs vehicle or indicated otherwise.
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Supplemental Figure 6.4. Platelet aggregation and activation of blood samples from healthy volunteers in presence 
of MK-1026. (A) Washed platelets (250x109/L) from healthy volunteers were incubated with vehicle or MK-1026 (3.3 
µM). Aggregation was induced by (i) 2MeS-ADP (1 µM), (ii) collagen type I (5 µg/mL), (iii) thrombin (1 nM) or (iv) U46619 
(1 µM). Aggregation responses were measured during 8 minutes. (B) PRP (250x109/L) from healthy volunteers were 
incubated with vehicle or MK-1026 (5 µM) for 10 minutes at 37°C and stimulated with ristocetin (2 mg/mL). Aggregation 
responses were measured during 8 minutes. (C) Washed platelets (100x109/L) were stimulated with 2MeS-ADP (1 µM) 
or thrombin (1 nM) for 15 minutes and analysed by flow cytometry. Shown are percentages of platelets binding FITC-
labelled PAC1 mAb against integrin αIIbβ3 and AF647-labelled CD62P mAb for α-granule secretion, respectively. Data are 
represented as means ± SEM (n=5-6), * p<0.05.
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Supplemental Figure 6.5. Thrombus formation under flow with blood from healthy volunteers in presence of MK-1026 
over multiple microspots. (A) Representative brightfield and fluorescence images and (B) quantification of control (white 
bars), MK-1026 (sand-coloured bars) over (i) collagen type I, (ii) collagen type III, (iii) vWF co-coated with laminin, (iv) vWF 
co-coated with rhodocytin, (v) vWF co-coated with ristocetin and (vi) vWF co-coated with fibrinogen. Data are shown as 































































































































































































































































































































































































































































































































































































































Supplemental Figure 6.6. Thrombus formation under flow with blood of WT or Btk-KO mice over collagen type I 
surface. (A) Quantification of brightfield and fluorescence images of control (white bars) or MK-1026 (sand-coloured bars) 
over collagen type I. Parameter 1-8 are as described for Supplement Figure 6.2. (B-C) Platelet activation in whole blood 
induced by (B) 2MeS-ADP (1 µM) or (C) PAR4AP (100 µg/mL). Histograms show the percentages of platelets binding PE-
labelled JON/A monoclonal antibody or PerCP-labelled CD62P mAb in WT and Btk-KO mice. Data are presented as means 
± SEM (n=5-6), * p<0.05, ** p<0.01 vs vehicle or indicated otherwise.
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Supplemental Figure 6.8. Thrombus formation and aggregation with blood samples of ibrutinib-treated patients 
with or without bleeding. Citrated whole blood from patients receiving ibrutinib treatment was perfused for 3.5 
minutes at a wall shear rate of 1,000 s-1 over coated microspots. Quantification of brightfield and fluorescence images 
of ibrutinib-treated patients with a ISTH BAT score of 0-1 (black dots) or a ISTH BAT score over a value of 2 (red dots) 
over (A) collagen type I, (B) vWF co-coated with rhodocytin and (C) vWF co-coated with laminin. Parameters 1, 6-8 are 
as described for Supplement Figure 6.2. (D) Light transmission aggregometry was induced in isolated platelets (250x109/
L) by collagen (1 µg/mL), rhodocytin (1 µg/mL), 2MeS-ADP (1 µM), U46619 (1 µM) or thrombin (1 nM). Scatter plots 
show the percentage of aggregation of patients receiving ibrutinib with a low bleeding score (0-1, black dots) or a 
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Background: Currently antiplatelet drugs, used for treatment of arterial thrombosis, often 
coincide with an increased risk of bleeding. Hence, platelet inhibitors that preserve haemostasis 
are warranted. Multiple tyrosine kinase inhibitors (TKIs), used for cancer treatment, have been 
reported to inhibit platelet function, with minor bleeding symptoms. In this study, we investigated 
the antiplatelet properties of several clinically used TKIs as exploration of possible repurposing 
these compounds as antiplatelet drugs.
Methods: Eight TKIs were selected based on the affinity for tyrosine kinases expressed 
in platelets and limited bleeding symptoms. Whole blood samples, platelet-rich plasma (PRP) 
or isolated platelets from healthy donors were pre-incubated with the TKI or vehicle. Platelet 
aggregation, activation, intracellular calcium mobilisation and whole blood thrombus formation 
under flow were determined. 
Results: Overall, the TKIs with the highest affinities for platelet-expressed targets strongly 
inhibited platelet functions. Dasatinib and sunitinib dose-dependently reduced collagen-induced 
aggregation in PRP and washed platelets, while pazopanib, cabozantinib and vatalanib inhibited 
this response in washed platelets only, and fostamatinib, axitinib and lapatinib showed no or 
limited effects. Fostamatinib effectively reduced whole blood thrombus formation under flow on 
collagen, as well as other substrates. Pazopanib, sunitinib, dasatinib, axitinib and vatalanib mildly 
reduced thrombus formation on collagen. Intracellular calcium measurements and activation 
responses in isolated platelets were inhibited by dasatinib, fostamatinib, sunitinib and pazopanib. 
After glycoprotein-VI receptor-stimulation fostamatinib, cabozantinib and vatalanib decreased 
the highly activated platelet population, whereas negative, resting populations were increased.
Conclusions: Strong inhibitory effects of dasatinib, fostamatinib, sunitinib and pazopanib 
pointed to interference in early collagen receptor-induced signalling events, when compared to 
cabozantinib and vatalanib. Since Fostamatinib, sunitinib, pazopanib and vatalanib are reported to 
cause no more than mild bleeding symptoms, these are promising candidates to explore further 
as antiplatelet drugs.
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Introduction
Ischaemic heart disease and stroke accounted >15 million deaths worldwide in 2019, 
making arterial thrombosis a leading global cause of death1. The major underlying cause are 
the thrombotic complications of atherosclerosis, either via plaque rupture or erosion2, 3. Current 
treatment is mostly (dual) antiplatelet therapy, such as aspirin and clopidogrel that prevent 
thromboxane A2 release and ADP receptor activation, respectively
4. However, these inhibitors 
mostly have an irreversible mode of action on platelet G-protein coupled receptor (GPCRs) 
signalling pathways and coincide with an increased risk of bleeding5. Therefore, novel antiplatelet 
drugs are being developed that inhibit thrombosis, but do not interfere in haemostasis5. In 
this respect glycoprotein (GP)VI and C-type lectin-like receptor 2 (CLEC-2) receptors, as well as 
downstream tyrosine kinases, have been postulated as interesting antithrombotic targets6.
 GPVI is an immunoreceptor tyrosine-based activation motif (ITAM)-linked receptor, 
activated by collagen and fibrin(ogen), resulting in initial platelet activation and subsequent 
thrombus formation7-9. Deficiency of GPVI in mice suppressed arterial thrombosis without 
substantial prolongation of bleeding time10, 11. Inhibition of GPVI has also been reported to protect 
from thrombosis upon plaque rupture in mice12, 13. Furthermore, patients with defects in GPVI 
have only a mild bleeding diathesis14 or remain asymptomatic15. Two GPVI inhibitors showing 
promising antithrombotic effects, are currently being tested in phase II clinical trials: the Fab 
fragment ACT017 and Revacept, a collagen binding dimeric GPVI-Fc fusion protein6. However, a 
disadvantage of these treatments is the administration via intravenous injections. 
CLEC-2 is a hemITAM-linked receptor, activated by the endogenous ligand podoplanin16. 
CLEC-2 deficient mice are protected from arterial thrombus formation and displayed only a 
minor effect on haemostasis17, 18. In contrast, deficiency of both GPVI and CLEC-2 resulted in lack 
of cessation of tail bleeding, as well as profound reduction of arterial thrombosis19. In human 
blood, a monoclonal antibody (mAb) to CLEC-2 has been shown to block CLEC-2 induced platelet 
activation in vitro20. However, no clinical trials targeting CLEC-2 have started until now. 
 Both GPVI and CLEC-2 heavily depend on tyrosine kinase signalling including Syk, Btk 
and Src family kinases (SFK)21. In addition, other receptor signalling pathways, likely to a lesser 
extent, use include tyrosine kinases, such as those evoked by GPIb, integrin αIIbβ3, Axl and Tie, 
which are receptors for vWF, fibrinogen, Gas6 and angiopoietin, respectively22, 23. With such a 
wide mode of action on platelet activation, while leaving GPCR signalling mostly intact, tyrosine 
kinase inhibitors (TKIs) may provide an alternative way to inhibit platelet activation6. During the 
past decades, many orally available TKIs have been developed for cancer treatment24, 25, with 
different inhibitory profiles against tyrosine kinases (Table 7.1). These compounds have been 
shown to be well tolerated, and in general cause only a mild increase in risk of bleeding. The 
Syk inhibitor fostamatinib, used for treatment of chronic immune thrombocytopenic purpura 
(ITP), has been reported to reduce GPVI- and CLEC-2 stimulated platelet aggregation, with only 
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minor effects on bleeding time in mice26, 27. Notably, TKIs targeting a broad spectrum of tyrosine 
kinases including the receptors for vascular endothelial growth factor (VEGFR), platelet-derived 
growth factor (PDGFR) and Kit are used for the treatment of renal cell carcinoma. These include 
sunitinib, pazopanib, axitinib and cabozantinib (Table 7.1). We have recently shown that sunitinib 
and pazopanib inhibit collagen-induced platelet function both in vitro and in patients receiving 
treatment28, 29. Axitinib and cabozantinib also have targets that are present in platelets24 and have 
been associated with increased risk of bleeding30, but no effects on platelet function have been 
reported. On the contrary, several TKIs used for treatment of breast and colon cancer have limited 
affinity for tyrosine kinases present in platelets, without reported bleeding24. These include 
lapatinib and vatalanib (Table 7.1). 
 The aim of the present study was to systematically evaluate the antiplatelet properties 
of eight clinically used TKIs, and to assess their potential for repurposing of these compounds as 
antiplatelet drugs. Therefore, we investigated the effects of these compounds on platelet function 




The active metabolite of fostamatinib (R406) was obtained from InvivoGen (San Diego 
CA, USA). Active metabolites of axitinib (A-1107), cabozantinib, dasatinib and pazopanib were 
AP: acute-phase; BC: breast cancer; CLL: chronic lymphocytic leukaemia; CML: chronic myeloid leukaemia; CP: chronic-
phase; CSF-R: colony-stimulating factor receptor; EGFR: epidermal growth factor receptor; ErbB2: human epithelial 
growth factor 2; FGFR: fibroblast growth factor receptor; GIST: gastrointestinal stromal tumour; HR: hormone receptor; 
LB: lymphoid blast; MB: myeloid blast; MCRC: metastatic colorectal cancer; MKs, megakaryocytes; ND: not determined; 
NSCLC: non-small-cell lung cancer; OC: ovarian cancer; PDGFR: platelet-derived growth factor receptor; PNET: primitive 
neuroectodermal tumour; RCC: renal cell carcinoma; SFK: Src family kinase; STS: soft tissue sarcoma; TC: thyroid cancer; 
VEGFR: vascular endothelial growth factor receptor.
Table 7.1: Characterization of TKIs used for cancer treatment with targets present in platelets. 
TKI Reported Targets
Targets in 




Syk, Src, Fgr, Fyn, lck, 
Lyn, Yes B-cell lymphoma, CLL No 54
Suni�nib VEGFR, PDGFR, CSF-R, 
Ret, Kit, Flt3
(Ret, Kit) RCC, GIST, PNET Yes 30, 66, 68, 69
Pazopanib VEGFR, PDGFR, FGFR, 
Kit, Fms, Itk, Lck
Lck (Kit) NSCLC, OC, RCC, STS, TC Yes 30, 66
Axi�nib VEGFR, PDGFRβ Lck, Yes, Axl, Tie RCC Yes 30, 66
Lapa�nib EGFR, ErbB1-2 ND ErbB2+ HR- or HR+ BC No 66, 71
Vatalanib VEGFR, PDGFRβ, Kit (Kit) MCRC No 72
Dasa�nib PDGFR, EFGR, BCR-ABL, 
EphA2, Kit, SFK 
SFK: Src, Fyn, Lck, Lyn, 
Yes, Btk, (Kit)
Yes 66, 67CP CML, AP MB, LB CML
Cabozan�nib VEGFR, Met, Ret, Kit,
Flt3, Axl, Tie
Axl, Tie (Ret, Kit) Yes 30, 70TC, RCC
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purchased from LC Laboratories (Woburn MA, USA). The active metabolite of lapatinib (GW-
572016) was purchased from Selleckchem (Houston TX, USA), whereas the active metabolite 
of sunitinib came from Pfizer (New York NY, USA). The active metabolite of vatalanib (PTK787) 
was obtained from Adooq Bioscience (Irvine CA, USA). Bovine serum albumin (BSA), D(+)-
glucose, unfractionated heparin and apyrase were purchased from Sigma-Aldrich (Saint Louis 
MO, USA). Horm collagen type I came from Takeda (Hoofddorp, the Netherlands), whereas 
the agonists collagen-related peptide crosslinked (CRP-XL) and von Willebrand factor III (vWF-
III) were obtained from CambCol Laboratories (Cambridge, UK). Rhodocytin was purified from 
Calloselasma rhodostoma venom as described previously31. Thrombin was from Enzyme Research 
Laboratories Inc (South Bend, IN, USA). U46619 (thromboxane A2 receptor agonist) came from 
Cayman Chemicals (Ann Arbor MI, USA). 2-Methylthio-adenosine-diphosphate (2MeS-ADP) 
and D-phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK) were obtained from Santa Cruz 
Biotechnology (Dallas TX, USA). Laminin was purchased from Octapharma (Lachen, Switzerland), 
whereas Fura-2-AM and allophycocyanin (APC)-labelled mouse anti-human CD63 monoclonal 
antibody (mAb, clone MEM-259) were obtained from Invitrogen, Fisher Scientific (Carlsbad CA, 
USA). Fluorescein isothiocyanate (FITC)-labelled PAC1 mAb against activated human integrin αIIbβ3 
(340507), Phycoerythrin (PE)-labelled annexin A5, Brilliant Violet (BV)510-conjugated mouse anti-
human CD42b mAb (clone HIP1) and BV421-labelled rat anti-human TLT-1 mAb (clone 268420), 
were purchased from BD Bioscience (Franklin Lakes NJ, USA). FITC-conjugated α-fibrinogen mAb 
was purchased from DAKO (F0111; Santa Clara CA, USA). Alexa Fluor (AF)568-conjugated annexin 
A5 was purchased from Molecular Probes, Life Technologies (New York NY, USA). Peridinin-
chlorophyll-protein cyanine5.5 (PerCP Cy5.5)-conjugated mouse anti-human CD62-P mAb (clone 
AK4) and AF647-labelled mouse anti-human CD62-P mAb (clone AK4) were obtained from 
Biolegend (London, UK). FITC-conjugated annexin A5 was from Pharmatarget (Maastricht, the 
Netherlands).
Blood collection and platelet isolation
In accordance with the declaration of Helsinki and approval of the local medical ethical 
committee (Maastricht University Medical Centre+, MUMC+), we obtained full informed consent 
from all participants. Blood from healthy volunteers was collected in 3.2% trisodium citrate tubes 
by venipuncture, after discarding the first 3 mL of blood. Blood cell counts and haematological 
parameters were assessed, using a Sysmex XP300 (Kobe, Japan). 
Platelet-rich plasma (PRP) or platelets were isolated from whole blood as described 
previously32, 33. Washed platelets were resuspended in Hepes buffer, pH 7.45 (10 mM Hepes, 136 
mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 1 mg/mL glucose, and 1 mg/mL bovine serum albumin). 




Thrombus formation under flow was determined as described34. Briefly, glass coverslips 
were coated with 3 microspots of collagen type I (100 µg/mL), collagen type III (100 µg/mL), vWF 
(50 µg/mL) co-coated with laminin (100 µg/mL) or vWF co-coated with rhodocytin (250 µg/mL), 
vWF co-coated with ristocetin (250 µg/mL), or vWF co-coated with fibrinogen (250 µg/mL) and 
mounted in a parallel plate flow chamber. Citrated blood samples were incubated with the TKIs 
axitinib, cabozantinib, dasatinib, fostamatinib, lapatinib, pazopanib, sunitinib, vatalanib or vehicle 
for 10 minutes at room temperature. Pre-incubated whole blood samples were recalcified in 
presence of PPACK (40 µM) and perfused at a wall shear rate of 1000 s-1 for 3.5 minutes. Platelet 
activation properties were determined by post-perfusion with Hepes buffer (supplemented with 
2 mM CaCl2 and 1 U/mL heparin) containing FITC-conjugated α-fibrinogen mAb (1:80), AF647-
conjugated αCD62P mAb (1:100), and AF568-conjugated annexin A5 (1:200). Brightfield and 
fluorescence images were captured using an EVOS microscope (Bothel WA, USA).
Analysis of microscopic data
Microscopic images were analysed using specific scripts in the open-access Fiji software 
(Laboratory for Optical and Computational Instrumentation, University of Wisconsin-Madison, WI, 
USA) as described34, 35. Multiple thrombus formation parameters were obtained from brightfield 
images including P1: morphological score of platelet adhesion and thrombus formation (scale 
0-5), P2: surface area coverage of adhered platelet (% SAC), P3: platelet aggregate contraction 
score (scale 0-3), P4: platelet aggregate multilayer score (scale 0-3) and P5: coverage of multi-
layered platelet aggregation (% SAC). From fluorescence images, platelet activation parameters 
were obtained by determining P6: integrin αIIbβ3 activation (% SAC), P7: P-selectin expression 
(% SAC) and P8: phosphatidylserine (PS) exposure (% SAC). Heatmaps were generated from the 
mean values per parameter for each surface for comparative data analysis. Values were scaled 
from 0-10 based on the highest value of each parameter for each surface. For visualization of the 
effects, subtraction heatmaps were generated by subtraction of scaled control data from each TKI 
condition and heatmaps were filtered based on significant differences (p<0.05). Heatmaps were 
generated using R Core Team (i386 3.2.5; Vienna, Austria).
Platelet aggregation by light transmission aggregometry
Isolated platelets or PRP (250x109 platelets/L) were incubated with TKIs or vehicle for 
10 minutes at 37°C. Maximal aggregation was induced by collagen type I (1 µg/mL), 2MeS-ADP 
(1 µM), U46619 (1 µM), rhodocytin (1 µg/mL) or thrombin (1 nM). Platelet aggregation was 
recorded using a Chronolog optical aggregometer (Havertown PA, USA). The maximum amplitude 
was quantified at 8 minutes after agonist addition.
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Cytosolic Ca2+ measurements
Washed platelets (200x109 platelets/L) were loaded with Fura-2-AM and changes in 
cytosolic Ca2+ ([Ca2+]i) were measured in 96-well plates using a FlexStation 3 (Molecular Devices, 
San Jose, CA, USA), as described36, 37. Briefly, platelets in suspension were preincubated with 
TKIs or vehicle for 10 minutes at room temperature. Pre-loaded and -incubated samples were 
stimulated by CRP-XL (10 µg/mL). Changes in Fura-2 fluorescence were measured in duplicate, 
and ratio values were calculated. Data are presented as [Ca2+]i in nM or area under the curve 
(AUC) in nMs.
Platelet activation by flow cytometry
Washed platelets (25x109 platelets/L) were incubated with TKIs or vehicle for 10 minutes 
at room temperature. Platelets were stimulated, in the presence of 2 mM CaCl2, by CRP-XL (5 
μg/mL), 2MeS-ADP (2 μM), or thrombin (4 nM) for 15 minutes, and simultaneously stained for 
multiple activation markers using an antibody mix consisting of FITC-conjugated PAC1 (1:20), 
BV510-conjugated αCD42b (1:50), BV421-conjugated αTLT1 (1:50), APC-conjugated αCD63 
(1:20), PerCP-Cy5.5-conjugated αCD62P (1:500) mAbs. For measuring phosphatidyl-serine (PS) 
exposure, platelets were activated with a combination of CRP-XL (5 μg/mL) and thrombin (4 
nM) for 1 hour at 37°C, and post-labelled with PE-conjugated annexin A5. Samples for activation 
markers as well as PS exposure were fixed after stimulation for at least 30 minutes at 4°C in the 
dark using a 0.3% fixation buffer, before measuring 10,000 events per sample on a BD FACSCanto 
II (BD bioscience, Franklin Lakes, NJ, USA).
Analysis of flow cytometric data
Separate FCS files were opened in FlowJo V10 software (Treestar, Ashland OR, USA) and 
checked for data anomalies by FlowAI38. Before concatenation, event count per sample was set at 
5,000 events by DownSample for equal weighing of every sample. Resulting file was subjected to 
t-distributed stochastic neighbour embedding (tSNE) analysis to reduce the high dimensionality 
to a 2D plot. FlowSOM analysis was used to identify five clusters39. Fractions of platelets present 
in the resulting FlowSOM populations were determined per original sample. Each platelet 
population was characterised by the expression level of the different markers.
Statistical analysis
Data are shown as mean ± standard error of mean (SEM). GraphPad Prism 8.3.0 software 
(La Jolla, CA, USA) was used for statistical analysis with an unpaired non-parametric t-test (Mann-
Whitney) or one-way ANOVA. A p-value less than 0.05 was considered to be statistically significant, 




Characteristics of selected TKIs 
For this study, eight reversible multi-target TKIs were selected based on published affinities 
for tyrosine kinases (TKs) expressed in platelets, and reported minor bleeding risk (Table 7.1, 
Figure 7.1)24. Dasatinib and fostamatinib display high affinity for platelet-expressed Syk and Src-
family kinases (SFKs), while sunitinib, pazopanib, axitinib and cabozantinib show moderate to mild 
affinity for only some of these platelet-expressed targets (Figure 7.1). Dasatinib and fostamatinib 
are known as inhibitors of the GPVI, CLEC-2 and αIIbβ3 activation pathways in platelets
26, 40, but 
have not been systematically evaluated. Lapatinib and vatalanib have unknown affinities for 
platelet-expressed kinases (Figure 7.1, Table 7.1).
Distinct effects of selected TKIs on collagen-induced platelet aggregation in the presence 
or absence of plasma
Impaired platelet function by TKIs is described to be due to inhibition of in particular the 
ITAM-linked receptor GPVI24, 25. Therefore, we first investigated the effects of the active metabolites 
of different TKIs on collagen-induced aggregation responses. Dose-response curves with isolated 
platelets showed distinct effects of the different TKIs (Figure 7.2, dotted lines). The most potent 
aggregation inhibition was observed with dasatinib (>90% inhibition with 1 µM, Figure 7.2A). 
Surprisingly, the combined SFK and Syk-inhibitor fostamatinib, with several targets in platelets, 
did not show a relevant inhibitory effect (Figure 7.2B). For the weaker SFK inhibitors sunitinib, 
pazopanib, and cabozantinib, aggregation in washed platelets became nearly abolished with 33 
µM (Figure 7.2C-D, F) Unexpectedly, vatalanib without assumed targets in platelets also inhibited 
this response at 33 µM (Figure 7.2H). IC50 values of these four TKIs were between 6-13 µM and a 
Kd (nM) IC50 (nM)
+++ Very strong <0.01 <0.1
++ Strong <0.1 <1
+ Moderate <1 <10
± Mild <10 <100



























Dasa�nib +++ +++ ± +++ +++ +++ ± +++ ± - - ± ±
Fostama�nib +++ ++ +++ ++ ++ ++ +++ + ± + + + +
Suni�nib ± ± ± + + + - ± - +++ ± + +
Pazopanib ± ± ± ± ± ± ± - - - ± - -
Axi�nib - ± - ± - ± - - - + + - -
Cabozan�nib - - - - - - - - - + ± - -
Lapa�nib - - - - - - - - - - - - -







Figure 7.1. Affinity profile of common tyrosine kinase inhibitors (TKIs) for relevant tyrosine kinases implicated 
in platelet activation. Shown is a heatmap of the affinity-based dissociation constants (Kd)62-64 or IC50 values
65 of 
the indicated TKIs. Values are from binding experiments with indicated purified kinases, including Src family kinases 
(SFK), Syk, Tec family kinases (TFK), focal adhesion kinases (FAK) and MEK. Colour coding with highest affinity (lowest Kd 
or IC50) shown in deep red and lowest affinity (highest Kd or IC50) shown in white. Data are based on ref 
24.
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concentration of 10 µM was used for further experiments (Table 7.2). Axitinib and lapatinib with 
limited or no TK targets slightly affected the aggregation response to collagen at the highest dose 
tested of 100 µM (Figure 7.2E, G). 
As most TKIs are protein-bound in plasma, dose response curves were also determined 
in platelet-rich plasma (PRP; Figure 7.2, solid lines). Upon collagen stimulation, the strongest 
inhibitory effect in PRP was also observed with dasatinib (IC50 of 0.4 µM, and >90% inhibition 
at 3.3 µM, Figure 7.2A). In patient studies, plasma concentrations up to 0.1 µM dasatinib are 
reported41, which concentration thus was used in following experiments (Table 7.2). Inhibition 
with fostamatinib, also resulted in a small but significant decrease of the aggregation response 
(±20% inhibition, Figure 7.2B). For sunitinib, significant inhibition (60%) was reached at 33 µM, 













































































































































Figure 7.2. Dose-dependent effects of TKIs on platelet aggregation induced by collagen. Washed platelets or 
PRP (250x109/L) were incubated with vehicle (<0.1% DMSO) or TKI for 10 minutes. Dose response curves of 
inhibition of aggregation induced by collagen type I (1 µg/mL) for (A) dasatinib, (B) fostamatinib, (C) sunitinib, (D) 
pazopanib, (E) axitinib, (F) cabozantinib, (G) lapatinib or (H) vatalanib, measured in either PRP (solid line) or washed 
platelets (dotted line). Maximum aggregation responses were determined at 8 minutes; data are shown as means ± 
SEM (n = 6). * p<0.05. ** p<0.01, *** p<0.001.
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Cabozan�nib 33 10  or 33
Lapa�nib 33 33
Vatalanib 33 10 or 33
TKI
Concentra�on (µM)
Abbreviations: PRP: platelet-rich plasma; WB: whole blood; WP: washed platelets
was used for further analysis in whole blood experiments. In contrast to washed platelets, the 
aggregation responses in the presence of pazopanib, cabozantinib or vatalanib were not, or barely 
inhibited in PRP (Figure 7.2D, F, H). In agreement with the responses in washed platelets, axitinib 
and lapatinib did not show altered collagen-induced aggregation in PRP (Figure 7.2E, F). For the 
latter set of compounds, no more than 20% inhibition was observed in PRP, for which reason the 
highest concentration of 33 µM was used for plasma-containing experiments (Table 7.2).
Whole blood thrombus formation over (non)collagen surfaces u nder flow is  most 
strongly affected by high affinity TKIs
To explore the effects of the TKIs under physiologically relevant circumstances, we 
investigated platelet activation and thrombus formation under flow on coated surfaces, triggering 
a range of platelet receptors, i.e., GPVI, GPIb, CLEC-2, and integrins α6β1 and αIIbβ3. Blood samples 
were pre-incubated with one of the TKIs (applied at mostly 33 µM, see Table 7.2), and perfused 
over multiple microspots, containing collagen type I or III, or vWF co-coated with either laminin, 
rhodocytin, ristocetin or fibrinogen. Microscopic analysis of brightfield and fluorescence images 
resulted in five different thrombus parameters (P1-5) and three platelet activation markers (P6-8) 
(Suppl. Figure 7.1). In agreement with previous results34, different types of platelet thrombi were 
formed on the various surfaces with the control condition (Figure 7.3A). A systematic analysis 
was performed for evaluating the effects of each TKI by generating a subtraction heatmap for the 
eight different parameters, which were scaled (0-10) per parameter and per surface (Figure 7.3B). 
In contrast to the limited effect on collagen-induced aggregation, fostamatinib at 33 µM was 
most potent in suppressing thrombus formation and platelet activation under flow, on collagen as 
well as non-collagen surfaces (Figure 7.3A, B). Dasatinib at 0.1 µM also reduced collagen-induced 
thrombus formation under flow. On the vWF co-coated surfaces, this concentration of dasatinib 
did not affect the thrombus parameters (Figure 7.3B). Sunitinib in particular affected multiple 
parameters of thrombus formation on the two collagen surfaces, but showed limited effects 
on other surfaces. Pazopanib, axitinib and vatalanib showed weak inhibition, only affecting 1-2 
Table 7.2. Concentrations of TKIs used in platelet function assays
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Figure 7.4. Effects of different TKIs on GPVI-induced intracellular calcium responses. Fura-2-loaded platelets 
(200x109 /L) were pre-incubated with vehicle or TKI for 10 minutes and stimulated with CRP-XL (10 µg/mL) in presence 
of 2 mM CaCl2. Histograms show maximal rises in [Ca
2+]i (n=6). Black dotted lines indicate average of control values. 










Collagen I Collagen III vWF + Laminin vWF + Rhodocytin vWF + Ristocetin vWF + Fibrinogen
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Figure 7.3. Effects of eight TKIs on whole blood thrombus formation under flow on different thrombogenic surfaces. 
Blood samples were pre-incubated with vehicle or TKI for 10 minutes. Samples were then recalcified in the presence of 
PPACK and perfused for 3.5 minutes at a wall shear rate of 1000 s-1 over six different coated surfaces. After perfusion, 
the formed thrombi were stained with AF568-annexin A5, FITC-α-fibrinogen and AF647-α-CD62P to detect PS exposure, 
integrin αIIbβ3 activation and P-selectin expression, respectively. (A) Representative brightfield images of control or 
fostamatinib-treated blood after flow over collagen type I, collagen type III, vWF plus laminin, vWF plus rhodocytin, vWF 
plus ristocetin or vWF plus fibrinogen. (B) Subtraction heatmap representing significantly altered effects of parameters 
P1-P8 (normalized and analysed as in Suppl. Figure 7.1). P1 = morphological score of platelet adhesion and thrombus 
formation, P2 = surface area coverage of adhered platelets, P3 = platelet aggregate contraction score, P4 = platelet 
aggregate multilayer score, P5 = coverage of multi-layered platelet aggregation, P6 = αIIbβ3 activation, P7 = P-selectin 
expression, and P8 = PS exposure. Results from vehicle control runs were set at 0. Effects were filtered for significant 
alterations (p<0.05) with TKIs.
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parameters on collagen type I and III. Mainly the size, height and density of the thrombi were 
reduced (Figure 7.3B, Suppl. Figure 7.1). The inhibition of thrombus formation with dasatinib 
or sunitinib was in line with the effects seen in aggregation of PRP. Also, the weaker effects of 
the other TKIs (pazopanib, axitinib, cabozantinib, lapatinib and vatalanib) (Figure 7.3B) were in 
agreement with the PRP aggregation results. Together, this indicated that the TKIs with highest 
affinities for kinase targets in platelets (dasatinib, fostamatinib and sunitinib) had the largest 
impact on whole blood thrombus formation under flow.
Differential effects of TKIs on GPVI-induced calcium signalling
To further explore the inhibitory effects of the TKIs on platelet signalling, we measured 
the GPVI-induced intracellular calcium responses. Platelets were loaded with the probe Fura-2, 
preincubated with vehicle or TKI, and then stimulated with the GPVI agonist CRP-XL. Markedly, 
dasatinib, fostamatinib, sunitinib and pazopanib significantly decreased or even abolished the 
maximum intracellular calcium signal (Figure 7.4). In contrast, intracellular calcium rises were 
unchanged in the presence of axitinib, cabozantinib, lapatinib and vatalanib (Figure 7.4). Similar 
effects were seen when comparing the slope and area-under-the curve of these responses 
(not shown). In general, these results are in line with the observed effects on collagen-induced 
aggregation. However, cabozantinib and vatalanib showed 30-70% inhibition of platelet 
aggregation platelets. This suggested that for dasatinib, fostamatinib, sunitinib and pazopanib 
the effects were mediated by early GPVI-induced signalling events in accordance with Syk or SFK 
inhibition, whereas for cabozantinib and vatalanib the anti-aggregatory effects are downstream 
of the calcium rises.
Diverse effects of fostamatinib, cabozantinib and vatalanib on platelet activation 
markers and platelet populations 
In order to further explain the selective anti-aggregatory effects of fostamatinib, 
cabozantinib and vatalanib, we investigated their effects on GPVI-induced integrin αIIbβ3 activation, 
secretion of α- and δ-granules and lysosomes. In general, all platelet activation markers were 
reduced in the presence of cabozantinib (33 µM), vatalanib (33 µM) and fostamatinib (33 µM) 
(Figure 7.5A). Fostamatinib consistently inhibited all GPVI-induced activation responses. In 
contrast, PS exposure was not inhibited by fostamatinib in isolated platelets (Figure 7.5A). The 
effects of cabozantinib and vatalanib on CRP-induced platelet activation were more restricted. 
Cabozantinib and vatalanib both inhibited integrin αIIbβ3 activation, in line with the inhibition of 
collagen-induced aggregation in washed platelets. Furthermore, cabozantinib inhibited δ-granule 
and lysosome secretion, whereas vatalanib resulted in reduction of α-granule secretion. PS 
exposure was also not affected by cabozantinib and vatalanib. As sustained high calcium rises are 
a prerequisite for PS exposure, the absence of effects on PS exposure by the TKIs is in agreement 
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with the calcium responses that remained unchanged by cabozantinib and vatalanib. Hence, 
cabozantinib and vatalanib suppress platelet integrin activation and secretion at doses that do 
not influence the calcium response.
To evaluate a differential sensitivity of platelets towards these TKIs in terms of activation 
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Figure 7.5. Effect of TKIs on populations of activated platelets in response of GPVI. Washed platelets (25x109/L) were 
incubated with vehicle, fostamatinib (33 µM), cabozantinib (33 µM) or vatalanib (33 µM) for 10 minutes. Platelet activation 
was induced by 5 µg/mL CRP-XL for 15 minutes and simultaneously labelled for activated integrin αIIbβ3 (PAC1-FITC), 
α-granule secretion (αTLT1-BV421, αCD62P-PerCP Cy5.5) and δ-granule/lysosome secretion (αCD63-APC). Separately, PS 
exposure was induced using 5 µg/mL CRP-XL plus 4 nM thrombin for 60 minutes at 37°C, labelling was with annexin A5-PE. 
(A) Histograms of integrin αIIbβ3 activation, TLT1, P-selectin and CD63 expression as well as PS exposure as percentages of 
control condition. (B) Distribution profiles of platelet populations after stimulation with CRP-XL. (i) 2D plots visualising the 
platelet fractions per population in the presence of vehicle, fostamatinib, cabozantinib or vatalanib. (ii) Characterisation 
of CRP-XL-induced platelet populations based on relative expression levels of activation markers determined by FlowJo 
analysis, using tSNE and FlowSOM plugins. (C) Histograms visualising the platelet fractions per population in the presence 
of vehicle (white bars), or fostamatinib, cabozantinib or vatalanib (coloured bars). Data are shown as means ± SEM (n=6), 
* p<0.05, ** p<0.01.
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by the presence of fostamatinib, cabozantinib or vatalanib. Comparison of the four different 
activation markers, reflecting stages of granular secretion and integrin activation, rendered up 
to five different populations (Figure 7.5Bii) upon stimulation with CRP-XL. These were ranging 
from low up to very high expression levels for all markers with an equal expression of the control 
marker GPIb throughout the samples. The changes in distribution of these populations in the 
presence of the TKIs were illustrated by 2D scatterplots that visualised the distribution of the 
populations (Figure 7.5Bi). Population 1 with low-level platelet activation (resting platelets), 
appeared to be significantly increased with fostamatinib, cabozantinib or vatalanib upon GPVI 
stimulation. On the other hand, population 5 with high activation of αIIbβ3 and high secretion of 
α-, δ-granules and lysosomes was decreased in the presence of these TKIs (Figure 7.5C), whereas 






































































































































































































































Figure 7.6. Platelet aggregation and activation induced by different activation pathways in presence of different 
TKIs. (A) Washed platelets (250x109/L) were incubated with vehicle (control), fostamatinib (33 µM), cabozantinib (33 
µM) or vatalanib (33 µM) for 10 minutes. Platelet aggregation was then induced with 1 µM 2MeS-ADP, 1 µM U46619 
(thromboxane A2 analogue), 1 µg/mL rhodocytin or 4 nM thrombin. Aggregation responses were measured for 8 minutes. 
Histograms show aggregation as percentage of control (dotted line). (B-C) Washed platelets (25x109/L) were incubated 
with vehicle (control) or TKI for 10 minutes. Platelets were activated by (B) 2 µM 2MeS-ADP, or (C) 4 nM thrombin for 15 
minutes. Simultaneous labelling was for activated integrin αIIbβ3 (PAC1-FITC), α-granule secretion (αTLT1-BV421, αCD62P-
PerCP Cy5.5) and δ-granule/lysosome secretion (αCD63-APC). Histograms of integrin αIIbβ3 activation, TLT1, P-selectin and 
CD63 expression, as percentages of control condition (dotted line). Data are shown as means ± SEM (n = 6), * p<0.05. ** 
p<0.01, *** p<0.001.
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the simultaneous inhibition of secretory and integrin-activating platelet responses by these TKIs.
In whole blood perfusion experiments, we observed inhibitory effects of fostamatinib 
on thrombus formation on vWF co-coated surfaces. To determine effects of fostamatinib, 
cabozantinib and vatalanib on platelet activation induced by other agonists, platelet aggregation 
was investigated in response to ADP, the thromboxane A2 analogue U46619, the CLEC-2 agonist 
rhodocytin or thrombin. Fostamatinib only reduced rhodocytin-induced aggregation (Figure 
7.6A), in agreement with Syk signalling underneath CLEC-226. In contrast, cabozantinib significantly 
inhibited the aggregation responses to ADP and rhodocytin, while vatalanib prominently reduced 
the responses to ADP and U46619, and slightly to thrombin (Figure 7.6A). In line with these 
aggregation results, vatalanib suppressed ADP- and thrombin-induced integrin αIIbβ3 activation, 
TLT1 expression and P-selectin expression (Figure 7.6B, C). Upon thrombin stimulation also 
δ-granule and lysosome secretion were partially inhibited (Figure 7.6C). In contrast to the observed 
reduction in ADP-induced aggregation with cabozantinib, no inhibition of platelet activation was 
observed in response to ADP (Figure 7.6B, C). Taken together, this suggested that the latter two 
compounds inhibited signalling entities in pathways other than induced by GPVI.
Discussion
In this work we explored the antiplatelet properties of the TKIs dasatinib, fostamatinib, 
sunitinib, pazopanib, cabozantinib, axitinib, lapatinib, and vatalanib, to investigate the possible 
repurposing of these compounds as antiplatelet drugs. Overall, we observed that the TKIs with 
the highest reported affinities for targets in platelets (dasatinib, fostamatinib and sunitinib) at 
doses used showed the strongest inhibition on collagen-dependent whole blood thrombus 
formation under flow. Furthermore, fostamatinib was the most effective inhibitor of thrombus 
formation also on vWF plus rhodocytin, or vWF plus laminin. In the presence of other TKIs 
thrombus formation was no more than mildly reduced only on collagen. Intracellular calcium 
measurements and activation responses in isolated platelets showed that the inhibitory effects of 
dasatinib, fostamatinib, sunitinib and pazopanib were in line with proposed inhibitory effects on 
Syk and/or SFK, i.e., downstream of GPVI-induced platelet activation. At the doses tested, calcium 
measurements indicated that effects of the low-affinity inhibitors cabozantinib and vatalanib are 
downstream of phospholipase Cγ phosphorylation. 
 The present strong effects of the active metabolite of fostamatinib (R406) with high 
affinity for Syk on thrombus formation and PS exposure under flow are in line with a previous 
study using the selective Syk inhibitor PRT-06031837. However, our results obtained in isolated 
platelets are in contrast to other studies26, 42. These studies demonstrated significant inhibition of 
collagen- or rhodocytin-induced platelet aggregation with low concentrations of R406, whereas 
we observed only minor inhibition at higher concentrations. The difference may be due to longer 
incubation time of the platelets with the inhibitor in our study. As fostamatinib is a reversible 
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inhibitor, the incubation time could be of importance, however, we did observe strong inhibition 
in whole blood perfusion experiments using the same pre-incubation time. Furthermore, others 
have incubated with fostamatinib for even longer time-periods in platelets as well as other 
cell types, making transient inhibition unlikely27, 43. In addition, fostamatinib strongly inhibited 
GPVI-induced PS exposure in whole blood thrombus formation under flow, however, in isolated 
platelets this response was not affected. PS exposure is dependent on sustained high intracellular 
calcium levels44, which we showed to be inhibited by fostamatinib. As PS exposure is triggered by 
dual stimulation of CRP and thrombin in our setting, this might overcome the partially decreased 
calcium signal induced by GPVI-stimulation in the presence of fostamatinib and thereby resulting 
in normal PS exposure. 
 Several of the investigated TKIs are used for treatment of metastatic renal cell carcinoma 
(mRCC) patients, i.e., sunitinib, pazopanib, cabozantinib and axitinib. Our results with sunitinib 
and pazopanib are consistent with a moderate inhibition of SFK, Syk and other relevant tyrosine 
kinases in platelets (Figure 7.1). For both compounds only mild bleeding effects have been 
reported30. Cabozantinib is used mainly as second- or third-line treatment for mRCC patients, 
and axitinib (combined with pembrolizumab) in first line mRCC, but their effects on platelets 
have not been investigated thus far. For cabozantinib, we report a reduced collagen-, CLEC-2- and 
ADP-induced aggregation in washed platelets, but no effect on thrombus formation. This is in line 
with no more than limited reported bleeding30. Axitinib at the dose of 33 µM used was essentially 
ineffective in most assays. We did observe limited effects on thrombus height and contraction 
in whole blood perfused over collagen. Notably, axitinib is described to induce mild (and in rare 
cases severe) thrombocytopenia in 15-20% of the patients45-47, which points to a megakaryocytic 
rather than platelet function defect contributing to the reported bleeding48, 49. 
Lapatinib and vatalanib have been reported to have limited affinity for tyrosine kinases in 
platelets and remain without reported bleeding24. In agreement with Li et al.50, lapatinib did not 
alter thrombus formation in whole blood perfusion, as well as intracellular calcium responses 
and aggregation in isolated platelets. Surprisingly, in the presence of vatalanib, we did observe 
inhibition of thrombus size, height, and contraction on collagen under flow at 33 µM, which is 
in contrast to the observations of Li et al., but the used concentration was not reported50. In 
addition, in isolated platelets vatalanib inhibited collagen-, ADP-, TxA2- and thrombin-induced 
aggregation, as well as platelet activation. As GPVI-induced intracellular calcium rises were not 
affected by vatalanib, this suggested that vatalanib affects platelet signalling downstream of 
calcium. Vatalanib was developed to inhibit all VEGF receptors, and is mostly used for treatment 
of patients with colorectal cancer51. As no platelet tyrosine kinases are reported to be affected by 
this compound, further research is required to investigate the inhibitory mechanism in platelets.
In washed platelets, dasatinib, sunitinib, pazopanib, cabozantinib, and vatalanib 
prominently inhibited collagen-induced aggregation, while in PRP this response was unaffected 
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(cabozantinib and pazopanib) or required a higher concentration of the TKI to achieve inhibition 
(dasatinib, sunitinib and vatalanib). For pazopanib, this is in line with previous findings28, and 
explained by high plasma binding52-55. Indeed, in patients with TKI treatment, the bioavailability 
of the drug is considered to be influenced by plasma binding with implications for drug toxicity 
and response56. In line with this, for the TKIs that did not or limitedly inhibited collagen-induced 
aggregation in PRP, we also observed no or only limited effects on thrombus formation under 
flow. 
 For the doses used of fostamatinib, cabozantinib and vatalanib we investigated effects 
on secretion and integrin activation in more detail. Most consistent effects were observed with 
fostamatinib, which moderately inhibited all GPVI-induced activation responses. Cabozantinib 
and vatalanib inhibited integrin αIIbβ3 activation along with aggregation. Interestingly, cabozantinib 
mildly suppressed δ-granule and lysosome secretion, whereas vatalanib reduced the α-granule 
secretion. The reason for this difference is unclear. Furthermore, we used two markers to measure 
of α-granule secretion, namely P-selectin (CD62P) and TLT-1. Although, in general we observed 
similar results using both markers with several agonists as well as inhibitors, it has been reported 
that TLT1 is more sensitive marker for platelet activation than P-selectin57. When a soluble TLT-1 
is released in the plasma, it enhances platelet aggregation58, 59 and has been demonstrated to 
regulate early clot formation though the stabilization of αIIbβ3 outside-in signalling
60. Hence, this 
may provide an additional mechanism of the inhibitory effect of vatalanib.
We determined the distribution of the single platelet activation markers among different 
populations to further zoom in on the effects of fostamatinib, cabozantinib or vatalanib on 
GPVI-induced platelet activation. In general, in the presence of TKIs the population with highly 
expressed activation markers was decreased, whereas the population with negative expression of 
these markers was increased. This integrated approach suggested that pre-incubation with TKIs 
may affect the general responsiveness of the heterogeneous platelet populations61.
 In conclusion, we observed that fostamatinib was the most effective inhibitor of 
thrombus formation on collagen under flow, and that pazopanib, sunitinib, dasatinib, axitinib, 
and vatalanib also mildly reduced this process. Furthermore, the TKIs showed variable inhibiting 
effects in isolated platelets stimulated with several agonists. As especially fostamatinib, sunitinib, 
pazopanib, and vatalanib have been associated with mostly manageable or no bleeding events, 
these may be promising candidates to explore further as antiplatelet drugs. Clinicians should 
be aware of the antiplatelet properties of TKIs in general, especially when patients are already 
treated with antiplatelet or anticoagulant drugs.
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Since the beginning of this century, a new class of anti-cancer agents, tyrosine kinase 
inhibitors (TKIs), has been developed and approved for the treatment of several malignancies1, 2. 
These TKIs inhibit growth factor receptors (tyrosine kinases, Table 8.1) involving angiogenesis and 
tumour development and thereby improving progression free survival (PFS) and overall survival 
(OS)3. As most TKIs inhibit multiple protein tyrosine kinases (Table 8.1), they inevitably also affect 
other cell types. One of the side effects described for several TKIs is (mild) bleeding or thrombosis4. 
Platelets are well known for their involvement in haemostasis, and they also contain multiple 
protein tyrosine kinases (Syk, Src family kinases (SFK), Btk), which are essential for their activation. 
Hence, these TKIs may also affect platelet function. Therefore, the overall aim of this thesis was to 
provide more insights in the off-target effects of TKIs on platelet function (Chapter 1). In the next 
paragraphs of this chapter, the observations described throughout this thesis are discussed in 
relation to the current literature, as well as clinical implications and future perspectives are given. 
Altogether, the findings reported in this thesis may provide relevant insights for monitoring the 
bleeding risk in patients receiving TKI treatment by assessing quantitative and qualitive platelet 
traits, especially in the presence of anti-coagulant or anti-platelet drugs.
Platelet signalling and TKIs
It has been described that several TKIs, for different cancer types, inhibit platelet function 
upon treatment, which can contribute to the risk of bleeding5-7. Chapter 2 shows an overview 
Figure 8.1. Overview of the tyrosine kinases expressed in platelet signalling (in yellow) downstream of 
multiple platelet receptors, resulting in different platelet responses. The intervention points of the TKIs (based on the 




of the currently used TKIs in cancer treatment and the effects on platelet function. Throughout 
the Chapters 3-7, we used in total 11 TKIs (acalabrutinib, axitinib, cabozantinib, dasatinib, 
fostamatinib, ibrutinib, lapatinib, MK-1026, pazopanib, sunitinib and vatalanib) to explore the 
effects on platelet function in vitro and in cancer patients. Table 8.1 gives an overview of the anti-
platelet effects from different assays, that were observed after in vitro treatment with these 11 
TKIs. Overall, the majority of inhibited responses were demonstrated to affect the GPVI-pathway, 
and for several TKIs (ibrutinib and fostamatinib), (also) effects upon CLEC-2 or GPIb stimulation 
Figure 8.1. Continued. The intervention points of the TKIs (based on the Kd values described in Chapter 2) investigated 
in this thesis are indicated in red.  
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could be observed. Given the defined affinities in our review in combination with the results 
obtained for the 11 TKIs tested here, we visualised the proposed interference of these TKIs in the 
platelet signalling pathways (Figure 8.1). 
In whole blood perfusion, effects on thrombus formation were mainly restricted to the 
glycoprotein (GP)VI-pathway as observed for dasatinib, sunitinib, pazopanib and vatalanib. Only 
ibrutinib and fostamatinib showed to be effective towards GPIb (combined with CLEC-2 or α6β1)-
induced thrombus formation (Table 8.1, Chapter 3, 4, 6 and 7). Ibrutinib and fostamatinib specifically 
inhibit Btk/Tec or Syk, respectively. Both proteins are important mediators in coupling cell surface 
receptors to downstream signalling events and are in close proximity in most signalling pathways8, 
9. This suggests that direct targeting of Btk or Syk in platelet signalling by TKIs is more effective to 
inhibit platelet function as compared to TKIs primary targeting growth factor receptors. Also, a 
difference can be observed between inhibition of Btk and Syk. Btk inhibition by ibrutinib mainly 
inhibits GPIb-associated thrombus formation, whereas Syk inhibition with fostamatinib shows to 
affect thrombus formation with GPIb, as well as GPVI. As binding and activation of Syk initiates 
downstream signalling involving Btk in GPVI, CLEC-2 and GPIb-signalling, this hints towards the 
concept that inhibition higher upstream in platelet signalling results in more efficient inhibition.  
In isolated platelets almost all inhibitors more prominently inhibited GPVI-induced 
aggregation, except fostamatinib, axitinib and lapatinib. For fostamatinib this contrasts to the 
papers of Spalton et al. and Lhermusier et al.10, 11, who observed complete inhibition of collagen- 
and/or rhodocytin-induced platelet aggregation with already low concentrations of the active 
metabolite of fostamatinib. The only difference between these studies and the study in chapter 7, 
is the incubation time of the platelets with the inhibitor. We pre-incubated for 10 minutes, while 
in the earlier studies platelets were incubated for 1-5 minutes with fostamatinib. As fostamatinib 
is a reversible inhibitor, the incubation time could be of importance, however, we did observe 
strong inhibition in whole blood perfusion experiments using 10 minutes pre-incubation of whole 
blood. 
The lack of GPVI-induced aggregation for axitinib and lapatinib is in line with literature 
findings. Although axitinib is associated with bleeding7, 12, no inhibition of platelet function has 
been reported. In about 15-20% of the patients, axitinib is described to induce mild (grade 1-2) 
thrombocytopenia13, 14, and in rare cases (<1%) severe (≥ grade 3) thrombocytopenia is reported15. 
For axitinib it is proposed that increased bleeding in these patients is caused by a decrease in 
platelet count rather than platelet inhibition. For lapatinib increased bleeding risk has not been 
reported and, furthermore, thrombus formation under flow (in vitro) was also unaffected16. Hence, 
these observations show that axitinib and lapatinib do not have off-target effects on platelets. 
All other TKIs investigated in this thesis (acalabrutinib, cabozantinib, dasatinib, MK-1026, 
pazopanib, sunitinib and vatalanib) show most pronounced effects in platelets upon collagen 




activation for pazopanib, sunitinib, dasatinib and vatalanib. This suggests that the GPVI pathway 
is most sensitive for inhibition with TKIs. GPVI, GPIb-IX-V and CLEC-2 are most potent receptors 
for thrombus formation at high-shear stress conditions17. They share several common tyrosine 
kinases (Fyn, Lyn, Syk, Btk, etc) in signal transduction in platelets17, 18. As TKIs are able to affect 
multiple of these tyrosine kinases, it is expected that more pathways should be inhibited. 
However, a possible explanation for the restriction of effects to the GPVI pathway could be the 
amount of copy numbers present in platelets. Of these receptors, GPIIbIIa (integrin αIIbβ3) and 
GPIb are the most abundantly expressed receptor on platelets with around 80,000 and 25,000 
copies, respectively19-21. GPVI and CLEC-2 receptors are far less expressed with only 6,000-10,000 
and 2,000 copies reported, respectively19, 22, 23. Therefore, it could be expected that GPVI and 
CLEC-2 are relatively more affected as compared to GPIb as less receptors (lower copy number) 
remain active. Signalling pathways of receptors with a higher expression, such as GPIIbIIa and 
GPIb, might still be partially functional as more receptors are available, making it more difficult 
to observe inhibition. Moreover, it is indicated by Spalton et al.10 that GPVI is more dependent on 
Src family kinase (SFK) phosphorylation and FcγR signalling, whereas the CLEC-2 pathway is more 
reliant on Syk phosphorylation. Together this encourages that TKIs have probably a higher affinity 
for SFKs rather that Syk, resulting in more specific inhibition of the GPVI pathway.
Plasma protein binding of TKIs influencing drug availability and platelet 
inhibition
In (almost) all chapters of this thesis inhibition of platelet traits, qualitative and/or 
quantitative, by different TKIs is the central point of view. Although in vitro effects were present 
in almost all conditions tested, inhibition by TKIs was more pronounced in isolated platelets as 
compared to the presence of plasma (platelet-rich plasma or whole blood) (Table 8.1). This meant 
that a higher dose of a TKI was often needed to elicit similar inhibition in PRP or whole blood 
as compared to washed platelets. Strikingly, pazopanib and cabozantinib prominently inhibited 
aggregation of washed platelets to several agonists, while in PRP this response was unaffected 
(Table 8.1). This phenomenon is caused by high plasma binding of the TKIs (>95%)24-27. In patients 
with TKI treatment, the bioavailability of the drug is likely to be influenced by this plasma binding 
with implications for drug toxicity and response28. This shows the importance of the comparison 
between in vitro testing of these agents in presence or absence of plasma, as well as measuring 
effects present in patients receiving treatment. For clinical implications it is might point to adapting 
dosing regimens based on the pharmacokinetic/dynamic characteristics of TKIs29 or more ideally 
by monitoring the unbound plasma concentration of a TKI during treatment30. For example, we 
measured levels of sunitinib and its metabolite in plasma, serum and isolated platelets at 2 and 
4 weeks on treatment in patients with a 4/2 scheme (4 weeks dosing, 2 weeks rest) in Chapter 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































sunitinib and its metabolite at both timepoints, however, a remarkable increase of metabolite 
concentration was observed in isolated platelets as compared to sunitinib concentration. This 
suggested a higher uptake of the active form of sunitinib by platelets in their granules, though 
both compounds were equally present in plasma. Therefore, it might also be of interest to not 
only monitor plasma concentrations at 2 of 4 weeks on treatment (dependent on treatment 
schedule)31, but also measure the uptake of (active) compound by platelets as this might predict 
the platelet inhibitory effects.  
Involvement of quantitative and quantitative platelet traits in bleeding 
tendency in patients
In the review in Chapter 2, 11 out of almost 40 TKIs are reported with an increased risk of 
bleeding or bleeding events. Given the key role of platelets in haemostasis, both platelet count 
and platelet function are relevant to prevent bleeding32, 33. In Chapters 3 and 5, we have shown 
that not only platelet function, but also platelet count is already decreased after 2 weeks after 
pazopanib or sunitinib treatment, as compared to pre-treatment (Table 8.2). Although TKIs are 
known to be associated with platelet dysfunction6, 34, impaired platelet function is not always 
found to be the cause of increased bleeding tendency35, 36. For multiple TKIs, including dasatinib 
(Chapter 7), an association is found with drug-induced immune thrombocytopenia, defined as 
a platelet count below 50x109/L37-39, resulting in an increased risk of bleeding. While most of 
the patients included in Chapters 3 and 5 did not show thrombocytopenia, we did observe an 
overall decrease in platelet count upon pazopanib or sunitinib treatment (Table 8.2). This change 
in platelet count correlated with the inhibition of platelet function after sunitinib treatment, as 
well as with the plasma concentration of the metabolite of sunitinib (Chapter 5). This point to 
the idea that platelets are exposed to significant levels of sunitinib resulting in (mild) anti-platelet 
effects. Alternatively, sunitinib may act on the megakaryocytes, thereby decreasing platelet count 
and possibly also affect platelet function. As plasma concentration and plasma protein binding of 
sunitinib (or its metabolite) could be of importance in toxicity and response to a TKI treatment30, 
this pointed toward a monitoring tool for off-target effects and/or progression-free survival. 
Whilst several studies propose that TKI-associated platelet dysfunction does not cause 
bleeding35, 36, almost all the patients included in Chapter 3, 5 and 6 did report (mild) bleeding 
episodes upon TKI treatment in the absence of thrombocytopenia (Table 8.2). This may imply 
that pharmacological platelet inhibition does play a role in the increase in bleeding risk. In 
agreement, we see impairment of GPVI-induced platelet activation, aggregation or thrombus 
formation upon treatment in vitro and/or in patients, some with additional effects on CLEC-2- or 
GPIb-induced platelet responses. It has been reported that targeting GPVI via GPVI inhibitors 
or GPVI depletion in mice or patients does not (significantly) impair haemostasis40-45. However, 




















































    






















































































































































































































































































































































































































































































































































































































































































studies mainly determined the contribution of platelet GPVI- and CLEC-2 receptors themselves in 
haemostasis40, 43. However, in case of several TKIs, the inhibition in platelet signalling underneath 
these receptors is described to be via SFKs (Fyn, Lyn) or Syk11, 46-49. As the GPVI, CLEC-2 and GPIb 
pathways all require SFKs and/or Syk in its signalling, it overall suggests that multi-target TKIs can 
elicit combined inhibition of GPVI plus CLEC-2 or possibly GPIb signalling pathways. This could be 
more potent than targeting solely one receptor and, hence, relevant for bleeding tendency. In 
combination with a decrease in platelet count, this might even further increase the bleeding risk. 
As cancer patients often have a cardiovascular history50, 51, anti-platelet or anti-coagulant 
drugs are prescribed to prevent recurrent cardiovascular events. Anti-platelet therapies, such as 
clopidogrel and aspirin, are reported to be associated with an increased risk of bleeding52-54. As 
TKIs are described to increase this risk as well, in Chapter 5, we investigated the synergistic effects 
of sunitinib and aspirin as anti-platelet medication on thrombus formation and fibrin formation to 
elucidate the impact on haemostasis. We demonstrated that sunitinib suppressed procoagulant 
activity and prolonged the time to fibrin formation, which was aggravated by aspirin treatment. 
Therefore, a combination of TKIs and anti-platelet therapies may be expected to increase the 
frequency or grade of bleeding. Though such dual treatment of TKI with anti-platelet or anti-
coagulant drugs could be increasing the bleeding risk, this  might also be beneficial for the 
patients. It has been shown that anti-platelet therapies have anti-tumour effects in hepatocellular 
and colorectal cancer55, 56. Hence a combination of TKI with anti-platelet therapy could enhance 
the anti-tumour effects. For example, erlotinib together with aspirin is described to enhance 
sensitivity of the cancer as compared to aspirin alone, thereby increasing the anti-cancer 
activity57. The application of anti-platelet drugs is even more favourable, as it was shown that 
low doses of aspirin could be used as treatment for off-target effects, such as skin rash caused 
by erlotinib-treatment58. Additionally, for some TKIs, anti-platelet treatments can be useful as 
nilotinib is associated with an increased risk of thrombosis59. Yet, not all anti-platelet drugs show 
a positive correlation in combination with TKI treatment. The study of Haoula et al.60 highlights 
the importance of drug-drug interactions between clopidogrel and other anticoagulants in 
combination with TKIs. This urges for better understanding of dual treatment with TKIs and anti-
platelet or anti-coagulant therapies to monitor patients.
Overall, we showed that multiple TKIs inhibit platelet function via different pathways and 
that this combination may contribute to the reported bleeding risk in patients. In addition, for 
other TKIs inhibiting the GPVI-induced platelet function together with a decrease in platelet 
count, as seen with pazopanib and sunitinib, might also explain the mild bleeding tendency 
observed during treatment. Hence, the combination of the inhibitory effects on platelet traits 
together with anti-platelet or anti-coagulant drugs urges for better understanding and possibly 





 Platelets not only have an important role in haemostasis, they have also been described 
to be implicated in tumour development and growth61-64. Platelets are known to take up various 
pro- and antiangiogenic proteins into their α-granules61, 62, 65. These granules can be secreted 
upon platelet activation by activating factors expressed or secreted by tumour vasculature 
such as thrombin and ADP. In turn, the secreted proangiogenic factors can stimulate tumour 
growth and metastasis by stimulating angiogenesis61, 66, improving vasculature integrity67, 68 and 
inducing resistance to therapy69, 70. Due to this promoting role of platelets in tumour angiogenesis 
and progression, as well as the correlation with reduced survival, platelets are an interesting 
target for cancer therapy. Although numerous drugs have been developed to target platelet 
receptors71, limitations for implications occur due the role of platelets in haemostasis associated 
with increased bleeding tendency52-54. Yet anti-platelet treatment have been described to reduce 
tumour angiogenesis, growth and progression72, 73 by direct inhibition of the tumour or via indirect 
via inhibition of platelet secretion, thereby decreasing proangiogenic protein concentrations in 
the tumour environment74. Hence, the TKIs investigated in this thesis could also indirectly affect 
tumour growth via the inhibiting effects on platelet function, as we did observe inhibition of 
platelet activation and/or secretion upon GPVI stimulation with acalabrutinib, cabozantinib, 
fostamatinib, ibrutinib, pazopanib, sunitinib and vatalanib in isolated platelets. However, the 
principle of platelet-mediated anti-cancer effect of TKIs needs to be further investigated. Platelet 
inhibition remains contradictory and needs to be balanced, as it can improve cancer prognosis, 
as well as increase the risk of bleeding. In line with the inhibition of platelet function with TKIs 
observed throughout this thesis, one might argue that monitoring patients is needed to profit 
from the anti-tumour effects and keep the risk of undesirable bleeding to a minimum. 
 In addition, platelet production can be (greatly) enhanced by malignant (solid) tumours62, 
75. An increased platelet count or thrombocytosis (platelet count of >400x109/L) is recognized as 
a predictor of poor prognosis in patients with different cancer types75, 76. As platelets are able to 
take up all sorts of compounds into their granules, it is not unlikely for anti-cancer agents to be 
sequestered as well. The study of Sabrkhany et al.77 showed that platelets take up sunitinib in 
their granules in vitro and in patients. In turn, we showed in Chapter 5 that both sunitinib and 
its metabolite were present in isolated platelet of sunitinib-treated patients and that platelet 
function is impaired. Besides high plasma binding of anti-cancer or anti-platelet agents, the 
ability of platelets to sequester these compounds might influence the bioavailability for the 
tumour, especially in thrombocytosis, i.e. increased amount of platelets. This might result in 
reduced inhibition of tumour growth as a lower concentration would be circulating in the blood. 
Also, thrombocytosis might not only be a consequence of cancer, it might be a paraneoplastic 
abnormality that is associated with a vicious cycle of promoting tumour cells, platelet activation 
and stimulating thrombocytosis75. Therefore, reducing the thrombocytosis before starting 
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treatment by interfering with this feedback-loop could be relevant. This could be accomplished 
via inhibition of platelet function with anti-platelet agents or heparins, however this could result 
in bleeding implications78, 79. Another approach to intervene with tumour growth and metastasis 
is inhibition of interleukin-6 (IL-6) by the IL-6 antibody siltuximab. This will deplete the increased 
growth factor levels present and additionally decrease platelet count80. Clinical trials with ovarian 
cancer, renal cell carcinoma and castration resistant prostate cancer already show beneficial 
effects80-82.
Clinical significance for renal cell carcinoma patients
The TKIs used for treatment of patients with metastatic renal cell carcinoma (mRCC), i.e. 
sunitinib and pazopanib, have been the focus of Chapters 3, 4 and 5 of this thesis. Furthermore, 
we also studied the effects of cabozantinib, used mainly as 2nd or 3rd line treatment for mRCC 
patients, and axitinib, combined with pembrolizumab in first line mRCC83, 84, on platelet functions 
in Chapter 7. In the Netherlands, good risk mRCC patients are treated with a TKI when metastases 
have occurred. Patients often have a large tumour thrombus in the renal vein, which means that 
local surgery is no longer possible. However, this is usually no consideration to start anticoagulation 
therapy. When started with 50 mg/day sunitinib, systemic concentrations of sunitinib should be 
50-100 ng/mL85. However, for a substantial group of patients, this dosing schedule may result in 
much higher peak levels, resulting in toxicity86. In daily practice, sunitinib levels (steady state) in 
serum could be determined if patients experience serious side effects and if the levels are too 
high (>100 ng/mL31), the treatment dose could be adjusted accordingly. In addition, sunitinib 
levels could also be determined if patients have no side effects at all, as the sunitinib level is 
probably too low (<50 ng/mL31). 
Hamilton et al.87 have shown that the decrease in platelet count upon sunitinib treatment 
may serve as a prognostic value with regard to tumour development. In Chapter 5, we have 
demonstrated that this reduction in platelet count also coincides with a reduction in platelet 
function as well as sunitinib levels in plasma and serum. Together, this implies that both qualitative 
and quantitative platelet traits may serve as a monitoring tool with regards to sunitinib treatment 
in mRCC patients. Furthermore, similar observations have been reported for neutrophil-to-
lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR) ratio. A NLR greater than 1.9 but below 
3 and PLR over 160 are described to be favourable prognostic factors88, 89. Also, an increase in 
eosinophils have been reported to be a beneficial factor upon therapy in patients with renal cell 
carcinoma upon treatment90, 91.
Also relevant for mRCC, although no longer used, is the classification of metastatic disease 
into groups with regards to overall survival, according to the Memorial Sloan-Kettering Cancer 
Centre (MSKCC)/Motzer citeria92; good, intermediate and poor risk. Currently, a switch has been 




classification. For this purpose, 6 parts of pre-treatment are scored, with one point per item, 
looking back one year before starting systemic treatment: Time from diagnosis to treatment 
initiation <1 year, Karnofsky performance status (KPS) <80%, haemoglobin (Hb) concentration 
<12 g/L, serum calcium concentration >upper limit of normal (ULN), neutrophil count >ULN and 
platelets count> ULN93. With no points, the patient has a good risk for survival, at 1-2 points 
intermediate risk and from 3 on the risk is poor. For the good risk patients, it appeared that 
sunitinib was superior to the immuno-agents nivolumab/ipilimumab, and was equivalent to 
pembrolizumab plus axitinib94, 95. Therefore, sunitinib has become a mainstay not only for first-
line treatment in this particular risk group, but also in second line treatment after nivolumab/
ipilimumab. The results of the present thesis with regard to the effects of sunitinib on platelet 
count and function, are thus in agreement with the incorporation of platelets into this IMDC 
classification. 
Future perspectives
 To summarise, this thesis increased the knowledge of how TKIs can influence platelet 
function and contribute to reported bleeding events. In brief, in vitro experiments throughout 
this thesis demonstrate that impaired platelet function is more pronounced in isolated platelets 
as compared to whole blood perfusion, mainly affecting GPVI-induced platelet activation in 
presence of plasma. Only ibrutinib and fostamatinib showed (additional) inhibition of CLEC-2 
and/or GPIb-induced platelet activation and aggregation. In addition, the observed suppression 
of aggregation and thrombus formation with sunitinib was aggravated by anti-platelet (aspirin) 
therapy. Our studies involving patients demonstrated that pazopanib or sunitinib treatment 
slightly decreased platelet count together with (limited) effects on the qualitative platelet traits, 
whereas for patients treated with ibrutinib impaired collagen-, rhodocytin- and vWF-induced 
aggregation and thrombus formation was observed. Moreover, we showed that for sunitinib the 
inhibition in quantitative and qualitative platelet traits could be correlated with the (effective) 
sunitinib levels in patients. Altogether, the inhibition of multiple platelet activation pathways, the 
reduction in platelet count, or TKI treatment combined with antiplatelet agents might contribute 
or even increase the reported bleeding tendencies of these TKIs. Therefore, patients should 
be monitored by measuring platelet function or (active) compound levels in serum, plasma or 
isolated platelets 2-4 weeks after start treatment or additionally in case of changes like dose 
reduction, reoccurrence of side effects or altering treatment schedule. Though, more research is 
needed to determine effects on sunitinib concentration in long term and whether possible effects 
extinguish over time, as our study in Chapter 6 is limited to follow-up period of maximal 12 weeks 
and limited in patient numbers due to dose reduction or discontinuation of medication (upon 
decease).
 To further develop the findings of this thesis towards better and improved patient care, 
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more research is needed. Our patient study with sunitinib showed the correlation between 
quantitative and qualitative platelet traits with (active) sunitinib levels. Due a limited number 
of patients, no correlation could be observed between these parameters and bleeding and/or 
progression. Therefore, it would be interesting to investigate whether changes in platelet traits or 
concentration of unbound sunitinib (or other TKIs) in plasma or isolated platelets could predict 
response to therapy or bleeding in a larger cohort. This knowledge might lead to a way to follow 
patients more closely to prevent bleeding or monitor progression. As we observed aggravated 
effects on platelet function of sunitinib together with aspirin, more research into the combined 
anti-platelet effects of different anti-platelet or anti-coagulant drugs with TKIs is necessary. 
Especially patients receiving both anti-cancer and anti-platelet therapies could be at increased 
risk for bleeding. 
 The application of TKIs in treatment of other diseases, e.g. thrombosis, would also be 
fascinating to study. TKIs already have inhibiting effects on platelets mainly via the GPVI pathway, 
therefore, these drugs might be possible to use as anti-platelet drugs in (deep vein) thrombosis, 
which is also suggested recently by other studies96, 97. These TKIs are already approved in the 
clinic, ergo easier to test in other diseases involving thrombosis or thrombo-inflammation, in a 
short period of time as side effects are already reported. Additionally, due to the relative high 
affinity described for tyrosine kinases, relatively low therapeutic concentrations of TKI could be 
able to selectively inhibit platelet function without possibly increasing bleeding risk. 
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In the last decades, tyrosine kinase inhibitors (TKIs) have been developed as a new type 
of anti-cancer agents. These TKIs inhibit growth factor receptors (tyrosine kinases) involved in 
angiogenesis and tumour development, thereby improving progression free survival. As tyrosine 
kinases are expressed in many cell-types, and most TKIs inhibit multiple protein tyrosine kinases, 
they inevitably have off-target effects. One of the side effects described for several TKIs is (mild) 
bleeding. Blood platelets, well-known for their involvement in haemostasis, also contain multiple 
protein tyrosine kinases, which are essential for their activation. Therefore, the overall aim of 
this thesis was to provide more insights in the unintended effects of TKIs on platelet function. 
Chapter 1 provides a brief background on platelet activation processes and thrombus formation, 
with additional focus on the involvement of tyrosine kinases in the different activation pathways. 
To look more closely into the different TKIs and their anti-platelet effects, in Chapter 2 a 
detailed literature-based review is given, which provides an extended overview and mechanistic 
insight into the action of TKIs in current clinical use. The targets of these TKIs were compared 
with the tyrosine kinases present in platelets and the possibility to be linked to anti-platelet 
effects. This revealed that (for some TKIs) the knowledge on affinity for their targets does not 
completely align with published effects on platelets and reported bleeding events. In addition, 
clinical consequences of platelet inhibition by treatment with TKIs were discussed. Conversely, 
given the role of platelets in tumour progression, we discussed whether platelet inhibition can be 
an interesting strategy to inhibit tumour growth and monitor response to therapy. 
Pazopanib is an oral TKI used for treatment of advanced renal cell carcinoma (RCC). In 
Chapter 3, we investigated the effects of pazopanib on platelet function in vitro and in RCC patients 
on-treatment. We found that pazopanib (dose-dependently) reduced GPVI-induced platelet 
responses and thrombus formation under flow in blood from healthy volunteers. Pazopanib 
inhibited tyrosine phosphorylation and intracellular calcium signalling in platelets stimulated 
via the collagen receptor glycoprotein (GP)VI, subsequently leading to reduced exposure of 
phosphatidylserine (PS) as a marker for procoagulant activity. In addition, we analysed blood 
samples from 10 RCC patients before and 14 days after receiving pazopanib as monotherapy. 
This treatment caused an overall lowering in platelet count, with 3 patients experiencing mild 
bleeding. The effects of pazopanib on these patients’ platelets were mainly confined to a 
reduction in GPVI-dependent procoagulant activity. Control experiments indicated that higher 
pazopanib concentrations were required to inhibit GPVI-mediated PS exposure in the presence 
of plasma. Together, these results indicated that pazopanib suppresses GPVI-induced platelet 
activation responses in a way partly antagonized by the presence of plasma. 
Another multi-target TKI used for the treatment of advanced RCC is sunitinib. This 
compound was reported to affect collagen-induced activation under non-coagulating conditions. 
In Chapter 4, we investigated the effects of sunitinib on thrombus formation induced by other 




observed that both thrombus formation and PS exposure under flow were affected by sunitinib 
on collagen type I and III. Upon tissue factor-triggered coagulation, sunitinib decreased PS 
exposure and fibrin formation. In blood from cancer patients more pronounced effects of 
sunitinib were observed in lung and pancreatic as compared to neuroglioblastoma and other 
cancer types. Cancer patients commonly suffer from cardiovascular disease as a co-morbidity, 
and may be at risk for (secondary) thrombotic events. Therefore, these patients are treated with 
anti-platelet drugs such as aspirin, which irreversibly inhibits platelet activation and is associated 
with an increased bleeding risk. As both sunitinib and aspirin are associated with bleeding, we 
further investigated the synergistic effects of both compounds in this setting. Compared to 
sunitinib alone, the combination of sunitinib with aspirin resulted in further reduction of platelet 
aggregation, thrombus formation and PS exposure on collagen under flow with(out) coagulation. 
In conclusion, sunitinib suppressed collagen-induced procoagulant activity and delayed fibrin 
formation, which was aggravated by aspirin treatment. 
 To investigate the effects of sunitinib not only in vitro, but also in cancer patients, 
in Chapter 5 we investigated the quantitative and qualitative changes in platelet traits as a 
function of the sunitinib levels and the occurrence of bleeding in RCC patients on treatment 
with sunitinib. Blood was collected from 20 metastatic RCC (mRCC) patients before treatment, 
and at 2 weeks, 4 weeks and 3 months after sunitinib administration. In sunitinib-treated mRCC 
patients, concentrations of sunitinib and its active metabolite in plasma and serum were highly 
correlated. The active metabolite was relatively increased in the patients’ platelets compared 
to sunitinib. On average, a continued reduction in platelet count was observed on-treatment, 
which was significantly related to the inhibitor levels in plasma/serum. Principal component and 
correlational analysis showed that the concentration of (active) sunitinib in plasma/serum was 
linked with a reduction in both platelet count and collagen-induced platelet aggregation. The 
reduced aggregation in part associated with reported bleeding, but did not correlate to disease 
progression. In conclusion, sunitinib induced reduction in quantitative and qualitative platelet 
traits may reflect the effective sunitinib levels in the patient. 
The mechanism underlying the increased bleeding tendency with TKIs often remains 
unclear. Therefore, in Chapter 6 we investigated the effects of three Btk inhibitors, two irreversible 
(ibrutinib and acalabrutinib) and one novel reversible inhibitor (MK-1026), on platelet function in 
healthy volunteers, patients and Btk deficient mice, together with off-target effects on tyrosine 
kinase phosphorylation. All three inhibitors impaired GPVI- and CLEC-2-mediated aggregation, 
activation and secretion in isolated platelets in a dose-dependent manner. Only ibrutinib inhibited 
thrombus formation on von Willebrand Factor (vWF) co-coated surfaces, while on collagen this 
process was not affected. In blood from Btk-deficient mice, collagen-induced thrombus formation 
under flow was reduced, but preincubation with either inhibitor was without additional effects. 
MK-1026 showed less off-target effects upon GPVI-induced tyrosine kinase phosphorylation as 
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compared to ibrutinib and acalabrutinib. In ibrutinib-treated patients, GPVI-stimulated platelet 
activation and adhesion on vWF-co-coated surfaces were inhibited, while CLEC-2 stimulation 
induced variable responses. The dual inhibition of GPVI and CLEC-2 signalling by Btk inhibitors 
might account for the increased bleeding tendency, with ibrutinib causing more high-grade 
bleedings due to additional inhibition of platelet-vWF interaction. As MK-1026 showed less off-
target effects and only affected activation of isolated platelets, it might be promising for future 
treatment. 
Although multiple TKIs are reported to increase the risk of bleeding, mainly minor 
bleeding symptoms are described. The currently used anti-platelet drugs for treatment of arterial 
thrombosis coincide with a greater risk of bleeding. Hence, platelet inhibitors that preserve 
haemostasis are warranted. In Chapter 7, we investigated the anti-platelet properties of several 
clinically used TKIs as exploration of possible repurposing of these compounds as anti-platelet 
drugs. Eight TKIs were selected based on the affinity for tyrosine kinases expressed in platelets and 
published bleeding symptoms. Overall, the TKIs with the highest affinities for platelet targets most 
strongly inhibited platelet function. Dasatinib and sunitinib dose-dependently reduced collagen-
induced aggregation in platelet-rich plasma and washed platelets, while pazopanib, cabozantinib 
and vatalanib inhibited this response in washed platelets only, and fostamatinib, axitinib and 
lapatinib showed no or limited effects. Fostamatinib effectively reduced whole blood thrombus 
formation on collagen under flow, as well as on vWF plus rhodocytin or laminin. Pazopanib, 
sunitinib, dasatinib, axitinib and vatalanib (mildly) reduced thrombus formation only on collagen. 
Intracellular calcium measurements and activation responses in isolated platelets were inhibited by 
dasatinib, fostamatinib, sunitinib and pazopanib. Simultaneous measurement of different platelet 
populations raised by collagen receptor-stimulation showed that fostamatinib, cabozantinib and 
vatalanib decreased highly activated platelet populations, whereas negative, resting populations 
were increased. Altogether, the inhibitory effects of dasatinib, fostamatinib, sunitinib and 
pazopanib suggested interference in early collagen receptor-induced signalling events, whereas 
for cabozantinib and vatalanib the effects may be more downstream. Fostamatinib, sunitinib, 
pazopanib and vatalanib have been associated with mild or no bleeding events and, hence, may 
be promising candidates to explore further as potential anti-platelet drugs.
In Chapter 8 are the most important findings of this thesis are discussed in perspective 
of the current literature. With this thesis we would like to raise awareness for the potential anti-
platelet effects of several TKIs during cancer treatment, which could be enhanced in the presence 
of antithrombotic drugs, thereby increasing the bleeding risk. Changes in platelet features and 
unbound plasma concentrations of TKIs upon treatment could provide tools for monitoring and 







In de afgelopen decennia zijn tyrosine-kinaseremmers (TKI’s) ontwikkeld als een nieuw 
type antikankerbehandeling. Deze TKI’s remmen in de eerste plaats groeifactor-receptoren 
(tyrosine kinasen) op tumor- en vaatwandcellen. Op deze manier worden angiogenese en 
tumorontwikkeling geremd, waardoor de progressie-vrije overleving bij patiënten wordt 
verbeterd. Omdat tyrosine kinasen in veel celtypen in het lichaam tot expressie komen, hebben 
ze onvermijdelijk bijwerkingen. Een van de beschreven bijwerkingen bij meerdere TKI’s is (milde) 
bloedingen. Bloedplaatjes, die bekend staan om hun betrokkenheid bij hemostase, bevatten ook 
meerdere tyrosine kinasen die essentieel zijn voor hun activering. Het algemene doel van dit 
proefschrift was om meer inzicht te geven in de onbedoelde effecten van TKI’s op de functie 
van bloedplaatjes. Hoofdstuk 1 geeft een korte achtergrond over de processen van activering 
van bloedplaatjes en daaropvolgende trombusvorming, waarin we extra focus leggen op de 
betrokkenheid van tyrosine kinasen in de verschillende activeringsroutes. 
 Om meer inzicht te krijgen in de verschillende TKI’s en hun effecten op bloedplaatjes 
effecten, wordt in Hoofdstuk 2 een gedetailleerd literatuuronderzoek beschreven. Hierin 
tonen we een uitgebreid overzicht van TKI’s die in de huidige kliniek gebruikt worden voor de 
behandeling van verschillende soorten kanker, almede de cellulaire aangrijpingspunten voor hun 
werking. De doelwitten van deze TKI’s zijn vergeleken met de tyrosine kinasen die aanwezig zijn 
in bloedplaatjes, en indien mogelijk gekoppeld aan anti-bloedplaatjes effecten. Hieruit bleek dat 
(voor sommige TKI’s) de kennis over affiniteit voor hun doelwitten niet volledig overeenkomt 
met gepubliceerde effecten op bloedplaatjes en de gerapporteerde bloedingen. Daarnaast zijn de 
klinische gevolgen van bloedplaatjesremming door behandeling met TKI’s besproken. Omgekeerd, 
gezien de rol van bloedplaatjes in tumorprogressie, vroegen we ons af of bloedplaatjesremming 
een interessante strategie zou kunnen zijn om tumorgroei te remmen, danwel de respons op 
therapie te volgen.
 Pazopanib is een orale TKI die gebruikt wordt voor de behandeling van gevorderd 
niercelcarcinoom (RCC). In Hoofdstuk 3 onderzochten we de effecten van pazopanib op 
bloedplaatjesfunctie in vitro en bij RCC-patiënten tijdens hun behandeling. De resultaten 
lieten zien dat pazopanib (dosisafhankelijk) de bloedplaatjesreacties en trombusvorming 
onder stromingscondities na stimulatie van de collageen receptor glycoproteïne VI (GPVI) 
verminderde in het bloed van gezonde vrijwilligers. Pazopanib remde de fosforylering van 
tyrosine kinasen en de intracellulaire calciumsignalering in bloedplaatjes gestimuleerd via GPVI. 
Dit leidde vervolgens tot verminderde expressie van fosfatidylserine (PS) welke belangrijk is 
voor het bevorderen van de bloedstolling, de zogenaamde procoagulante activiteit. Daarnaast 
analyseerden we bloedmonsters van 10 RCC-patiënten vóór en 14 dagen na inname van 
pazopanib als monotherapie. Deze behandeling veroorzaakte een algehele verlaging van het 
aantal bloedplaatjes, waarbij 3 patiënten lichte bloedingen ervaarden. De effecten van pazopanib 




de GPVI-afhankelijke bevordering van de procoagulante activiteit. Controle experimenten lieten 
zien dat hogere pazopanib concentraties nodig waren om de GPVI-gemedieerde PS-expressie in 
aanwezigheid van plasma te kunnen remmen. Samen gaven deze resultaten aan dat pazopanib 
de GPVI-geïnduceerde activeringsreacties van bloedplaatjes onderdrukt op een manier die 
gedeeltelijk wordt tegengewerkt door de aanwezigheid van plasma.
 Een andere TKI die wordt gebruikt voor de behandeling van gevorderd RCC is sunitinib. Van 
dit geneesmiddel is beschreven dat deze de collageen-geïnduceerde activering van bloedplaatjes 
onder niet-stollende omstandigheden beïnvloedt. In Hoofdstuk 4 onderzochten we de effecten 
van sunitinib op trombusvorming geïnduceerd door andere tyrosine kinase-afhankelijke 
receptoren, evenals de effecten onder stollende condities. We hebben waargenomen dat zowel 
trombusvorming als PS-expressie onder stromingscondities werden geremd door sunitinib 
op collageen type I en III. Bij aanwezigheid van weefselfactor om bloedstolling te induceren, 
verminderde sunitinib de PS-expressie op bloedplaatjes en de vorming van fibrine. In bloed 
van kankerpatiënten werden meer uitgesproken effecten van sunitinib waargenomen in long- 
en alvleesklierkanker in vergelijking tot hersenkanker (neuroglioblastoma) en andere typen van 
kanker. Kankerpatiënten lijden vaak mede aan hart- en vaatziekten en hebben mogelijk verhoogd 
risico op (secundaire) trombotische gebeurtenissen. Daarom worden deze patiënten behandeld 
met medicatie tegen bloedplaatjesaggregatie zoals aspirine, wat de activering van bloedplaatjes 
onomkeerbaar remt en gepaard gaat met een verhoogd bloedingsrisico. Omdat zowel sunitinib als 
aspirine geassocieerd zijn met een verhoogd risico op bloedingen, hebben we de synergistische 
effecten van beide geneesmiddelen in deze setting verder onderzocht. Vergeleken met sunitinib 
alleen, resulteerde de combinatie van sunitinib en aspirine in een verdere vermindering van de 
aggregatie, trombusvorming en PS-expressie van bloedplaatjes op het collageen oppervlak onder 
stromingscondities, zowel in aan- als afwezigheid van bloedstolling. Samenvattend, sunitinib 
onderdrukte de collageen-geïnduceerde bevordering van de bloedstolling en vertraagde de 
vorming van fibrine; deze onderdrukking werd versterkt door behandeling met aspirine.
 In Hoofdstuk 5 hebben we de kwantitatieve en kwalitatieve veranderingen in 
eigenschappen van bloedplaatjes onderzocht in relatie tot de sunitinib concentratie in het bloed, 
en het optreden van bloedingen bij RCC-patiënten na behandeling met sunitinib. Bloed werd 
afgenomen van 20 patiënten met gevorderd RCC vóór start met behandeling en 2 weken, 4 
weken en 3 maanden na behandeling met sunitinib. De concentraties van sunitinib en de actieve 
metaboliet in het plasma en serum van RCC-patiënten behandeld met sunitinib waren sterk 
gecorreleerd. De concentratie van de actieve metaboliet was relatief verhoogd in de bloedplaatjes 
van de patiënten in vergelijking met sunitinib. Gemiddeld werd er tijdens de behandeling een 
aanhoudende afname van het aantal bloedplaatjes waargenomen, wat significant verband 
hield met de concentratie van de remmers in het plasma en/of serum. Principal component- en 
correlatieanalyses toonden aan dat de concentratie van (actief) sunitinib in het plasma en/of 
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serum verband hield met een vermindering van zowel het aantal bloedplaatjes als de collageen-
geïnduceerde aggregatie. De verminderde aggregatie was gedeeltelijk geassocieerd met de 
gerapporteerde bloedingen, maar correleerde niet met de progressie van de ziekte. Concluderend 
kan de door sunitinib geïnduceerde vermindering van kwantitatieve en kwalitatieve kenmerken 
van bloedplaatjes een weerspiegeling zijn van de effectieve sunitinib concentratie in de patiënt. 
 Het mechanisme dat ten grondslag ligt aan de verhoogde bloedingsneiging bij TKI’s blijft 
vaak onduidelijk. Daarom hebben we in Hoofdstuk 6 de (onbedoelde) effecten onderzocht van 
drie Btk-remmers op de functie van bloedplaatjes in het bloed van gezonde vrijwilligers, patiënten 
en Btk-deficiënte muizen. Het betreft twee irreversibele remmers (ibrutinib en acalabrutinib), 
en een nieuwe, reversibele remmer (MK-1026). Alle drie de remmers verminderden de GPVI- 
en CLEC-2-gemedieerde aggregatie, activatie en secretie van geïsoleerde bloedplaatjes op een 
dosisafhankelijke manier. Alleen ibrutinib verminderde trombusvorming op von Willebrand 
Factor (vWF) in combinatie met rhodocytine, laminine of fibrinogeen, terwijl op collageen geen 
effecten werden gezien. In het bloed van Btk-deficiënte muizen was de collageen-geïnduceerde 
trombusvorming onder stromingscondities verminderd, maar er werden geen additionele 
effecten waargenomen na toevoeging van de Btk-remmers. MK-1026 liet minder onbedoelde 
bijwerkingen zien bij GPVI-gestimuleerde tyrosine kinase fosforylatie in vergelijking tot ibrutinib 
en acalabrutinib. Bij patiënten onder behandeling met ibrutinib werden de GPVI-geïnduceerde 
activering en adhesie van bloedplaatjes geremd op de oppervlakken gecombineerd met vWF, 
terwijl variabele responsen werden waargenomen met CLEC-2 stimulatie. De duale remming 
van GPVI- en CLEC-2-signalering door Btk-remmers kan verantwoordelijk zijn voor de verhoogde 
bloedingsneiging, met meer hoogwaardige bloedingen bij behandeling met ibrutinib als gevolg 
van extra remming van bloedplaatjes adhesie aan vWF. Omdat MK-1026 minder off-target 
effecten liet zien en alleen de activatie van geïsoleerde bloedplaatjes beïnvloedde, zou dit een 
veelbelovende toekomstige behandeling kunnen zijn. 
 Hoewel het is beschreven dat meerdere TKI’s het risico op bloedingen verhogen, betreft 
dit voornamelijk milde bloedingssymptomen. De momenteel voorgeschreven medicatie tegen 
aggregatie van bloedplaatjes ter behandeling van arteriële trombose geven een groter risico 
op bloedingen. Daarom zijn bloedplaatjes remmers noodzakelijk die de hemostase behouden. 
In Hoofdstuk 7 hebben we van verschillende klinisch gebruikte TKI’s de remmende effecten op 
bloedplaatjes onderzocht ter verkenning van het gebruik van deze geneesmiddelen als anti-
bloedplaatjes medicatie. Acht TKI’s werden geselecteerd op basis van de affiniteit voor tyrosine 
kinasen die tot expressie komen in bloedplaatjes en de gepubliceerde bloedingssymptomen. Over 
het algemeen remden de TKI’s met de hoogste affiniteit voor tyrosine kinasen in bloedplaatjes, 
de functie van bloedplaatjes het sterkst. Dasatinib en sunitinib verminderden dosisafhankelijk 
de collageen-geïnduceerde aggregatie in zowel de aanwezigheid van plasma, als in geïsoleerde 




bloedplaatjes remden. Fostamatinib, axitinib en lapatinib vertoonden geen of beperkte effecten. 
Fostamatinib verminderde effectief de vorming van een trombus in bloed dat werd gestroomd 
over een collageen oppervlak, evenals over een oppervlak van vWF samen met rhodocytine 
of laminine. Pazopanib, sunitinib, dasatinib, axitinib en valatalanib verminderden (licht) de 
vorming van de trombus alleen op het collageen oppervlak. Intracellulaire calciummetingen en 
activeringsreacties in geïsoleerde bloedplaatjes werden geremd door dasatinib, fostamatinib, 
sunitinib en pazopanib. Gelijktijdige meting van verschillende populaties van bloedplaatjes 
opgewekt door stimulatie van de collageen receptor toonde aan dat fostamatinib, cabozantinib 
en vatalanib de sterk geactiveerde populatie van bloedplaatjes verlaagden, terwijl de negatieve, 
rustende populaties toenamen. Al met al suggereerden de remmende effecten van dasatinib, 
fostamatinib, sunitinib en pazopanib interferentie in de vroege signalering van de collageen 
receptor-geïnduceerde activering, terwijl voor cabozantinib en vatalanib de effecten verder 
stroomafwaarts kunnen zijn. Fostamatinib, sunitinib, pazopanib en vatalanib zijn in verband 
gebracht met milde of geen bloedingen en kunnen daarom veelbelovende kandidaten zijn om 
verder te onderzoeken als potentiële geneesmiddelen om bloedplaatjes te remmen.
 In Hoofdstuk 8 worden de belangrijkste bevindingen van dit proefschrift besproken in 
het perspectief van de huidige literatuur. Met dit proefschrift willen we het bewustzijn vergroten 
voor de mogelijke remmende effecten van verschillende TKI’s op bloedplaatjes tijdens de 
behandeling van kanker. Deze zouden bovendien versterkt kunnen worden in aanwezigheid van 
antitrombotische middelen, waardoor het risico op bloedingen verder toeneemt. Veranderingen 
in de kenmerken van bloedplaatjes en ongebonden plasmaconcentraties na behandeling met 





Cancer is a leading cause of death worldwide, with almost 10 million deaths in 20201. 
One of the hallmarks of cancer is to chronically sustain cell proliferation caused by mutations in 
or amplification of oncogene-encoded proteins or growth factor receptors2. As these proteins 
include (tyrosine) kinases, cancer cells are described to have abnormal kinase activity which 
is known to drive processes such as cell proliferation, differentiation, migration, survival and 
angiogenesis3, 4. In the past two decades, increased understanding of this process has resulted 
in  the development of many small molecule tyrosine kinase inhibitors (TKIs) as targeted therapy 
for cancer. In current settings of cancer treatment, TKIs significantly increase the progression-free 
survival of patients upon (lifelong) treatment. As tyrosine kinases are present in many cell-types, 
long-term treatment is often associated with (serious) adverse events including bleeding. 
Platelets are important players in haemostasis and platelet production and function rely 
on several tyrosine kinases, suggesting that platelet count and function may be affected by TKIs. 
Hence, this may play a role in the increased risk of bleeding observed upon treatment with 
several TKIs. Yet, knowledge on whether and/or how platelets are affected by TKIs is limited. 
Therefore, we aimed to provide more insights in the effects of different TKIs on platelet function. 
To define what was known on the relation between TKIs and platelets at the start of this research, 
in Chapter 2 an overview is given of the currently used TKIs in cancer treatment and the effects 
on platelet function. In order to extent the existing knowledge, we investigated platelet responses 
in the presence of different TKIs in vitro and in cancer patients (Chapter 3-7). Throughout this 
thesis, we showed that the majority of TKIs inhibit platelet responses mediated by the collagen 
receptor glycoprotein (GP)VI, e.g. activation, aggregation and/or thrombus formation. In some 
cases (additionally) CLEC-2- or GPIb-induced thrombus formation was inhibited by TKI treatment. 
These results unravelled parts of the underlying mechanism of platelet inhibition by these TKIs. 
As these mechanisms still remain incomplete or unknown for some TKIs, this could provide 
new fields of interest for fellow researchers. Furthermore, with our studies involving (specific) 
cancer patients upon TKI treatment (Chapter 3, 5 and 6), we were able to gain knowledge on the 
interactions between platelet traits and TKI levels in the blood of these patients. We found that 
in renal cell carcinoma patients not only platelet function, but also platelet count, was affected 
by the TKIs sunitinib and pazopanib. For sunitinib, we discovered that the (active) compound 
levels in plasma or serum correlated with platelet count and function in these patients. This 
effect was measured already two weeks after the start of treatment, while response to therapy 
is normally not monitored until three months after start of treatment by a CT-scan. These plasma 
concentrations of sunitinib (or its metabolite) could be of importance for toxicity and the response 
to treatment, pointing towards platelets as a monitoring tool for compound effects, both on- and 
off-target. These results could be of interest for clinicians and cancer patients (hopefully) resulting 
in (early) therapeutic drug monitoring and increased quality of life during treatment. Therefore, 




also other cells) could be of great importance to provide ways to monitor and improve treatment. 
These studies would enhance our understanding of the exact mechanism underlying the side 
effects, which could lead to the development of new drugs with reduced side effects. 
Cancer patients often have a cardiovascular history5, 6 and are prescribed with anti-platelet 
or anti-coagulant drugs to prevent recurrent cardiovascular events. As anti-platelet medications, 
such as clopidogrel and aspirin, are also associated with an increased bleeding risk bleeding7-9, 
in Chapter 4 we examined whether there are synergistic effects on platelet function of dual 
treatment that could further increase the bleeding risk in TKI-treated cancer patients. We showed 
that aspirin aggravated the effects of sunitinib in platelet aggregation as well as delaying platelet-
dependent coagulation in whole blood perfusion over a collagen surface. With these results we 
would like to raise awareness among clinicians of combining anti-platelet therapies and TKIs as 
this may result in an increased bleeding risk in patients. 
 As current anti-platelet therapies are associated with bleeding and thrombotic events may 
still occur, there is a need of better anti-thrombotic drugs. The platelet GPVI and CLEC-2 receptors 
are important players in arterial thrombosis and thrombo-inflammation with supporting roles 
in haemostasis10. A deficiency of GPVI or CLEC-2 does not significantly influence haemostasis11, 
12, making these receptors interesting targets for anti-thrombotic drugs10, 13. As these receptors 
rely on tyrosine kinases for their underlying signalling pathways, we studied the anti-platelet 
properties of several clinically used TKIs with the aim to explore possible repurposing of these 
compounds as anti-platelet drugs. As several of the tested TKIs are described with only minor 
bleeding events, the GPVI inhibition observed with these TKIs might suggest that these could 
be promising candidates as anti-platelet drugs. However, more research with regard to dosage 
to estimate efficacy and toxicity in thrombotic patients is needed. With additional research, 
repurposing TKIs could be of great interest for clinicians, in particular cardiologists, as these TKIs 
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